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SUMMARY
The longevity of filarial nematodes is dependent on secreted 
immunomodulatory products. Previous investigation of one such product, ES- 
62, has suggested a critical role for post-translationally attached 
phosphorylcholine (PC) moieties. In order to further investigate this, I 
attempted to produce ES-62 lacking PC by using a variety of enzymes and 
enzyme inhibitors. The resultant material was, unfortunately, never 100 % 
PC-free, and the results were also highly variable. As an alternative 
approach it was therefore decided to place the gene for ES-62 into the Pichia 
pastoris recombinant gene expression system. It was hoped that the gene 
expression system, being eukaryotic in nature, would side-step solubility 
issues previously encountered when an Escherichia co//-based system was 
attempted, as it would be able to perform the post-translational modifications 
necessary for production of a correctly folded protein, whilst avoiding 
hyperglycosylation issues frequently encountered when using a 
Saccharomyces cerev/s/ae-based system. The procedure was successful, 
and an abundant supply of recombinant protein was available for use.
When the recombinant protein's biochemical features were compared with 
parasite-derived ES-62, which has been shown to be tetrameric in form, the 
former was found to consist of a mixture of apparently stable tetramers, 
dimers and monomers. Nevertheless, the recombinant protein was 
considered to be an adequate PC-free ES-62 as it was recognized by
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existing antisera against the parasite-derived protein including a monoclonal 
antibody (mAb) that recognised a conformational determinant.
However, subsequent to this, differences were found in the recombinant 
protein’s sensitivity to a panel of enzymes when compared to the parasite- 
derived material, and recognition of parasite-derived ES-62 by antibodies 
produced against the recombinant protein was found to be absent. Evidence 
was also observed suggesting that although the recombinant material 
appeared to act similarly to the parasite-derived material in terms of 
modulation of cytokine production by bone marrow-derived dendritic cells 
(bmDCs), the mechanism by which this result was achieved appeared to be 
different from that elucidated for the parasite-derived material: it seemed that 
the recombinant protein’s mode of action was independent of TLR4 or 
MyD88, in comparison to the parasite-derived ES-62. It was also observed 
that the recombinant material appeared to have a higher content of mannose 
than the original protein, an unexpected finding considering the evidence that 
Pichia is much less likely to hyperglycosylate than other yeast-based 
recombinant gene expression systems such as S.cerevisiae.
In an attempt to explain the differences observed, recombinant ES-62 was 
subjected to structural analysis and was found to (i) contain 3 changes in 
amino acid composition; (ii) demonstrate significant alterations in glycan 
composition; (iii) show major differences in protein secondary structure. The 
effects of these alterations in relation to the observed change in 
immunogenicity were investigated and the finger was pointed at the changes
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in secondary structure. A major take-away message from the data is that 
recognition by existing antibodies is insufficient proof that recombinant 
proteins can be used to mimic parasite-derived material in studies on 
nematode immunology and vaccination.
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Chapter 1: Introduction
1.1 LYMPHATIC FILARIASIS AND ONCHOCERCIASIS
There are eight species of filarial nematodes known to infect humans, three 
of which, namely Wuchereria bancrofti, Brugia malayi and Onchocerca 
volvulus (Figs 1.1 A, B and C respectively) are responsible for much of the 
morbidity seen in the Tropics (World Health Organisation (WHO), 1997). 
Currently it is estimated that one hundred and fifty million people suffer from 
at least one of these named parasites, with a further one billion at risk of 
infection (Ottesen et al., 1997; Fig. 1.2). Symptoms range from skin lesions 
to elephantiasis and blindness, with onchocerciasis being the second 
commonest cause of preventable blindness in Sub-Saharan Africa (Hoerauf 
et al., 2003).
Lymphatic filarial nematodes infect approximately 120 million people in 80 
different countries worldwide, with an estimated one billion people at risk 
fwww.fiiariasis.oraL Over 40 million of the people infected are severely so 
(Molyneux, 2001), and there is still a great deal of stigmatism attached to the 
disease (WHO fact sheet no 102 Rev. Sep. 2000). Of all the people infected 
over forty percent live in India, one third in Africa, with the majority of the last 
portion living in Asia, the Pacific and the Americas. Nine out of ten of all 
lymphatic filariasis incidences are caused by W.bancrofti and most of the 
remaining ten percent are caused by B.malayi (www.fiiariasis.org). The 
pathology resulting from a worm infection can range from uncomfortable, at 
best, to the classic example of lymphatic filariasis-associated pathology.
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elephantiasis. It is true, however, that acute episodes are often caused by a 
secondary bacterial or fungal infection of the skin, as damage to the 
lymphatic system underneath has lowered the defences (Shenoy et al., 1999; 
Dreyer et al., 2000a and 2000b).
Onchocerciasis is the second commonest cause of preventable blindness in 
Sub-Saharan Africa (Thylefors et al., 1995; Lewallen and Courtright, 2001) 
and is found in 37 countries worldwide: 30 are in Africa, in which 99 percent 
of infected individuals live (WHO/TDR). It is estimated that 18 million people 
are infected (mentioned in Basanez et al., 2006), with over 120 million people 
are at risk of infection. The disease causes severe itching or dermatitis in 
more than 6.5 million of those infected, and blindness in 270,000, with severe 
visual impairment in a further 500,000 (WHO, 1995a).
The main burden of these diseases is the morbidity that they cause: 
lymphatic filariasis is the cause of an estimated 5.5 million disability adjusted 
life years (DALYs), and onchocerciasis is thought to be responsible for 1 
million DALYs (Molyneux et al., 2003).
1.1.1 Lymphatic Filarial Nematodes and O.volvulus Lifecycles
The transmission cycles of both lymphatic filariasis, caused by W.bancrofti 
(Fig. 1.3) and B.malayi (Fig. 1.4) and onchocerciasis, caused by O.volvulus 
(Fig. 1.5) rely upon an Intermediate vector.
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In the case of the causative agents of lymphatic filariasis, the vector is the 
mosquito. The main three vectors for W.bancrofti are of the Culex species in 
most urban and semi-urban areas of Africa, Anopheles species in more rural 
areas of Africa, and Aedes species in many of the endemic Pacific Islands 
(Sasa, 1976). B.malayi is spread mainly by mosquitoes of the Mansonia (the 
major vector), and Anopheles species in some areas too (Sasa, 1976).
The vector of O.volvulus is the blackfly, the major vectors being complexes of 
sibling species of Simulium: Most of Africa’s main vectors belong to the 
S.damnosum complex, while the main vectors in Uganda, Tanzania, Ethiopia 
and the Congo belong to the S.neavei complex. In Latin America the most 
important vectors are S.ochraceum (Mexico and Guatemala), S.metallicum 
(Venezuela), S.exiguumI (Equador) and S.oyapockense (Brazil) (Zea Flores, 
1990; Shelly, 1988).
The worms are so thin as to appear thread-like, and their ability to survive 
within the host for many years has been well documented: the reproductive 
lifespan of the adult causative agents of lymphatic filariasis can be between 4 
and 8 years (Michael et al., 2004), whilst in onchocerciasis the mean fecund 
lifespan of an adult female is estimated as 9-11 years (Habbema et a i,
1992). The female worms produce thousands of microfilariae (mf) a day. In 
the case of lymphatic filariasis, mf circulate in the bloodstream, and are taken 
up in a bloodmeal by the vector. Over the course of 7-12 days in the 
mosquito, these immature larvae develop into infective larvae, which migrate 
to the mouthparts of the mosquito to ensure they will be passed on to the
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next person bitten, thus completing the transmission cycle (Figs 1.3 and 1.4). 
The mf produced by adult female O.volvulus, living in nodules under the skin, 
migrate though the body and cause many different symptoms after they die 
by stimulating host inflammatory reactions. The nodules can be 1-5 cm in 
diameter and are most commonly found on the skin covering protrusions of 
bones, e.g. hips (WHO, 1987). Much the same as for lymphatic filariasis, the 
mf are taken up in a blood meal by the vector. The larvae mature from the 
immature to infective stage and migrate to the mouthparts to ensure further 
transmission when the vector next feeds, and hence the cycle continues (Fig 
1.5).
1.1.2 Symptoms of Lymphatic Filariasis and Onchocerciasis
Fifteen years ago, it was suggested that lymphatic filariasis infection had two 
polar groups of disease state: those with chronic pathology and no 
detectable circulating mf, and asymptomatic patients with high levels of 
circulating mf (Ottesen, 1992). Since then, lymphatic filariasis has been split 
into three general groups of infection type in endemic areas:
1. Asymptomatic: the majority of people seem devoid of outward sign of 
disease or clinical features, with the exception of a high level of mf in 
their bloodstream. These individuals seem to tolerate the parasites 
immunologically, but have been shown, in some cases, to harbour
hidden damage to their kidneys and, as could be predicted, their 
lymphatic system (WHO Fact Sheet No. 102, 2000).
2. Acute: the patient suffers from painful inflammation of the lymph 
nodes and ducts, which is often associated with nausea, vomiting and 
a fever. This is referred to as “filarial fever”, attacks of this becoming 
more frequent dependent on the severity of the chronic disease.
3. Chronic: associated with swelling of an arm or leg, genitals (e.g. 
hydrocoele, although this only occurs in those infected by Wuchereria 
bancrofti.) or vulva and breasts. Men appear to display these most 
severe symptoms more frequently than women, with ten to fifty per 
cent of men as opposed to ten per cent of women affected in 
communities where the disease is endemic (WHO Fact Sheet No. 
102, 2000).
A small section of the community appear to be immune to infection, being 
devoid of any symptoms or mf, despite constant exposure to infected vector 
bites (Maizels and Lawrence, 1991). These individuals have been termed 
“endemic normals” (Day, 1991).
As secondary bacterial infections lead to worsening of lymphodema and its 
deterioration into elephantiasis, hygiene, skin care which makes provision for 
the prevention, detection and treatment of “entry lesions”, appropriate 
footwear and elevation of the affected limb, coupled with prophylactic 
antibiotics in some cases are all key to its prevention (McPherson et al., 
2006; Dreyer et al., 2002). Acute episodes of elephantiasis, although often a
direct symptom of parasite infection (Kumaraswami, 2000) are more 
frequently caused by a secondary bacterial or fungal infection of the skin, 
facilitated by cracks and fissures due to lymphatic damage underneath, and 
are preventable by following basic hygiene techniques (Shenoy et al., 1999, 
Dreyer et al., 2000a, 2000b).
The symptoms of onchocerciasis, caused by the mf, which can live for 2 
years (Habbema et al., 1992) vary from skin rashes, lesions, severe itching 
(Brieger et al., 1998; WHO, 1995b) and skin de-pigmentation to 
lymphadenitis (which can result in elephantiasis of the limbs or the genitals 
and hanging groins) to vision being critically impaired or even lost if the mf 
migrate to the eye (river blindness) (Hall and Pearlman, 1999; Pearlman and 
Hall, 2000). These symptoms are generally seen in the patient one to three 
years after infection, when production of mf by adult worms begins. In the 
last few years the importance of Wolbachia (of the order Rlckettlales) 
bacterial symboints in the reproduction of O.volvulus (Taylor and Hoerauf, 
2001; Bandi et al., 2001) and the inflammatory pathology associated with 
disease (Taylor and Hoerauf, 1999; Saint-André et al., 2002; Taylor, Bandi 
and Hoerauf, 2005) has become increasingly clear.
1.1.3 Control of Vectors/disease
At present, the methods for controlling these diseases concentrate on the 
use of therapeutic drugs and vector control. For lymphatic filariasis treatment
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a yearly dose of 6 mg/kg diethylcarbamazine (DEC), and 400 mg 
albendazole is used (Ottesen, 2000) or the patient can use DEC fortified 
cooking salt daily for 6-12 months (www.filariasis.com: WHO, 2000). In areas 
where onchocerciasis is endemic, filariasis treatment involves yearly dosing 
schemes of a combination of 150 [ig/kg ivermectin (a microfilariacidal drug) 
and 400 mg albendazole (a macrofiiariacidal drug), as DEC treatment can 
lead to discomfort and possible danger caused by the rapid O.volvulus mf 
death e.g. rash, itching, fever, headaches, etc.
As just mentioned, the treatment of onchocerciasis also involves yearly 
dosing of the population with ivermectin, although in the last few years the 
importance of Wolbachia symboints in the reproduction of O.volvulus 
(mentioned earlier) has become increasingly clear (Taylor and Hoerauf, 
2001; Bandi et al., 2001) thereby proving a new potential for drug targets.
In 1993 the theory was first formulated that lymphatic filariasis could be 
eradicated (Centers for Disease Control (CDC), 1993). Achieving this target 
is a complicated procedure, as although elimination in some situations has 
been simple and successful, other long-term intervention programmes have 
not achieved this goal (Southgate, 1992; Pichon, 2002). W.bancro/f/infection 
transmitted by Anopheles species was eliminated as a consequence of a 
house spraying malaria control campaign in some Melanesian Islands 
(Webber, 1977) which employed the pesticide Dichloro-diphenyl- 
trichloroethane (DDT). Later it was shown that Anopheles species- 
transmitted B.malayi was eliminated by mass drug administration of DEC
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(Zhang, et al., 1991). At the same time, there are other Melanesian Islands 
where 50 years of DEC distribution has still not eliminated W.bancrofti 
transmitted by Aedes species (Pichon, 2002). The Global Alliance to 
Eliminate Lymphatic Filariasis, created in 2000, now comprises 37 
organisations from public and private sectors, as well as academia, 
governmental bodies and non-governmental developmental organisations 
(NGDO). It has set itself the collective ambitious goal of eliminating lymphatic 
filariasis by 2020 (Molyneux and Zagaria, 2002). There have been two 
strategies developed to achieve this; interrupting transmission and controlling 
morbidity (Ottesen et al., 1997). interrupting transmission has focussed on 
reducing mf in the host. It has been possible to decrease levels by up to 90 
percent for at least one year using two different single dose, two-drug 
treatments (one being 400 mg albendazole and 6 mg/kg DEC and the other 
being 400 mg albendazole and 200 p.g/kg ivermectin) (Gyapong et al., 2005). 
Mathematic modelling supports the theory that transmission could be 
interrupted successfully using 4-6 years of repeated annual mass dosing of 
the available two therapies mentioned earlier (Stolk et al., 2003; Ottesen, 
2000; Molyneux and Zagaria, 2002).
In the case of onchocerciasis, the Onchocerciasis Control Programme 
(OCP) (WHO, 1974-2002) involved the use of insecticides on the fast flowing 
fresh water preferred by Simulium in 11 countries of West Africa (Tsalikis,
1993) for the first two decades of its existence. With the donation of 
ivermectin by Merck in 1987, the shift of the programme moved on to the
annual and semi-annual mass distribution of ivermectin, replacing the earlier 
spraying methods, which were problematic in forested areas. By the time the 
OCP had run its course in 2002, it had prevented 600,000 cases of blindness 
and allowed 18 million children to be born without the risk of blindness 
(Basanez et al., 2006). The work carried out by the OCP Is carried on by The 
African Programme for Onchocerciasis Control (APOC) that was launched in 
1995, and is due to cease in 2007, with the goal of eradicating the disease in 
non-OCP countries by a combination of annual ivermectin dosing schemes 
and environmentally-friendly vector elimination in a few isolated areas 
(Richards et al., 2001). APOC also works in partnership with NGDO, a 
Geneva based coordination group who share the goal of global control of 
onchocerciasis by mass distribution of ivermectin (Sékétéli et al., 2002). The 
achievements of the programmes over the years cannot be allowed to give 
way to complacency, as much remains to be done: there are stiil some areas 
in which O.volvulus infection remains not only of a high level but also 
widespread (Osei-Atweneboana et al., 2007), even after up to 19 years of 
annual ivermectin treatments. Another problem which researchers and 
programme workers need to be aware of is the possibility of drug resistance. 
Osei-Atweneboana et al., (2007) gathered evidence suggesting the 
emergence of drug-resistant parasites and although we must be mindful of 
this, it has been emphasised that this should not dissuade the programme 
from its yearly ivermectin dosing regime. While the current regime is adhered 
to, researchers are investigating other avenues of control of the disease,
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such as ani\-Wolbachia therapies (Basanez et al., 2006; Taylor, Band! and 
Hoerauf, 2005). When doxycyciine was administered at 100 mg per day for 6 
weeks, a reduction in Wolbachia accompanied by a subsequent disruption of 
embryogenesis of worms lasting 18 months was observed (Hoerauf et a!.,
2001). Another goal would be the generation of a macrofilariclde for 
O.volvulus, but at present there is no such drug available. The ultimate 
control measure would obviously be a vaccine, to complement ivermectin 
use, and there are currently several possible O.volvulus vaccine antigens for 
which there is great hope, and which have been proven to induce protection 
against O.volvulus infection (Nutman, 2002; Notez and Ferris, 2006).
1.1.4 Diagnosis of Disease
Diagnosis of lymphatic filariasis was, up until a short time ago, dependent on 
identifying the parasites in blood samples. The parasites display a periodicity 
which further complicates diagnosis, as blood samples would have to be 
taken late at night e.g. around midnight, or midday where diurnal periodicity 
is seen. This method’s sensitivity is affected by the fact that it would 
obviously not be able to diagnose amicrofilaremic patients. Regarding 
Bancroftian filariasis, this situation was Improved by the advent of enzyme- 
linked immunosorbent assays (ELISA) for circulating filarial antigen (More 
and Copeman, 1990). The rapid card test has proved invaluable, as this test 
is not restricted by the periodicity of the parasite as it detects circulating
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filarial antigen, requires no laboratory facilities, limited instruction and only a 
drop of blood (Weil et al., 1997). It is highly sensitive and specific (Simonsen 
and Dunyo, 1999), and has become the preferred method for mapping global 
endemicy by the Global Programme to Eliminate Lymphatic Filariasis 
(Molyneux and Taylor, 2001; Molyneux and Zagaria, 2002). Recently a rapid 
dipstick test for Brugian filariasis has been developed, which relies on the 
recognition of lgG4 antibodies instead of filarial antigen, and also comes in 
an ELISA form (Rahmah et a!., 2001a and 2003). This test shows very high 
sensitivity and specificity, and can also Identify most cases of W.bancrofti- 
caused lymphatic filariasis whilst showing no cross-reaction with other 
common helminth and protozoal parasites (Rahmah et al., 2001b). This test 
is not as straight forward as the card test, and therefore could not be used in 
lieu of a CFA test.
The classic method of diagnosis of human onchocerciasis is Identification of 
mf in a skin snip (WHO, 1995a), from which it is possible to produce a 
numerical value of microfiiadermia. New diagnostic methods would obviously 
be desirable due to the discomfort of skin snipping and the risk of HIV and 
other pathogen person-to-person transmission. The development of an array 
of recombinant filarial antigens has paved the way for immunodiagnosis of 
onchocerciasis (Ramachandran, 1993), but unfortunately this is unable to 
differentiate an active and past infection (Nutman et al., 1994). The unique 
repetitive Deoxyribose nucleic acid (DNA) sequence 0-150 (Harnett et al., 
1989) has been used as the basis of a polymerase chain reaction (PGR)-
1 2  -
based assay of skin snips (Zimmermann et al., 1994). These new techniques 
are as yet unfortunately still on the horizon when it comes to field diagnosis. 
Rapid epidemiological mapping of onchocerciasis (REMO) can give a rough 
assessment of endemic areas. A rapid epidemiological assessment (REA) 
involving the assessment of nodules on a sample of men (Taylor, Duke and 
Munoz, 1992) is carried out in communities that are deemed to be high risk 
due to ecology and behaviour of vectors (Ngoumou and Walsh, 1993). This 
information can then be used to grade the area as hypo-, meso- or hyper­
endemic, and a targeted mass ivermectin treatment of areas that fall into the 
latter two classifications can be carried out.
1.2 IMMUNOMODULATION OF THE HOST BY FILARIAL 
NEMATODES
In general, the perspective of researchers is that filarial nematodes are able 
to modulate the host’s immune system via the immunomodulatory 
excretory/secretory, or ES molecules they produce, ranging from enzymes 
and enzyme inhibitors, such as cystatins and serpins, to fatty acid and retinol 
binding proteins, to non-peptide structures e.g. PC on molecules such as ES- 
62, found in Acanthocheilonema viteae (discussed in detail later) (for reviews 
see Harnett and Parkhouse, 1995; Malzels, Blaxter and Scott, 2001). These 
products are purported to lead to the long lifespan of the worms, which can 
be in excess of five years (Subramanian et al., 2004). Infected individuals
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have been shown to display immune responses deemed “defective”, as they 
do not result in the eradication of the infection.
1.2.1 Helminth Immunomodulation of Humans
Although precise details of these alterations to the immune responses have 
yet to be agreed on, the general profile seen in humans, especially in 
asymptomatic patients, appears to be consistent with a T helper 2 (Th2)-like 
immunological phenotype. Extremely high levels - up to 95% immunoglobulin 
(lg)G4 are seen, coupled with a down-regulation of all other subclasses of 
IgG (Kurniawan-Atmadja et al., 1998, Kurniawan et al., 1993; Ottesen et al., 
1985). lgG4 normally only accounts for 5% of bloodstream antibody isotype, 
and is a somewhat useless antibody in this situation, due to its inability to 
activate complement or bind macrophages (m(|)) with high affinity, and also its 
tendency to be monovalent (Van der Winkel and Capel, 1993; Van Der Zee, 
Van Swieton and Aalbese 1986). lgG4 levels have been observed to reduce 
after treatment of infection with anti-filarial drugs (Atmadja et al., 1995). 
However, a similarity has been shown between the filarial antigen epitopes 
recognised by lgG4 and IgE, and it has therefore been proposed that lgG4 
may bind to sites recognised by IgE, thus blocking pathology, nematode 
killing, or a combination of both effected by this antibody (Hussain et al., 
1981). IgE levels are also found to be elevated in infected individuals, though
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this is much more pronounced in sufferers of chronic pathology (Kurniawan 
et al., 1993).
Those with heavy infections display a reduction in antigen-specific T cell 
responses (Greene, Fanning and Ellner, 1983; Yazdanbakhsh et al., 1993a) 
and high levels of Interleukin (IL)-4 accompanied by lowered levels of 
Interferon gamma (IFNy) and IL-5 (Nutman, Kumaraswami and Ottesen, 
1987; Mahanty et al., 1996a; Yazdanbakhsh et al., 1993b; Maizels et al., 
1995; Elson et al., 1995; Doetze et al., 1997; Sartono et al., 1997; Doetze et 
al., 2000) produced by peripheral blood mononuclear cells (PBMC) in 
response to filarial antigen. Increases are also seen in levels of IL-10 and 
Transforming growth factor beta (TGFp) at the microfilaraemic stage (Doetze 
et al., 2000; King et a!., 1993; Mahanty and Nutman, 1995).
The increase seen in IL-10 and TGFp would appear to be the main 
regulatory factor in repressing T cell proliferation, as proliferation was 
restored in cell culture when these cytokines had been neutralised (Doetze et 
al., 2000; King et al., 1993; Cooper et al., 2001). Anti-filarial chemotherapy 
has been shown to lead to not only the restoration of the antigen-specific 
proliferative response, but also a decrease in levels of IL-10 production 
(Yazdanbakhsh, van den Biggelaar and Maizels, 2001). The secretion of IL- 
10 and TGFp from PBMC of mf-positive patients indicated the involvement of 
a regulatory phenotype of T cell (Treg) in the down-regulation of IFNy and 
proliferative responses (King et al., 1993). Further evidence supporting a role 
for Tregs has been supplied by work undertaken on onchocerciasis (Doetze
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et al., 2000; Satoguina et al., 2002), leading to helminth diseases being 
thought of as Th2/Th3 type diseases.
1.2.2 Helminth Immunomodulation in Murine Models
In murine models, a similar pattern of immunoregulation is seen, with 
production of IL-4, IL-5, IL-10 and IL-13 by Th2-type CD4* cells, and often 
large amounts of IgE antibody (Fallon, Fookes and Wharton, 1996; Urban et 
al., 1996 and 2000; Finkelman and Urban, 2001). IL-10 production down- 
regulates IFNy (associated with Th1 responses) and has the ability to bring 
about immune anergy by reducing antigen presenting cell (APC) expression 
of Major histocompatability complex (MHC) and co-stimulatory molecules 
(Vella and Pearce, 1992; Cook et al., 1993; Van der Kiel] etal., 2002).
Murine models have been used to demonstrate that containment of the 
model filarial nematode Litomosoides sigmodontis relies upon CD4* T cells 
(Al-Qaoud et al., 1997). High levels of IL-4 are stimulated at different 
developmental stages of parasites: L3 Brugia were shown to induce IL-4 in 
various Inbred mouse strains (Osborne and Devaney, 1998; Lawrence et al., 
1995), and BALB/c mice implanted with adult Brugia also produced IL-4 
(Lawrence et al., 1994). IL-5 and IL-4 were shown to be crucial in 
establishing patency of an infection in BALB/c mice, as mf of L.sigmodontis 
survived longer and microfilaraemia was up to 100-fold higher if there was a 
deficiency in either cytokine (Maréchal et al., 1997; Le Goff et al., 2000). lL-5
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was also implicated In the control of worm development in primary infection 
in models of L.sigmodontis (Martin et al., 2000; Al-Qaoud et al., 2000; 
Volkmann et al., 2003). Transgenic mice designed to over-express IL-5 
displayed an increased capacity for parasite killing compared to wild-type 
(WT) when infected with L.sigmodontis (Martin et al., 2000), and increased 
parasite burden was observed In IL-5 deficient mice (Al-Qaoud et al., 2000; 
Volkmann et ai., 2003).
The mf loads of IL-4 deficient mice and IL-4 receptor a chain knock out (ko) 
mice, which are unable to respond to IL-4 or IL-13 were broadly the same 
(Volkmann et ai., 2003), making it seems unlikely that IL-13 contains mf in 
the absence of IL-4 in a compensatory way. The same study revealed IL-4R 
ko mice to harbour lower adult worm numbers in comparison to IL-4 ko and 
WT mice, and this finding has been reproduced by other groups (Nair and 
Allen, unpublished findings in Maizels et al., 2004). Nair and Alien also saw a 
T helper 1 (Thi) switch, which may allow for more efficient killing of the 
parasite, as IFNy has been shown to be crucial to control of the adult stage of 
the worm (Nair and Allen, unpublished findings in Maizels et al., 2004; 
Saeftel et al., 2001). Murine models have also hinted at a possible role for 
Treg cells, it has been suggested that IL-10, along with TGF(3, plays a role in 
reducing the Thi responses, as when these cytokines are neutralised in 
vitro, a partial recovery of proliferation and Th1 cytokine production is seen 
(Mahanty and Nutman 1995; King et ai., 1993; Ravichandran etal., 1997).
17
It Is natural to consider that Th2-type profiles induced by filarial nematodes 
and likewise other helminths may be brought about by APC, and Indeed 
there Is evidence for helminths and their products influencing these cells. 
Dendritic Cells (DC) matured in the presence of helminth products such as 
ES-62 (Whelan et al., 2000), as well as Schistosoma mansoni soluble egg 
antigen (SEA) (MacDonald et al., 2001) and the schistosome-associated 
sugar Lacto-A/-fucopentaose III (LNFPIII) (Thomas et al., 2003) as well as 
Nippostrongylus brasiliensis excretory-secretory antigen (NES) (Balic et al., 
2004) in vitro have been shown to induce Th2 responses. DCs pre-exposed 
to NES were unable to produce IL-12 in response to lipopolysaccharide 
(LPS), a bacterial product which stimulates Thi responses (Balic et ai., 
2004). Similarly, pre-exposure of DC to ES-62 has been shown to lead to 
increased IL-4 and reduced levels of IFNy when these cells were co-cultured 
with CD4^ T Cells (Whelan et al., 2000), discussed in more detail later. When 
mcj) are pre-exposed to ES-62, IL-6, IL-12 and TNFa responses to LPS are 
reduced (Goodridge et al., 2001), and similarly mcj) from Toxocara canis- 
infected mice have reduced IL-12 and TNFa production in response to LPS, 
though IL-6 levels remain the same (Kuroda et al., 2001).
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1.2.3 Molecules Produced by Filarial Nematodes and Their Effects on the 
Immune System
Immunomodulation resulting in a Th2 skew by glycans of both parasitic (e.g. 
B.malayl) and free-living nematodes (e.g. C.elegans) has also been reported 
(Tawill et al., 2004), even in the presence of complete freunds adjuvant 
(CFA), known to promote Th1 responses. This demonstrates the strength of 
the Th2 stimulatory potential of nematode glycans. It has been also recently 
been shown that Parelaphostrongyius tenuis synthesises and secretes 
glycans of a type not seen previously in nematodes. Due to the nature of 
these glycans being very similar to host glycans, it has been predicted that 
they are likely to aid evasion of the host immune system, rather than 
modulate its activity (Duffy et al., 2006).
There is somewhat limited knowledge at present on the immunomodulatory 
properties of lipids and lipid-associated moieties. Lyso-phosphatidylserine 
from schistosomes has been revealed to mature DCs in a way that leads to 
their induction of Treg cells that secrete IL-10 (Van der Kleij et al., 2002). 
This immune biasing seems to hinge upon a unique acyl chain that is absent 
in the mammalian host. The in vitro immunomodulatory capabilities of 
nematode glycolipids has been demonstrated (Deehan et ai., 2002), but the 
function of the lipid portions of these molecules has yet to be fully 
disseminated. It appears at present that much of the Immunomodulation 
associated with these glycolipids is related to the PC moiety (Deehan et ai.,
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2002). PC is also present on the glycoconjugates of different species of 
nematode (Haslam et al., 1999), attached via a phosphodiester linkage with 
GlcNAc in glycolipids and /V-glycans in proteins (Houston and Harnett, 2004). 
ES-62, from A.viteae is a prime example of a nematode-derived glycoprotein, 
and one of the most fully investigated molecules to date (discussed in detail 
later). There are, of course, many other immunomodulatory molecules 
produced by helminths. The interested reader is directed to reviews by 
Hartmann and Lucius (2003), Knox (2007), McDermott, Cooper and Kennedy 
(1999) and Maizels etal. (2004).
1.2.4 The Impact of Nematode Infection on Other Concurrent Infections
Due to the longevity within, and the immunomodulation of the host seen with 
filarial nematode infection, it is only natural to investigate the impact of the 
filarial-infected host immune phenotype on concurrent infections with other 
diseases. In most cases investigated, the results are difficult to interpret, and 
are often conflicting.
Malaria Is a disease that often occurs concurrently with helminth infections, 
as the regions where both types of disease are prevalent often overlap. 
Evidence gathered from studies of co-infections of malaria and helminths has 
indicated the development of a protective response against malaria to be 
decreased by helminth infection, which induces a Th2 phenotype (Nacher et 
al., 2002; Speigel et ai., 2003). Ascaris infections appeared to be linked to
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higher incidences of severe malaria in one study (Le Hesran et a i, 2004), 
whilst others found infection with the same causative agent to protect against 
cerebral malaria (Nacher et a i, 2000) or renal failure (Nacher et ai., 2001). A 
possible mechanism explaining helminths protection against cerebral malaria 
is the induction of the cytokines IL-10 and/or TGFp by helminths (Mahanty et 
a i, 1996b), which might serve to suppress the pro-inflammatory cytokines 
associated with cerebral malaria (Good et a i, 2005; Day et a i, 1999), 
decreasing the risk of severe malarial disease. When mice infected with 
L.sigmodontis were infected with Piasmodium chabaudi, the levels of severe 
malarial immunopathology and IFNy responsiveness of spleen cells to 
polyclonal stimulation was observed (Graham et ai., 2005). If mice were at 
the stage of helminth infection associated with immunomodulation 
(microfilariae positive), a reduction in the severity of the malaria was seen for 
a given parasite load. Pre-treatment of CBA/J mice with irradiated B.malayi 
larvae lessened the extent of P.berghei-Muced cerebral malaria, but 
anaemia worsened, and all mice died at a later time point (Yan et a i, 1997). 
The evidence from these studies provides support for the theory that 
helminth infection can impact on malarial disease. The differences between 
studies highlights the need for more work to be carried out in this field, with 
standardised methodologies, if concrete conclusions about the nature of 
these impacts are to be drawn.
Tuberculosis is another disease in which helminth co-infection has been 
investigated. One theory proposes that a helminth infection will hinder the
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powerful mycobacterium-specific Th1 response associated with protection, 
by either promoting an anti-inflammatory response, or by upsetting the 
Th1/Th2 balance. Many years ago, Prost, Nebout and Rougemont (1979) 
showed areas of onchocerciasis hyperendemicy to have double the 
incidence rate of lepromatous leprosy caused by mycobacterium leprae. 
Since then, decreased IL-4 production in response to mycobacterial antigens 
ex vivo by PBMC from onchocerciasis patients has been demonstrated 
(Stewart et al., 1999). At this point, not many epidemiological studies have 
been carried out, but in vitro experiments have provided information 
supporting the notion that helminths are capable of dampening the immune 
response to mycobacterial infections. When DCs and mcj) were pre-exposed 
to live microfilariae from B.malayi, it appeared to result in an inability of these 
cells to mature upon subsequent tuberculosis infection (Talaat et al., 2006). 
This study also indicated down-regulation of the DC-specific ICAM3-grabbing 
non-integrin (DC-SIGN) on DC surface. As this lectin receptor is required by 
Mycobacterium tubercuiosis for entry to DCs, filarial infected DCs may be 
less likely to be infected. As with malaria, more well-designed 
epidemiological studies into the immunomodulation in concurrent helminth- 
tuberculosis infections would be necessary to investigate the nuances of 
these organisms effects on one another, and to determine where the in vitro 
results would fit in to an in vivo situation.
HIV is a huge problem in the world today, and as HIV decreases the 
effectiveness of the immune system, it is a logical step to Investigate the
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impact of helminth infection on this disease. Again, the results are not very 
clear-cut. Hookworm infection appears to slow HIV disease progression, as 
measured by lower mortality and increased CD4 counts (Brown et al., 2004). 
Another study showed hookworm infection to have a negative association 
with susceptibility to HIV infection (Nielsen et al., 2006). The same study 
indicated infection with W.bancrofti to be positively associated with HIV 
infection. As is the case with helminth infection and the other diseases 
discussed, more studies would need to be carried out in order to more fully 
unravel the nature of the associations between helminth infections and other 
diseases.
1.3 ES-62
1.3.1 ES-62: A Brief History
ES-62 is a well-characterised secreted immunomodulatory molecule, first 
discovered in A.viteae, a filarial nematode of the gerbil, some 18 years ago 
(Harnett et ai., 1989). When the molecule was analysed under reducing and 
denaturing SDS-PAGE, it was discovered to have a molecular mass of 
approximately 62000 (Harnett et al., 1989), hence the name it was given. 
However, subsequent gel filtration analysis (Harnett et al., 1993) and 
sedimentation equilibrium data (Ackerman et ai., 2003) both provided 
evidence that the secreted molecule is found as a tetramer in its native form.
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ES-62 is without doubt the most abundant constituent of the ES products 
secreted by A.viteae being over ninety percent of the total protein secreted 
by adult worms (Harnett et al., 1989). Production has been shown to be 
restricted to the L4-adult stages of the parasite (Harnett et al., 1989), with the 
adult female worm being capable of generating 0.038pg~0.092pg h'^  
(Goodridge et ai., 2001).
The molecule is not unique to A.viteae. Homologues of ES-62 have been 
found not only in the feline filarial nematode Brugia pahangi, but also in the 
human filarial nematodes B. malayi and O. volvulus (Nor et al., 1997; Stepek 
et al., 2002), and ES-62 has been cloned from cDNA libraries of B.malayi 
(Stepek et al., 2004). This strongly suggests that ES-62 is active during 
infections of humans with filarial nematodes, making the study of this 
molecule and its effects on the immune system prudent.
ES-62 was originally found to share 37-39 % homology with seven proteins: 
murine (Genbank sequence no. 5442032) and human (7706381) 
aminopeptidase, rat liver annexin-like protein (7108713), human (5174527) 
and murine (9055234) plasma glutamate carboxypeptidase, mouse 
hematopoietic lineage switch 2 protein (9055234) and rat hematopoietic 
lineage switch 2 related protein (3851623) (Ackermann et al., 2003; Harnett, 
Harnett and Byron, 2003). In recent years, however, this family has been 
extended dramatically. These proteins have been proposed to belong to the 
same family, and possibly to have related structures and functions by 
sequence alignment. Consistent with this, ES-62 has been shown to possess
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aminopeptidase activity by in vitro experiments involving synthetic substrates 
(Harnett et ai., 1999b).
Biophysical analyses of ES-62 indicate the molecule to consist of 40 % a- 
helix, 16 % (3-sheet, 16 % |3-turn and 28 % unordered structure, as predicted 
by circular dichroism (CD) spectroscopy (Ackermann et ai., 2003). The 
biophysical analyses also suggested ES-62 to be a tightly bound tetramer 
formed from dimers (Ackermann et ai., 2003).
1.3.2 ES-62 and Glycans
Polyclonal rabbit anti-ES-62 was used to clone the full-length parasite 
derived molecule from an adult female A.viteae cDNA library (Harnett et al., 
1999b). ES-62 was found to be comprised of 474 amino acids (AA) with a 
molecular mass of 52.8 kDa and an isoelectric point of 5.96, by a 
combination of sequence analysis of the clone, and N-terminal AA 
sequencing and Q-TOF sequencing of tryptic peptides of native ES-62 
(Harnett et al., 1999b). When the PRINTS/PROSITE scanner was used to 
analyse the protein for conserved motifs, four potential /V-linked glycosylation 
sites were revealed in the ES-62 precursor (Harnett et al., 1999b). One of 
these sites is contained within the signal sequence and will therefore not be 
present on the mature protein. ES-62 has always been suspected of 
containing glycans, as the molecule was readily biosynthetically labelled with 
tritiated ([^H]) glucosamine soon after discovery (Harnett et al., 1989).
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Investigations into the nature of these glycans involved observation of the 
interactions of ES-62 with a panel of lectins (Harnett et a i, 1994) and 
digestion attempts using various glycosidases (Harnett et a i, 1993, Harnett 
et a i, 1994). These studies indicated that the glycans attached to ES-62 
were A/-type and probably high mannose, but yielded no evidence for the 
presence of any 0-type glycans. Fast atom bombardment mass 
spectroscopy (FAB-MS) also suggested a lack of O-type glycans, but 
revealed ES-62 to contain three types of A/-glycan (Haslam et a i, 1997). 
These types of A/-glycan were high mannose, as predicted by earlier studies; 
a truncated form, fully trimmed to its trimannosyl core and sub- 
stoichiometrically fucosylated and a form which had between one and four 
additional A/-acetylglucosamine (GlcNAc) residues on a trimannosyl core with 
and without fucosylation (Haslam et a i, 1997). The latter mentioned type of 
A/-glycan is the type to which it is proposed that PC is added (Fig. 1.7B 
mentioned later).
1.3.3 ES-62 and the Immune System
Over the years, ES-62's immunomodulatory effects on various different cell 
types of the immune system have been well-documented. Researchers 
accept that the early cytokine environment in which naïve CD4^ T cells 
interact with antigen can influence the phenotype of the resultant acquired 
immune response. Thus, it has been suggested that an immune response of
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a Th2 nature can be elicited by early exposure to IL-4 (Swain et al., 1990). 
Given its Th2-inducing properties, when ES-62's ability to induce IL-4 from 
naïve murine spleen cells was investigated, it was confounding to discover 
that none could be detected (Harnett et al., 1999a). This result was surprising 
given the ability of subcutaneousiy injected ES-62 to bring about a purely 
IgGI response in BALB/c mice, consistent with the theory that it produces a 
Th2 response. IL-4 production was observed in response to ES-62 by 
spleens from mice which had been pre-exposed to the parasite molecule, 
however, which indicated ES-62 to have tipped the balance of the re-call 
immune response in favour of a Th2 phenotype (Harnett et al., 1999a). The 
highly biased IgGI response is not seen In IL-4 knock-out (ko) mice, 
confirming the cytokine's importance in this response. However, the IL-4 ko 
mice do not, as seen in reaction to adult B.malayi (Lawrence et ai., 1995), 
produce any lgG2a response in way of compensation; therefore IL-4 does 
not block the lgG2a response. It would seem ES-62 blocks Th1 responses by 
some other mechanism, or does not generate this type of response. When 
ES-62 is injected into IL-10 ko mice, a mixed lgG1/lgG2a response is seen, 
implicating this cytokine in the suppression of an lgG2a response. Consistent 
with this, ES-62 has also been proven to induce IL-10 in naïve BALB/c 
spleen cells (Wilson et al., 2003).
DCs may have the ability to influence the differentiation of T cell function, due 
to their role as professional APC that are required for the priming and 
activation of CD4^ cells (Banchereau and Steinman, 1998). It was for this
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reason that ES-62's ability to mature DCs was investigated (Whelan et a i, 
2000). To assist in the determination of the effects of ES-62 on the 
maturation of DCs, the well-characterised in vitro Th cell assay involving 
CD4^ cells from the DO.11.10 transgenic mouse expressing a T-cell receptor 
(TCR) specific for an ovalbumin (OVA) peptide (Hsieh et ai., 1993). Naïve 
CD4^ cells from this system secrete more IFNy, than IL-4 when they are 
cultured with bone marrow derived DCs (bmDCs) that have been matured in 
the presence of LPS. When bmDCs were matured in the presence of ES-62, 
the cytokine profile shifted to a Th2-type phenotype, with a decrease in IFNy 
and an increase seen in the levels of IL-4 (Whelan et a!., 2000). It would 
appear that ES-62 has the ability to mature DCs in such a way that they are 
able to drive a Th2 response to unrelated antigens.
Co-cultures of ES-62-matured DCs with naïve CD4^ T cells from the 
DO. 11.10 system secrete IL-12, which is rather strange given that this is a 
Thi-promoting cytokine (Whelan et ai., 2000). The levels seen, however, are 
roughly one quarter of those seen in co-cultures of LPS-matured DCs with T 
cells of the same system (LPS being a constituent of bacterial cell walls 
which induces Th1 responses). As mentioned briefly earlier, mcj) are also 
found to transiently produce a small amount of IL-12 when stimulated by 
administration of ES-62. This initial production of IL-12 leaves the cells 
unable to produce the considerable amounts of IL-12, IL-6 and TNFa in 
response to classical stimulators such as LPS (Goodridge et al., 2001). As
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IL-12 is crucial for mounting a pro-inflammatory response, these m(}> are left 
unable to respond in a pro-inflammatory manner to any further stimuli.
There is much evidence for ES-62 having the ability to stop cells from being 
able to react to stimuli. ES-62 leads to B-cell anergy, by preventing antigen- 
receptor-llgation associated B cell proliferation (Harnett and Harnett, 1993), 
and is able to inhibit antigen receptor stimulated polyclonal activation of the 
human T cell line Jurkat (Harnett et al., 1998), as discussed later.
Using osmotic pumps for continuous release, it has also been shown that 
ES-62 in vivo results in a reduction In the proliferative response of murine 
spleen cells to T cell stimulants ex vivo (Wilson et ai., 2003). The 
immunomodulatory effects of ES-62 known to date are summarised in figure 
1.6 .
1.4 ES-62 AND PHOSPHORYLCHOLINE (PC)
1.4.1 PC
PC (Fig. 1.7A) is an important molecule found both in vertebrate and 
invertebrate eukaryotes, where it is present in the phospholipids, 
phosphatidylcholine and sphingomyelin, in the form of the polar head group. 
It is well known for its strong immunogenicity, which makes it ideal for
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studying the production and heterogeneity of an antibody response (Lee, 
Cosenza and Kohler 1974; Sigai, Gearhart and Klinman, 1975). It is also a 
major component of bacteria, where it is used not only for “housekeeping”, 
i.e. maintenance of cell shape, size and physiology (e.g. Streptococcus 
oralis: Horne and Tamasz, 1993), but seems to have several other distinct 
immunological properties. It has been used as a virulence factor, for example 
Cundell et al. (1995) showed bacterial surface-PC interaction with the 
Platelet Activating Factor (PAF) receptor on human endothelial cells to be 
crucial to their subsequent invasion. Conversely, IgM and IgGa antibodies 
generated against encapsulated PC-containing WU2 strain of type 3 
Streptococcus pneumoniae have been shown to be protective in mice (Brtles 
et al., 1981a and b), and rodent filarial nematode models have also provided 
information suggesting that this surface PC is targeted by the body to mount 
an IgM (protective) response against infective larvae (Al-Qaoud et al., 1998).
1.4.2 PC and Nematode Glycoproteins
The ES molecules released by parasites are often PC-containing 
glycoproteins (reviewed by Houston and Harnett, 1999a), and, as mentioned 
above, PC is also present on the surface of the infective stage (L3) of filarial 
nematodes. Many of the immunological effects exerted by ES-62 can be 
attributed to the PC moiety (discussed later), which is found attached to N- 
linked carbohydrate chains (Harnett et al., 1993).
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As found with bacteria, PC appears to be employed by filarial nematodes not 
only for survival, but also for virulence. Studies on A.viteae and B. pahangi 
(Houston and Harnett, 1996 and Nor et ai., 1997 respectively) have found PC 
containing glycoproteins to be a common component of internal structures in 
filarial nematodes. These seem to be distinct from those molecules which are 
excreted, as their molecular mass, synthesis rate and vulnerability to N- 
glycosidase cleavage differ from the excreted PC-glycans; suggesting that 
PC employed internally is essential to free-living. Further evidence for the 
theory that PC found internally in nematodes is unlikely to be related to 
parasitism has been provided by studies revealing PC to be present on the 
glycoproteins of C.eiegans', the free living nematode often used as a model 
(Gerdt et al., 1999, Houston and Harnett, unpublished results).
1.4.3 The Location and Nature of Attachment of PC to ES-62 and Other 
Nematode Glycoproteins
Twenty years ago, preliminary studies indicated that the PC moiety on filarial 
ES products might be attached to carbohydrate structures. Maizels, Burke 
and Denham (1987) discovered that an anti-PC mAb was unable to 
recognise Brugia species PC-containing molecules once they had been 
subjected to treatment with alkall/borohydrate. Evidence in support of this 
was obtained with successful biosynthetic radiolabelling of the PC-ES
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products of A.viteae (Harnett et a!., 1989), Onchocerca gibsoni (Harnett et 
al., 1994), and B.pahangi (Nor et al., 1997) with [^H]-glucosamine, the amino 
sugar. Investigation of the binding of filarial ES products containing PC to a 
panel of lectins strengthened this argument (Harnett et al., 1994; MacDonald, 
Copeman and Harnett, 1996) and started the process of defining the nature 
of these sugars. O.gibsoni-derWed material was suggested to contain both 
0-linked and possibly hybrid or complex /V-linked glycans (MacDonald, 
Copeman and Harnett, 1996), due to its interaction with peanut agglutinin 
(PNA) and Datura stramonium agglutinin (DSA). PNA binds the core 
disaccharide galactose (Gal)-|3(1-3)-GalNAc (and so recognises 0-linked 
chains, Goldstein and Hayes, 1978). DSA recognises Gal |3(1-4)-GlcNAc in 
complex and hybrid /V-glycans, and GlcNAc in O-glycans (Crowley et al., 
1984).
ES-62 appeared to contain high mannose structures (Harnett et al., 1994), 
due to the molecule’s recognition by Galanthus nivalis agglutinin (GNA), 
which binds terminal mannose residues a(1-3)-, (1-6)- or (1-2)-linked to 
mannose (Shibuya et al., 1988). The molecule was also recognised by 
concanavalin A (Con A), which recognises a-mannose and a-glucose 
(Goldstein, Hollerman and Merrick, 1965). /V-type glycans were also 
indicated by digestion of ES-62 by /V-glycosidase F (Harnett et al., 1993), 
and this enzyme digestion also indicated this type of glycan to be present on 
B.pahangi ES products (Nor et al., 1997). The presence of /V-glycans on both 
of these ES products was also suggested by the ability of tunicamycin, an
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antibiotic which inhibits the precursors of all N-Xype glycans (reviewed by 
Elbein, 1987) to inhibit PC attachment to ES-62 (Houston and Harnett, 1996) 
and both PC and glycan attachment to B.pahangi ES (Nor, Devaney and 
Harnett, 1997).
1.4.4 ES-62 and PC: Effects on B-ceiis
Since the discovery by Bach, Kohler and Levitt (1983) that a percentage of 
both human and murine B cells contain a non-immunoglobulin (Ig) receptor 
for PC, it has been elucidated that polyclonal antibody production arises 
when the receptor interacts with PC on S. pneumoniae (Beckmann and 
Levitt, 1984). The PC-containing immunomodulatory molecules excreted by 
filarial nematodes also seem to interact with this receptor: concentrations of 
ES-62 far above that of PC-containing molecules found in the bloodstream of 
filariasis patients lead to induction of low levels of B cell activation, as 
measurable by DNA synthesis, whereas concentrations comparable with the 
levels seen In patients’ bloodstream serve to prevent antigen-receptor- 
ligation associated B cell proliferation (Harnett and Harnett, 1993). The PC 
moiety of ES-62 would appear to be the cause of this, as PC conjugated to 
proteins such as albumin, and indeed PC alone can mimic ES-62’s activity in 
this situation. It was also found that PC-bovine serum albumin (BSA) injected 
on a weekly basis could decrease recovered B cell antigen-receptor-ligation
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associated activation (Harnett et al., 1999a): these data taken together 
suggest that the low levels of PC associated with the concentration range of 
PC-containing molecules in filariasis patients’ bloodstream seen clinically 
could be responsible for B-cell anergy, which could be a contributing factor in 
the well-documented immunomodulation associated with the molecules. ES- 
62 is able to anergise B cells by uncoupling the B Cell Receptor (BCR) from 
the ErkMAPKinase signalling cascade by targeting two major negative 
regulatory sites within the cascade (Fig. 1.8), the effect of both of these 
negative regulatory sites being targeted is a rapid, high level of 
desensitisation of the BCR coupling to the RasErkMAP kinase cascade 
(reviewed by Harnett and Harnett, 2001).
1.4.5 ES-62’s Immunomodulatory Effects on Other Cell Types can be 
Tentatively Ascribed to the PC Moiety
Although ES-62’s ability to induce IL-10 in naïve BALB/c spleen cells (Wilson 
et a i, 2003) has not yet been confirmed to be due to PC, previous evidence 
demonstrating B1 cells producing IL-10 in response to PC (Palanivel et a i, 
1996) suggests it may be the cause. As mentioned earlier, In BALB/c mice, 
ES-62 administration causes a highly biased IgGI response, consistent with 
the theory that it produces a Th2 response. (Harnett et ai., 1999a). When ES- 
62 was injected into IL-10 ko mice, an lgG2a response was observed,
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producing evidence that the PC portion of ES-62 was capable of blocking an 
lgG2a (Th1) response, possibly through inducing IL-10, which is able to 
down-regulate IFNy (the cytokine largely responsible for antibody class 
switching to lgG2a in mice (Bogdan et a i, 1992)).
Yet ES-62 produced with no PC attached (discussed later) injected into 
BALB/c mice induces a Th1/Th2 mixed response: lgG1/lgG2a (Houston, et 
al., 2000). It seems therefore that PC, in part at least, is responsible for 
blocking this lgG2a response and consistent with this, when PC was 
conjugated to BSA, it appeared to inhibit the albeit weak lgG2a response to 
BSA (Houston et al., 2000).
As mentioned earlier, ES-62 is also able to inhibit antigen receptor stimulated 
polyclonal activation of the human T cell line Jurkat (Harnett et al., 1998). 
Once again, evidence suggests this is caused by PC (Harnett et al., 1999a) 
and this is consistent with research showing B.malayi PC-containing 
molecules to be capable of non-specific inhibition of activation of human T 
lymphocytes (Lai et al., 1990). It Is not yet known If PC has a part to play in 
ES-62's ability to reduce the proliferative response of murine spleen cells to 
T cell stimulants ex vivo after in vivo exposure to ES-62 using osmotic pumps 
for continuous release (Wilson et ai., 2003).
it would appear that ES-62 is a complex immunomodulatory molecule with 
many effects across the different elements of the immune system ranging 
from modulation of B Cells, DCs and mcj) to antibody and cytokine production.
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It has recently been shown by Good ridge et al. (2005) that ES-62 appears to 
exert its immunomodulatory effects on m(j) and DCs through Toll-like receptor 
(TLR) 4 in a unique way. It was found that the ability of ES-62 to induce low 
levels of IL-12 from these cell types (Goodridge et a!., 2001; Whelan et a!., 
2000) was abrogated in m(j> and DCs from both Myeloid differentiation factor 
88 (MyD88) ko and TLR4 ko mice, suggesting TLR4 as a receptor for ES-62 
and implicating MyD88 in the intracellular signalling that follows, interestingly, 
ES-62 was able to exert its normal effects in C3H/HeJ mice, which have a 
mutation in the Toll Interleukin I (TIR) domain, making them unresponsive to 
LPS (Poltorak et a!., 1998). It would seem that ES-62 signals through TLR4 
in a non-classical manner. There is therefore a possibility that TLR4 is the 
non-lg receptor for ES-62 in B-cells (mentioned earlier).
1.5 ES-62 and Auto-immune/Allergic Diseases
1.5.1 The Hygiene Hypothesis
In the West, increased affluence often leads to people living cleaner lives, 
with children growing up with decreased contact with infectious agents such 
as helminth parasites. The Hygiene Hypothesis suggests the infectious 
agents we are exposed to have played a part in maturing our developing 
immune systems, and that our new, cleaner lives could lead to the immune 
system of a child not receiving the appropriate priming (Strachan, 1989). The
3 6
original hypothesis focussed on the ability of microbial infections to hinder 
allergies characterised by a Th2 profile (reviewed by Herz et al., 2000). 
Recently, the hypothesis has been expanded, investigating the possible link 
between a lack of helminth infections and the recent increase in diseases 
associated with unsuitable immune responses, e.g. asthma and type I 
diabetes. There has not been as marked an increase in frequency of allergic 
disorders in geographical areas with a high parasite load (Yazdanbakhsh, 
Kremsner and van Ree, 2002), and incidence and severity of a number of 
autoimmune diseases has been observed to be lower in regions with a high 
rate of helminthiasis (Sewell et al., 2002). Rheumatoid arthritis (RA), for 
example, has been shown to be reduced in filarial nematode-endemic 
regions, indicating environmental factors to play a part in altering 
development of the disease (Beighton, Solomon and Valkenburg, 1975; 
Dunne and Cooke, 2005). Groups such as Araujo et al., (2000) and Nyan et 
al. (2001) have verified the inverse relationship between worm-infection and 
allergy. Further evidence for this relationship has been provided by studies 
involving children of school-age infected with Ascaris in Equador (Cooper et 
al., 2003) and children with hookworm in Ethiopia (Dagoye et al., 2003). 
Such evidence lends weight to the hygiene hypothesis. In fact, data 
implicating helminth infection in the impediment or prevention of on-set of a 
wide range of autoimmune or allergic disorders is rapidly mounting.
3 7
1.5.2 Helminth Infection and Autoimmune/Allergic Disease
Animal disease models have corroborated this link between parasite infection 
and auto-immune disease: diabetes and experimental autoimmune (formerly 
allergic) encephalomyelitis (EAE) have been shown to be decreased by 
S.mansoni infection (Cooke et al., 1999, La Flamme, Ruddenklau and 
Backstrom, 2003 respectively). Perhaps not surprisingly, diseases which 
involve inflammation of the gut, can be treated with infection with the 
tapeworm Hymenolepis diminuta (Reardon et al., 2001) and the 
gastrointestinal nematode Trichinella spiralis (Khan et al., 2002) in the case 
of experimental colitis, Heligmosomoides polygyrus inhibits inflammatory 
bowel disease (IBD: Elliott et al., 2004). Treatment of human IBD with 
Trichuris suis (a whipworm whose natural host is the pig, and which cannot 
infect humans productively) has also proved effective (Weinstock, Summers 
and Elliott, 2005), with little evidence of side effects (Summers et al., 2003). 
T.suis has also been shown to exert considerable effects against Crohns’ 
Disease in almost 80 % of patients, and was also effecting against Ulcerative 
colitis, though not in as impressive a manner (Summers et al., 2003 and 
2005). There are also trials involving ascertaining the effectiveness of the 
human hookworm Necator amerlcanus against Crohns’ disease (Croese et 
al., 2006). The situation with helminths and autoimmune diseases is mirrored 
by that of heiminths and allergic disease: H.polygyrus infection has been 
shown to decrease food allergies (Bashir et al., 2002), and likewise airway
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allergies have been shown to be inhibited by infection with Strongoloides 
Stercoralis (Wang et al., 2001). Airway ailergies have also been shown to be 
reduced by infection with N.brasillensis, provided infection was at least two 
weeks prior to challenge (Wohlleben et al., 2004).
Naturally, there is still justified wariness of the use of live worm infection to 
treat conditions: such autoimmune intervention strategies are in their infancy, 
and much more work would need to be done to clearly define what, if any 
adverse effects instigating parasite infection may have. It must be borne in 
mind that such organisms still account for much morbidity in developing 
countries. It may not be wise, for example, to use this strategy in patients 
who are immuno-compromised or -suppressed. There is evidence that the 
immunomoduiation that arises from parasite infection may affect the anti­
tumour responsiveness of treated individuals (Borkow and Bentwich, 2000; 
McElroy etal., 2005; Bentwich, 2003).
1.5.3 Helminth-derived Products and Autoimmune/allergic Disease
A strategy with more mileage involves the utilisation of non-infective 
helminth-derived products, which can bring about the same effects as the 
organism they originate from without the risk of an uncontrolled infection. 
More advantageous still is the possibility that such products, or chemically 
synthesised versions of them may afford more control over 
immunoregulation. Several examples of this type of research already exist
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within the literature; Including the treatment of diabetes with S.mansoni eggs 
(Cooke et ai., 1999; El-Wakil et al., 2002) and soluble S.mansoni egg and 
worm products (Zaccone et al., 2003), and EAE can also be treated with 
S.mansoni eggs (Elliott et al., 2003). Likewise, S.mansoni eggs have been 
found to be beneficial in the case of experimental colitis (Elliott et a i, 2003).
1.5.4 ES-62 and Autoimmune/allergic Disease
As ES-62 has been shown to be an anti-inflammatory, Th2 inducing 
molecule, which produces these responses not only to itself, but also against 
heterologous antigens (Houston et a i, 2000; Marshall et a i, 2005), the effect 
of the molecule against arthritis was investigated. To this end, the 
prophylactic properties of ES-62 on the development of collagen-induced 
arthritis (CIA) in DBA/1 mice was ascertained (Mclnnes et ai., 2003b). The 
severity of developing CIA was significantly reduced in subjects pre-treated 
with the parasite molecule. This inhibition occurred concurrently with a 
suppression of collagen-specific lgG2a antibodies and an inhibition of 
collagen-specific TNFa, IL-6 and IFNy (proimflammatory/ThI cytokine) 
production. ES-62 significantly depressed the severity of developing CIA 
when given during type II collagen (CM) priming and intraperitoneal (i.p.) 
challenge, and continued treatment with ES-62 also lead to depression of 
articular disease. When the possible mechanisms by which ES-62 was 
achieving the effect were probed, it was discovered that the molecule was
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able to reduce the levels of Cll-induced IFNy, TNFa and IL-6, whilst 
enhancing Cll-induced IL-10 production from draining lymph nodes. This 
manipulation of immune responses by ES-62 was found to be specific as the 
levels of IFNy, TNFa and IL-5, as well as proliferation induced by Con A, 
analysed in tandem, remained unchanged. It would appear that ES-62's 
suppression of Cll-specific responses contributes to the molecule’s ability to 
significantly decrease the severity of developing CIA.
A significant reduction of arthritis progression in comparison to the vehicle- 
treated controls was observed when ES-62 was used therapeutically, once 
the disease was clinically detectable. This was measured by the number of 
subsequently recruited arthritic joints and slowed progression of articular 
swelling in the initially inflamed joint. Furthermore, ES-62 treatment led to a 
significant suppression of progressive articular inflammation and destruction 
(synovial hyperplasia and of cartilage and bone erosion) (Mclnnes et al., 
2003b and 2003a). The immunomodulatory effects exerted by ES-62 
remained very similar in the therapeutic experiments: when draining lymph 
nodes of subjects 24 h after ES-62 treatment had been completed were 
investigated, Cll-induced IFNy production had been significantly decreased in 
comparison to controls. ES-62 treatment appeared to have ablated Cll- 
induced TNFa and IL-6 production. The pro-inflammatory versus anti­
inflammatory cytokine bias was clearly shifted in the anti-inflammatory 
direction, as although Cll-induced IL-10 production was decreased, it was 
still readily detectable. Again, the effects of Con A stimulation remained
41
comparable in ES-62 and control groups. As observed in prophylactic use of 
ES-62, levels of Cll-specific lgG2a in the serum were significantly less in the 
treated group, demonstrating ES-62 to be capable of specific and effective 
reduction of established Th1 responses. Taken together, these data build a 
convincing case for the role of the immunomoduiation caused by ES-62 in 
the suppression of the progression of articular Inflammation in vivo.
In an effort to extend these findings from experimental to clinical 
observations, samples from arthritic patients were taken and compared to 
controls. When co-culture of cells from the blood of normal and RA human 
donors with myelomonocytic THP1 cells with and without ES-62 was 
compared, pre-exposure to the parasite molecule resulted in significantly less 
TNFa release compared with that of the controls. This appeared to be 
Independent of IL-10, indicating a difference in mechanism to that proposed 
for the murine model. When primary cultures derived from RA synovial fluid 
and membrane were carried out with and without ES-62, ES-62 was able to 
significantly decrease the levels of TNFa and IL-6 inducible by LPS, and this 
too was shown to be independent of IL-10 (Mclnnes et al., 2003b). These 
human studies eloquently illustrate ES-62's facility to interfere with crucial 
pro-inflammatory pathways ex vivo in the tissues affected by disease in RA. 
ES-62 has also been shown to be active in models of Systemic Lupus 
Erythematosus (SLE) and asthma, though not in the nod mouse model of 
diabetes (personal communication, WH). Clearly, there is much scope for the 
use of ES-62 in both a prophylactic and a therapeutic capacity for several
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diseases associated with aberrant immune regulation. It is of interest to our 
group to elucidate ES-62's mechanism of modulation as it couid contribute 
Invaluable information to enhance the search for therapeutics which mimic 
nematode ES-62'a anti-inflammatory properties for inflammatory diseases 
such as RA (discussed earlier) and to accurately pin-point the portions of the 
molecule responsible for these functions, with a view to identifying possible 
drug candidates for future therapies. There is much evidence showing many 
of the effects of ES-62 to be mimicked by PC alone, or PC conjugated to 
inert proteins such as OVA and BSA (discussed earlier). One avenue, 
therefore, to exploring possible drug candidates is to determine the extent of 
the role of PC in ES-62's immunomodulatory activities.
1.6 PC-Free ES62
1.6.1 Previous Methods of Producing PC-free ES-62
A method of producing PC-free ES-62 has been long sought-after by 
Professor Harnett's group. Success in this endeavour would help in 
examining the contribution of PC to the effects of ES-62 on the immune 
system. Another reason for interfering with the addition of PC to ES-62 was 
to determine the nature and location of this post-translational modification, 
i.e. what enzyme is responsible for it, and where in the secretory pathway 
does it take place, with a view to possible chemotherapy. As PC is an
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immunomodulatory epitope present on the ES products of many filarial 
nematodes (as mentioned earlier), it was hypothesised that prevention of the 
attachment of PC would lead to a decrease in the length of time the parasites 
would be able to survive in the host. Discovering how to remove PC from ES- 
62/prevent its attachment would also give a good indication of what 
structures on the molecule the PC is attached to.
1.6.1.1 The Use of Enzymes and Lectins to Probe the Nature of the 
Carbohydrate Structures to which PC is Attached to ES-62
As discussed earlier, evidence was gathered which suggested the PC moiety 
to by attached to ES-62 via an A/-linked glycan. /V-glycosidase F digestion of 
not only pH]-glucosamine-, but also f  H]-choline-labelled ES-62 led to a loss 
of radioactivity (Harnett et al., 1993; Houston and Harnett, 1999a) O- 
glycanase, on the other hand, was shown to have no such effect on pH]- 
glucosamine-labelled ES-62 (Harnett et al., 1993), implying ES-62 to contain 
no O-type glycans in its structure. Unfortunately, studies designed to more 
fully elucidate the nature of the /V-glycan structures did not provide any 
further data, as the enzymes chosen, endoglycosidases D, F and H failed to 
act on ES-62 (Harnett et al., 1994), though they were able to rule out the 
presence of the glycan structure targets of these enzymes on ES-62.
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1.6.1.2 Attempts to Produce PC-free ES-62 Using Various Inhibitors
A myriad of inhibitors has been employed over the years in an attempt to 
identify the enzyme/pathway responsible for addition of PC to ES-62, and 
where in the secretory pathway this occurs. As mentioned earlier, PC 
addition to ES-62 was hindered by tunicamycin (Houston and Harnett 1996), 
an antibiotic with the ability to inhibit the precursor of all A/-type glycans 
(reviewed by Elbein, 1987), indicating PC to be attached to ES-62 via this 
type of sugar.
The addition of PC to ES-62 was deemed to be a post-endoplasmic reticulum 
(ER) event, after work using inhibitors of intracellular trafficking was carried 
out. A panel of six inhibitors of protein vesicle transport was employed, that 
included DEC (Spiro et al., 1986), ammonium chloride (NH4CI, Maxfield,
1982), chloroquine (Carroll and Bird, 1991), carbonyl cyanide m- 
chlorophenylhydrazone (CCCP, Tartakoff, Vassalli and Détraz, 1977), 
monensin (Maxfield, 1982) and brefeldin A (Yewdeil and Bennink, 1989). 
From this panel, only brefeldin A (which prevents the transfer of protein 
vesicles from the ER to the golgi) obstructed secretion of ES-62 at a 
concentration with no general toxic effects on the worms (Houston, Cushley 
and Harnett, 1997). Furthermore, the ES-62 identified from whole worm 
extracts from brefeldin A incubated groups was shown to be PC-free.
When attempting to define the intracellular source of PC within the parasite 
used to post-translationally modify ES-62, enzymes of the Kennedy pathway
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for synthesis of PC (reviewed by Kent, 1995) were Investigated. It was found 
that A.viteae did not utilise cytidine diphosphosphate (CDP)-choline (the 
provider of PC in the Kennedy pathway. Fig. 1.9) for production of ES-62, 
even although biosynthetic radiolabelling using [^"^C]-CDP-choline resulted in 
phosphatidylcholine being labelled (Houston and Harnett, 1999b). 
Hexadecylphosphocholine (HEPC), a phospholipid analogue with the ability 
to inhibit CDP-choiine synthesis (Geilen, Wieder and Re utter, 1992) was 
used in cultures of worms to inhibit PC attachment to ES-62. A concentration 
which successfully inhibited PC addition whilst leaving general worm health 
(and therefore protein secretion in general) intact could not be found. PC-free 
ES-62 was produced using the choline analogue hemicholinium 3 (HC-3, 
Houston and Harnett, 1999b) to block the ability of choline kinase to convert 
PC and cytidine triphosphate (CTP) to CDP-choline (Fig. 1.9, Hamza et al.,
1983). This indicated choline kinase as an essential enzyme for production of 
ES-62 containing PC by A.viteae.
The site of PC addition to ES-62 was determined to be the medial golgi, and 
the carbohydrate structure to which the PC was attached to was considered 
to be likely to be MansGlcNAcs or MansGlcNAcs.This conclusion was arrived 
at using the results of experiments involving inhibitors of oligosaccharide 
processing. The culture of adult worms with deoxymannojirin (dMM), a 
mannose analogue, which inhibits mannosidase I in the cis golgi (Fig. 1.10, 
Elbein, 1987) resulted in PC-free ES-62, as determined by western blotting 
(Houston, Cushley and Harnett, 1997). ES-62 recovered from A.viteae
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cultured with swainsonine was found to have retained PC (Houston, Cushley 
and Harnett 1997). As swainsonine inhibits mannosidase II in the medial 
golgi, (Fig. 1.10) taken together, the results gathered using these inhibitors 
strongly suggests the location of PC addition to ES-62 to be in the medial 
golgi. When deoxynorijihmycin (dNM) was employed, protein secretion was 
practically eliminated (Houston, Cushley and Harnett, 1997). Although ES-62 
from worm extracts was shown to be PC-free, this inhibitor, a glucose 
analogue, preferentially inhibits glucosidase I in the ER (Hettkamp, Bause 
and Legler, 1982) and has been shown to result in the blockage of transport 
of some proteins from the ER (Lodish and Kong, 1984). Taking into account 
the brefeldin A data, suggesting PC to be added to ES-62 after the protein 
leaving the ER, this result is perhaps not surprising.
Despite the successes in determining where PC was added to ES-62 and at 
what point in the secretory pathway this occurred, ES-62 required 
dénaturation to be de-glycosylated using A/-glycosidase F. Of the inhibitors 
used, although some work was carried out with material produced using HC- 
3 and dMM (Houston et a i, 2000), these methods for producing PC-free ES- 
62 were ultimately found to be too inconsistent with respect to efficacy to 
warrant routine application.
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1.6.2 Recombinant Expression Vectors: An Alternative Method for Producing 
PC-free ES-62
A fresh approach adopted in the pursuit of PC-free ES-62 was to place the 
gene for ES-62 into a recombinant protein expression vector, which would 
not be capable of adding PC onto heterologous proteins.
1.6.2.1 Previous Attempts Using Recombinant Expression Vectors
The first expression vector employed was E.coli, the archetypal recombinant 
protein expression vector. Being a prokaryote, it would not be able to post 
translationally add PC, or indeed any sugars to the proteins it produced 
(Ackerman, 2002 PhD Thesis). The material produced using this method was 
mostly insoluble, found in inclusion bodies within the bacterial cells. When re­
folding was attempted, it was only achievable in a small portion of material. 
The resultant recombinant ES-62 (rES-62) was extremely aggregated, and 
therefore unsuitable for biophysical studies or in vivo experiments. At this 
point it was presumed that the sugars present on ES-62 were necessary for 
correct folding, that glycosylation on the parasite-derived ES-62 (pES-62) 
might shield the hydrophobic regions of the molecule, protecting it from 
insolubility, and that the tetrameric nature of ES-62 could also be dependent 
on the monomers being glycosylated (Ackerman, 2002, PhD Thesis).
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Within the scope of the same PhD, production of rES-62 using baculovirus 
was undertaken, to provide glycosylation, but again, avoid the addition of PC 
to heterologous proteins (Ackermann, 2002, PhD Thesis). The material 
produced using this method was soluble, and shown to be a sharper band 
than pES-62; this was thought to be due to the uniformity of addition of sugar 
by the Insect cells. It appeared from silver staining that some of the material 
may have been monomeric, but doubt was cast on the accuracy of this 
assertion by coomassie blue staining. It appeared either the proportion of 
monomeric ES-62 was below the level of detection of coomassie blue, or that 
the band had been an artefact of the silver staining, which can occur, and 
give rise to erroneous indications of contamination. Unfortunately, having 
passed this hurdle, and also proving recognition of the material by mono- and 
polyclonal anti-ES-62 antibodies, it appeared that the protein produced using 
this method was also unusable. Examination of the rES-62 absorption 
spectra led to the discovery of what appeared to be DNA contamination 
caused by rES-62 binding viral DNA, contamination from an unknown 
source, or incorrect folding. The maximum absorbance for rES-62 was 
260nm; proteins should normally have a peak at 280nm. Two different 
purification techniques (ultracentrifugation of samples for one hour, and 
treatment with DNAse) failed to alter the location of the absorbance peak, 
and therefore the contamination.
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1.6.2.2 A New Recombinant Expression Vector Attempt
An alternative method of producing PC-free ES-62 is to place its gene in the 
yeast Pichia pastoris, for recombinant protein expression. P.pastoris was 
developed as a host system for DNA transformation twenty years ago (Gregg 
et a!., 1985), and has proved a popular alternative (Bretthauer and 
Casteliino, 1999) to Escherichia coli or Saccharomyces cerevisiae due to the 
similar ease of manipulation of Pichia to the two systems, coupled with the 
benefit of its ability to perform the protein processing, folding and 
posttranslational modifications often necessary for production of a working 
eukaryotic protein, absent in E.coli, and its reduced hyperglycosylation as 
compared to S.cerevisiae, mentioned later. Pichia is a methylotrophic yeast: 
able to use methanol as its only carbon source. The first enzyme in the 
pathway of methanol consumption, alcohol oxidase (AOX) is produced 
extensively by the yeast due to its poor oxygen affinity. AOX can constitute 
up to 30% of the total soluble protein in cells grown in methanol (Couderc 
and Baratti, 1980) therefore, when wishing to express heterologous protein 
the alcohol oxidase promoter is the logical choice. The ability of Pichia to 
actively secrete proteins is desirable for the production of a pure protein, 
although naturally a signal sequence targeting it to the secretory pathway is 
necessary. A large percentage of all secreted protein will be the heterologous 
protein, due to the strength of the AOX promoter and Pichia secreting few 
native proteins, combined with the minimal médias’ low protein content.
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Another advantage of the Pichia system is that unlike S.cerevisiae, Pichia 
may not hyperglycosylate. Both yeasts have mostly high mannose type N- 
linked glycosylation, but the post translationally added oligosaccharide length 
is an average of 8-14 mannose residues per side chain versus 50-150 seen 
in S.cerevisiae (Grinna and Tschopp, 1989; Tschopp et al., 1987). The core 
oligosaccharides of Pichia do not contain terminal a1-3 glycan linkages, 
which are thought to be the cause of the hyper-antigenicity seen in proteins 
produced using S.cerevisiae (which does employ such linkages) thus 
rendering them practically unusable therapeutically. It is envisaged (though 
not proven) that such hyper-antigenicity will be less of a problem when using 
Pichia as the glycoproteins produced will more closely resemble the structure 
of higher eukaryotes (Cregg, Vedvick and Raschke, 1993).
The most frequently employed expression vectors contain the HIS4 gene for 
selection purposes, and are organised so that a restriction enzyme will create 
a linearized form conducive to producing His’^  recombinants by 
recombination at A0X1 or his4 locus. Regardless of where it inserts, the 
expression cassette has the same general structure (Fig. 1.11). Insertions 
are far more probable to occur than replacements (double crossover events) 
and multiple insertion arises at 1-10% of single insertion events 
spontaneously. Therefore, adding methanol to minimal media containing 
recombinant yeast will cause the stimulation of the promoter of the alcohol 
oxidase which will drive expression of the gene of interest, in this case ES- 
62.
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1.7 AIM OF PROJECT
It is therefore my aim during this project to
• Attempt to produce PC-free ES-62 using enzymes and enzyme 
inhibitors related to those used previously
• Sub-clone recombinant ES-62 into the Pichia recombinant expression 
system
• Culture Pichia in order to produce Recombinant ES-62 (rES-62)
• Purify the recombinant material
• Explore the biochemical properties of rES-62, including; molecular 
weight; quaternary structure; the nature of self-association and 
susceptibility to glycosidases and other enzymes and investigating the 
sugars attached to the molecule using assays to investigate binding to 
lectins
• Compare the antigenic properties of the recombinant protein with 
those of the parasite derived ES-62 using assays to investigate 
binding to anti-sera
• Compare the immunogenicity of rES-62 with that of parasite-derived 
ES-62 -  the nature of the antibody responses mounted by naïve 
BALB/c mice to the two molecules, investigation of cross-reactivity 
between antibodies raised against one molecule against the other, 
and vice versa, and investigation of immunomoduiation by rES-62 in
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comparison with pES-62, by examination of cytokine responses 
stimulated by rES-62 in comparison to pES-62 by bone marrow 
derived dendritic cells (bmDCs). I will also explore the nature of rES- 
62’s cytokine stimulatory abilities in knock-out mice which lack TLR4 
and TLR4 signalling capabilities, MyD88 and the Mannose receptor.
• Compare the structural properties of rES-62 with those of rES-62 
clones with one of the three putative A/-Glycosylation sites “Knocked 
Out”, for example: molecular weight, tetramers and monomers, 
binding to anti-sera, lectin binding, susceptibility to glycosidases and 
other enzymes.
Together, these experiments will hopefully shed more light on which 
components of ES-62 are essential to its manipulation of the immune 
responses of hosts.
-53
1.4 FIGURES
Figure 1.1. Causative Agents of Lymphatic 
Filariasis and Onchocerciasis
A. Wuchereria bancrofti microfilaria, (from 
http://medecinetropicale.free.fr). B. Brugia mal ayi L3 
Worm, (from www.tiar.org/tdb/e2k1/bma1/intro.shtml) 
and C. Onchocerca volvulus microfilaria (from 
www.cdfound.to.it)
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Figure 1.2. Worldwide Prevalence of Lymphatic 
Filariasis and Onchocerciasis.
Map showing worldwide prevalence of Lymphatic 
Filariasis, Onchocerciasis, and areas of co-endemicy 
(from
http://qlobalatlas.who.int/qlobalatlas/lnteractiveMappinq/rm 
m/default.asp?cat1 =010000000000&cat2=010900000000 
&cat3=010902000000&lev=3 (WHO))
55A-
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Figure 1.3. Simplified Lifecycle of the Causative 
Agents of Lymphatic Filariasis.
Simplified lifecycle of Wuchereria bancrofti. A 
mosquito becomes infected after taking a bloodmeal 
from a human infected with W.bancrofti, containing 
sheathed microfilariae (mf). The mf shed their 
sheathes and penetrate the midgut, then travel to the 
thorasic muscles. Here the L1 larvae develop into 13 
larvae, capable of infecting a human, and migrate to 
the mosquito head and proboscis. The cycle is 
continued when the mosquito takes a bloodmeal from 
an uninfected human, when the infective larvae are 
transferred from the vector to the bloodstream of the 
human. The 13 develop into adult worms, and reside 
in the lymphatic system, where they produce sheathed 
mf. These mf migrate to the lymph and blood 
channels. The cycle is completed when and uninfected 
mosquito takes a bloodmeal from an infected human, 
ingesting the mf.
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W.Bancrofti Lifecycle
Migrate to mosquito 
head and proboscis
Infective Stage: Mosquito 
feeds from human: L3 
larvae enter via skin
L1 Larvae 
develop to L3 
(infective)
In the mosquito 
sheaths are shed, 
and mf penetrate 
the midgut and 
migrate to the 
thorasic muscles
Mosquito Human
Mosquito feeds from 
human: microfilariae 
are ingested
L3 Develop into adults. 
Adult worms reside in 
the lymphatics
Diagnostic Stage: Adults 
produce microfilariae (mf, 
sheathed). Mf migrate into 
lymph and blood channels
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Figure 1.4. Simplified Lifecycle of the Causative 
Agents of Lymphatic Filariasis.
Simplified lifecycle of Brugia malayi. A mosquito 
becomes Infected after taking a bloodmeal from a 
human infected with W.bancrofti, containing sheathed 
mf. The mf shed their sheathes and penetrate the 
midgut, then travel to the thorasic muscles. Here the 
11 larvae develop into L3 larvae, capable of infecting a 
human, and migrate to the mosquito head and 
proboscis. The cycle is continued when the mosquito 
takes a bloodmeal from an uninfected human, when 
the infective larvae are transferred from the vector to 
the bloodstream of the human. The L3 develop into 
adult worms, and reside in the lymphatic system, 
where they produce sheathed mf. These mf migrate to 
the bloodstream. The cycle is completed when and 
uninfected mosquito takes a bloodmeal from an 
infected human, ingesting the mf.
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B.malayi Lifecycle
Migrate to mosquito 
head and proboscis
infective Stage: Mosquito 
feeds from human: L3 
lar\me enter via skin
L1 Larvae 
develop to 13 
(infective)t
Mosquito Human
in the mosquito 
sheaths are shed, 
and mf penetrate 
the midgut and 
migrate to the 
thorasic muscles
Mosquito feeds from 
human: microfilariae 
are ingested
L3 Develop into adults. 
Adult worms reside in 
the lymphatics
Diagnostic Stage: Adults 
produce microfilariae (mf, 
sheathed). Mf reach 
bloodstream.
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Figure 1.5. Simplified Lifecycle of the Causative 
Agents of Onchocerciasis.
Simplified lifecycle of Onchocerca volvulus. A blackfly 
becomes infected after taking a bloodmeal from a 
human Infected with W.bancrofti, containing 
unsheathed mf. The mf penetrate the midgut, then 
travel to the thorasic muscles. Here the LI larvae 
develop into L3 larvae, capable of infecting a human, 
and migrate to the blackfly head and proboscis. The 
cycle is continued when the blackfly takes a bloodmeal 
from an uninfected human, when the infective larvae 
are transferred from the vector to the bloodstream of 
the human. The L3 develop into adult worms, which 
are found In subcutaneous nodules, where they 
produce unsheathed mf. These mf are found in skin 
and lymphatics of connective tissues, and also in 
peripheral blood, urine and sputum. The cycle is 
completed when and uninfected blackfly takes a 
bloodmeal from an infected human, ingesting the mf.
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O.volvulus Lifecycle
Migrate to Biackfiy 
head and proboscis
Infective Stage: Biackfiy 
feeds from human: L3 
larvae enter via skin
L1 Larvae 
develop to L3 
(infective)\
Blackfly (genus s//T7u//t/m) Human
In the biackfiy mf 
penetrate the 
midgut and migrate 
to the thorasic 
muscles
Blackfly feeds from 
human: microfilariae 
are ingested
L3 Develop into adults in 
the skin. Adult worms 
reside in subcutaneous 
nodules
i
Diagnostic Stage: 
Adults produce mf 
(unsheathed). Mf are 
generally found in the 
skin and lymphatics 
of connective tissues. 
Sometimes mf are 
also found in 
peripheral blood, 
urine and sputum
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Figure 1.6. Immunomodulatory Properties of ES-62
Diagrammatic summary of the immunomodulatory 
properties of ES-62 on various cells of the immune 
system. 1. ES-62 has been shown to mature DCs in a 
way which induces Th2 responses to unrelated 
antigens, pushing the immune responses in a more 
anti-inflammatory direction. 2. Pre-exposure of mt|) to 
ES-62 leads to their inability to respond to subsequent 
Th1 inducing stimuli. 3. B1 cells are stimulated by ES- 
62 to produce IL-10, suppressing inflammation and 
polarising the immune responses.
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Figure 1.7. Phosphoryicholine and Its attachment 
site on the Glycans of ES-62
A. Chemical Structure of Phosphoryicholine (PC) and
B. The proposed attachment site on the glycans of ES- 
62. Proposed PC attachment sites on the A/-glycans of 
ES-62. PC on ES-62 has been found to be attached to 
a glycan with a trimannosyl core with and without 
fucosylation of the core, and carrying between one 
and four additional GlcNAc residues. It is likely that the 
PC is attached directly to GlcNAc (found to be the 
case with filarial nematode PC-glycolipids: Wuhrer, et 
al. (2000) in a phosphodiester linkage (Houston and 
Harnett 2004) and there may be at least two PC 
residues per glycan.
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Figure 1.8. ES-62 Uncouples the B Cell Receptor 
(BCR)-RasErkMAPKinase Cascade.
ES-62 primes the BCR to activate SHP-1 tyrosine 
phosphatase, maintaining the immunoreceptor 
Tyrosine-based activation motifs (ITAMS) in a 
dephosphoryiated (resting) state, thus stopping 
recruitment of the ShcGrb2Sos complexes necessary 
for activation of Ras. ES-62 also promotes the BCR- 
driven association of Pad with Erk, terminating any 
ongoing Erk signals. The action of ES-62 on these two 
negative regulatory sites results in a rapid, high level of 
desensitisation of the BCR coupling to the 
RasErkMAPKinase cascade.
-61A
sig
ES-62
She :as RafGrb2SHP-t Sos
MEK
Erk
PTK, Erk. NFkB
Pad Nucleus
Erk
61 -
Figure 1.9. The Kennedy Pathway of 
Phosphatidylcholine Synthesis.
Diagram showing the Kennedy Pathway of 
phospholipid synthesis, illustrating where HC-3 and 
HERC exert their effects. Choline is converted to 
phosphoryicholine (PC) by choline kinase, which is 
inhibited by HC-3. Phosphocholine citldyltransferase, 
which is inhibited by HEPC, converts PC to CDP- 
choline, which is then converted to 
phosphatidylcholine (PtdChol) by choline 
phosphotransferase. Finally PtdChol can be converted 
to sphingomyelin by sphingomyelin synthase (SM 
synthase).
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Figure 1.10. Sugar Biosynthetic Pathway in the 
Endoplasmic Reticulum and Golgi
Schematic representation of the sugar biosynthetic 
pathway from the Endoplasmic Reticulum (ER) and 
Golgi Apparatus, illustrating where various enzyme 
inhibitors exert their effect. In the ER (conserved from 
yeast to mammals) - MangGlcNAcaGlucosea is first 
trimmed by Glucosidase I to IVIangGlcNAczGlucosez, 
then trimmed to Man8GlcNAc2 by Glucosidase II and 
ER mannosidase. These enzymes are inhibited by 
dNM. In the cis region of the Golgi apparatus, 
Man8GlcNAc2 is trimmed to Man5GlcNAc2 by 
Mannosidase I (inhibited by dMM). As the A/-glycan 
moves through the mediai Golgi, an extra GlcNAc 
residue is added by GlcNAc transferase I and two 
more mannose residues are removed by mannosidase 
II (inhibited by swainsonine), to create ManaGlcNAcs
-6 3 A -
Endoplasmic Reticulum
Glucosidase I 
 >-
Glucosidase II 
and ER 
I ju Mannosidase
T
dNM dNM
C/s Goiqi
Î Mannosidase ' ^T
dMM
Medial Goiqi
Q GlcNAc T S oTransferase I Mannosidase
 àA -y
Swainsonine
•  = Glucose 
o = Mannose 
■ = N-Acetylglucosamine 
= Protein
63-
Figure 1.11. Expression Cassette for Insertion into 
Pichia pastoris.
Expression Cassette: crossover events with the Pichia 
pastoris genome can occur at any of the regions 
shown.
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Chapter 2: Materials and Methods
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2.1 CHEMICALS AND REAGENTS
The chemicals and reagents used throughout this study were provided by 
Alexis Corporation UK (Nottingham, UK), Amersham Biosciences (Little 
Chaifont, Bucks, UK), Applied Biosciences (Foster City, CA), BD Pharmingen 
(San Diego, USA), BDH Laboratory Supplies (Poole, UK), BioRad 
Laboratories (Hemel Hempstead, Hertfordshire, UK), Biosource (Supplier: 
Invitrogen Paisley, UK), Cadisch Precision Meshes (London, UK), 
Diagnostics Scotland (Edinburgh, UK), Corning (Supplier: Fisher Scientific), 
eBiosclence (Supplier: Insight Biotechnology Ltd, Wembley, UK), Fisher 
Scientific (Leicester, UK), GibcoBRL, Life Technologies (Supplier: Invitrogen, 
Glyko-Prozyme (Supplier: Europa Bioproducts Ltd., Wicken, UK), Greiner 
Bio-One Ltd. (Stonehouse, UK), invitrogen (Paisley, UK), Kirkegaard and 
Perry Laboratories Inc. (Supplier: Insight Biotechnology Ltd, Middlesex, UK), 
Lonza, Wokingham Ltd. (Wokingham, UK), Millipore (Supplier: Fisher 
Scientific, Leicester, UK), Pierce (Supplier: Perblo, Science UK, Cramlington, 
UK), PAA Laboratories Ltd., (Somerset, Yeovil UK), Premier International 
Foods, (Long Sutton, Lines, UK), Qiagen (Crawley, West Sussex, UK), 
Roche Diagnostics (Burgess Hill, East Sussex, UK), SAFC Biosciences 
(Andover, UK), Sigma-Aldrich (Gillingham, Dorset, UK), Stratagene 
(Amsterdam, The Netherlands) Techno Plastic Products ((TPP), 
Trasadingen, Switzerland) Thermo Electron Corporation (Supplier: Fisher 
Scientific), and Thermo Scientific (Basingstoke, UK).
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2.2 SOLUTIONS AND BUFFERS
2.2.1 GENERAL BUFFERS
10x Phosphate Buffered Saline fPBS)
1.37 M Sodium chloride (NaCi, BDH Laboratory Supplies)
0.03 M Potassium chloride (KCI BDH Laboratory Supplies)
0.08 M Disodium hydrogen orthophosphate (Na2HP04, BDH)
0.01 M Potassium dihydrogen orthophosphate (KH2PO4, Sigma-Aldrich) 
Adjust pH using hydrochloric acid (HCI, Sigma-Aldrich)/sodium hydroxide 
(NaOH, Sigma-Aldrich)
Ammonium Chloride pH 7.2 for Lvsinq Red Blood Cells 
0.168 M Ammonium chloride (NH4CI, Sigma-Aldrich)
Or
Boyles Solution for Lvsinq Red Blood Cells
0.17 M Tris ((hydroxymethyl)aminomethane): Tris, C4H11NO3, Sigma-Aldrich) 
-1 part
0.16 MNH4C I - 9 Parts
Add the two solutions together on the day of use and filter sterilise using a 
0.2 i^M filter.
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2.2.2 CULTURE REAGENTS
2.2.2.1 Worm Culture Reagents 
RPMI “complete”
Roswell Park Memorial Institute (RPMI) 1640 Medium (PAA Laboratories 
Ltd.) containing
2 mM L-Glutamine (Gibco, invitrogen, Paisley, UK)
100 U/ml Penicillin and 100 ^g/ml Streptomycin (10000 U/ml penicillin G 
sodium plus 10000 pg/ml streptomycin sulfate in 0.85% saline, Gibco, 
Invitrogen)
10ml of a 45 % Glucose Solution (C6H12O6, Sigma-Aldrich), to give a final 
concentration of 1 %
RPMI Lacking Choline fRPMI-c^
RPMI 1640 medium (modified R8758) lacking choline (SAFC Biosciences)
containing
2 mM L-Glutamine
100 U/ml Penicillin and 100 pg/ml Streptomycin 
1 % Glucose
-68
RPMI Lacking Glucose (RPMl-g)
RPMI 1640 
2 mM L-Glutamlne
100 U/ml Penicillin and 100 i^g/ml Streptomycin 
RPMI Lacking L-methionine (RPMI-ml
RPMI 1640 (modified R8758) medium lacking methionine (SAFC 
Biosciences) containing 
2 mM L-Glutamine
100 U/ml Penicillin and 100 p,g/ml Streptomycin 
1 % Glucose
2.2.2.2 Pichia pastoris (P.pastoris) Culture 
Yeast Extract Peptone Dextrose (YDPf Broth
1 % (weight by volume (w/v)) Yeast Extract (Sigma-Aldrich)
2 % (w/v) Peptone (Sigma-Aldrich)
2 % (w/v) Dextrose (Sigma-Aldrich)
1 M Potassium Phosphate Buffer pH 6.0
132 ml 1 M Dipotassium hydrogen orthophosphate (K2HPO4, Sigma-Aldrich) 
868 ml 1 M KH2PO4 (Sigma-Aldrich)
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Check pH, adjust using potassium hydroxide (KOH, Sigma- 
Aldrich )/Phosphoric Acid (H3PO4, Reidel de Haën, Sigma-Aldrich)
Minimal Dextrose (MD) Plates
1.34 % (w/v) Yeast Nitrogen Base (YNB, Sigma-Aldrich)
1 % (volume by volume (v/v)) Glucose (Sigma-Aldrich)
0.4 mg Biotin (Sigma-Aldrich)
10 % 1 M Potassium phosphate buffer pH 6.0
2 % Agar (Sigma-Aldrich)
Autoclave, allow to cool a little then pour.
Buffered Minimal GIvcerol (BMG) Broth
1.34 % (w/v) YNB
1 % (v/v) Glycerol (CsHsOs, Fluka, Sigma-Aldrich)
0.000004 % (w/v) Biotin
10 % 1M Potassium phosphate Buffer pH 6.0
Buffered Minimal Methanol (BMM) Broth
1.34 % (w/v) YNB
0.5 % Methanol (CH4O, Reidel de Haën, Sigma-Aldrich)
0.000004 % (w/v) Biotin
10 % 1 M Potassium phosphate buffer pH 6.0
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10 X Dextrose
20 % D-glucose (Sigma-Aldrich) 
Autoclave for 15 min then store at 4 ‘"C
YDP Medium/Aqar plates
1 % (w/v) Yeast extract (Sigma-Aldrich)
2 % (w/v) Peptone
2 % (w/v) Agar (for plates only)
Dissolve yeast extract, agar if making plates and peptone in 900ml distilled 
water (dH20), autoclave, allow to cool and add 1 % (v/v) lOx Dextrose 
solution and pour plates.
100 X Amino Acids (AA)
0.5 % (w/v) L-Glutamic acid (Sigma-Aldrich)
0.5 % (w/v) L-Methionine (Sigma-Aldrich)
0.5 % (w/v) L-Lysine (Sigma-Aldrich)
0.5 % (w/v) L-Leucine (Sigma-Aldrich)
0.5 % (w/v) L-isoleucine (Sigma-Aldrich)
Filter-sterilise by passing through a 0.22 p,m membrane (Stericup, Millipore, 
Fisher Scientific) and store at 4 °C
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10 X  YNB
3.4 % (w/v) YNB
10 % (w/v) Ammonium sulfate ((NH4)2S04, Sigma-Aldrich)
Heat to dissolve, then filter-sterilise by passing through a 0.22 |im membrane 
(Stericup, Millipore, Fisher Scientific) and store at 4 °C
10 X Methanol
5 % Methanol
Filter-sterilise by passing through a 0.22 [.im membrane and store at 4 °C
10 X  GIvcerol 
20 % (v/v) Glycerol
Filter-sterilise by passing through a 0.22 \.im membrane and store at 4 °C
500 X Biotin 
0.02 % (w/v) Biotin
Filter-sterilise by passing through a 0.22 j.im membrane and store at 4 °C
Minimal Media with GIvcerol (MMG)
20 % 1M Potassium phosphate buffer pH 6.0
6 % 10x YNB
1 % 500x Biotin 
6 % lOOx AA
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10 % lOx Glycerol
Top up to 1 L with autoclaved dHgO
Minimal Media with Methanol (MMIVh
10 % 1 M Potassium phosphate buffer pH 6.0
10 % lOx YNB
0.15 % 500x Biotin
10 % lOOx AA
10 % lOx Methanol
Top up to 1 L with autoclaved dH20
Storage Conditions for rES-62 
10 % (v/v) glycerol
0.01 M Magnesium sulfate (MgS04, Sigma-Aldrich).
Store at -20 °C
2.2.2.3 Cell Culture Reagents
Heat inactivated Foetal Calf Serum (HiFCSI
Foetal Calf Serum (Sigma-Aldrich) heated to 56 °C for at least 1 h
Dendritic Cell (PCI Media
RPMI 1640 containing 0.025 M 4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid (HEPES)
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10 % (v/v) HiFCS 
100 u/ml Penicillin 
100 [,tg/ml Streptomycin
10 % (v/v) x63-cell line conditioned media containing Granulocyte 
Macrophage-Colony Stimulating Factor (GM-CSF)
2.2.3 OTHER EXPERIMENTAL REAGENTS
GENERAL EXPERIMENTAL REAGENTS
2.2.3.1 Protein Assav
1:4 dilution Protein Assay Reagent (Biorad) in dH20 
Add 300 p,l of this dilution to 10 pi of sample/standard
2.2.3.2 Endotoxin Testing Kit Reagents (QCL-1000. Lonza)
Standard Endotoxin (Escherichia coli (E.coli) Strain 0111 :B4)
1 Endotoxin Units (EU) /ml in LAL reagent water (contained within kit)
LAL Lvsate
Contained within kit, reconstitute with 1.4 ml LAL reagent water
Chromogenic Substrate
2 mM in LAL reagent water
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Contained within kit, reconstitute with 6.5 ml LAL reagent water 
Stop Solution
25 % Acetic Acid (C2H4O2, Riedel de Haën, Sigma-Aldrich)
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2.2.3.3 Trichloroacetic Acid (TCA) Precipitation 
10 % Trichloroacetic Acid (TCA^
10 % (w/v) TCA (BDH)
0.01 M Choline chloride (Sigma-Aldrich)
2.2.3.4 Inhibitors
Erucvlphosphocholine f22.1.cis) (EPC. Alexis Corporation. UK^
0.01 M EPC/RPMI-c/m
rac-1 -Q-octadecvl-2-0-methvl-qlvcero-3-phosphocholine (EtimOCH.i, Sigma- 
Aldrich')
0.01 M Eti80CH3/RPMI-c/m
2.2.3.5 Buffers For Enzymes
Sodium Citrate Butfer pH 4.6 for B-N-acetvlhexosaminidase 
0.05 M Sodium citrate (C6H5Na307.2H20, Sigma-Aldrich)
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Correct pH to 4.6 using citric acid (C6H8O7.H2O, Sigma~Aldrich)/NaOH
Sodium Phosphate Buffer pH 7.0 for Recombinant Phosphorvlcholine 
Esterase (Pee)
0.02 M Sodium phosphate (disodium hydrogen orthophosphate, 
HNa204P.12H20, BDH)
Correct pH to 7.0 using 0.02M sodium dihydrogen orthophosphate 
(NaH2P04-H20, BDH)
2.2.3.6 immunoprécipitation 
Wash Buffer. pH 8.3
0.01 M Tris-HCI (Riedel de Haën, Sigma-Aldrich) pH 8.3 
0.05 M NaCI
0.1 % (w/v) Nonidet P-40 (NP40, Sigma-Aldrich)
Adjust pH using HCi
2.2.3.7 Sodium Dodecvl Sulfate-Polv-Acrvlamide Gel Electrophoresis (SDS- 
PAGE)
2.2.3.7.1 General Solutions 
Fixing Solution 
40 % Methanol 
7 % Acetic Acid
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staining Solution
40 ml Brilliant Blue Colloidal Concentrate (Sigma-Aldrich)
10 ml Methanol
Made up immediately before use
De-staining Solution 
25 % Methanol 
1 0  %  C 2 H 4 O 2
2.2.3.7.2 SDS-PAGE: BioRad System 
Solution A
0.41 M Acrylamide (C3H5NO, Sigma-Aldrich)
0.005 M N’N’methylene bisacrylamide (C7H10N2O2, Sigma-Aldrich)
Solution B
1.5 M Tris pH 7.5
Adjust pH to 8.8 using HCI
Solution C
0.5 M Tris pH 7.5
Adjust pH to 6.8 using HCI
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Sample Loading Buffer pH 6.8 for denaturing and reducing PAGE conditions 
The components of this buffer are detailed in table 2.2
Working Loading Buffer
95 % Sample Loading Buffer pH 6.8
5 % 2-Mercaptoethanol (2-ME)
5x Electrophoresis Buffer Containing SDS. pH 8.3 
1.24 M Tris pH 7.5
9.59 M Glycine {C2H5NO2, Sigma-Aldrich)
0.09 M SDS (Lauryl sulphate; sodium dodecyl sulfate)
Check pH but do not adjust
Sample Loading Buffer pH 6.8 for Non-denaturing and Reducing PAGE 
Conditions
The components of this buffer are detailed in table 1.3.
lOx Electrophoresis Buffer without SDS. pH 8.3
0.25 M Tris
1.92 M Glycine
Check pH but do not adjust
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2.2.3.7.3 SDS-PAGE: Novex System 
Sample Loading Buffer
25 % NuPAGE LDS Sample Buffer 4x (Noyex, Inyitrogen)
10 % NuPAGE Reducing Agent lOx (Noyex, Inyitrogen)
Electrophoresis Buffer: Outer Tank - NuPAGE 3-fN-
morpholinobropanesulfonica acid (MOPS) Buffer 1x 
5 % NuPAGE MOPS Buffer 20x (Noyex, Inyitrogen)
Electrophoresis Buffer: Inner Tank
0.25 % NuPAGE antioxidant (Noyex, Inyitrogen) in NuPAGE MOPS Buffer 1x 
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2.2.3.8 Polymerase Chain Reaction (PGR): Transformation into Pichia
ES-62 Primers
MJA121
5’- GAAGGGGTATCTCTCGAGAAAAGAGAGGCAGCTGTCCTTCCGGACA
AAACTGTCGCT
and
MJA122 5'- ATGGGAATTCTTATAGCTTTTTACGATCAGATTTCTCAGTAGT
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PCR Buffer
0.02 M Tris-HCI pH 8.8
0.01 M Potassium chloride (KCI, BDH)
0.01 M Ammonium sulfate ((NH4)2S04, Sigma-Aldrich)
0.002 M MgS04
1 % Triton X-100 (Sigma-Aldrich)
10 % Bovine Serum Albumin (BSA) (Fraction V, Sigma-Aldrich)
2.2.3.9 Western Blotting and Dot Blotting 
Transfer Buffer (for 1 gel)
50 ml NuPAGE 20x Transfer Buffer (Novex, Invitrogen)
1 ml NuPAGE Antioxidant (Novex, Invitrogen)
100 ml Methanol 
849 ml dH20
Transfer Buffer (for 2 gels)
50 ml NuPAGE 20x Transfer Buffer (Novex, Invitrogen)
1 ml NuPAGE Antioxidant (Novex, Invitrogen)
200 ml Methanol 
749 ml dH20
Tris Buffered Saline (TBS). oH 7.5 
0.02 M Tris
80
9 % (w/v) NaCI
Adjust pH using HCl/NaOH
TBS pH 7.5 plus Tween 20 (TBST^
0.1 % w/v Tween 20 (Slgma-Aidrich)/TBS pH 7.5
TBS pH 8.5 
0.1 M Tris 
0.3 M NaCI
Adjust pH using HCI/NaOH
Blocking Solution 
4 % (w/v) BSA/TBS pH 7.5/S.5
Primarv Antibodies
1:1000 dilution of KK6, a mouse mAb that recognises a conformational 
epitope on ES-62 (Stepek et al., 2002)/TBST
1:500 dilution of Rabbit ES-62 anti-serum (raised against purified ES-62, 
Harnett et a!., 1989)/TBS pH 8.5 containing 2.5 % (w/v) BSA 
1:1000 dilution TEPC 15 ((1 mg/ml, Sigma-Aldrich), a mouse IgA myeloma 
protein specific for PC, Sigma-Aldrich)/TBS pH 8.5 containing 2.5 % (w/v) 
BSA
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Secondary Antibodies
1:20000 dilution HRP-labelled anti-mouse IgG,(Sigma-Aldrich)/TBST for KK6 
primary antibody
1:100000 dilution alkaline phosphatase (AP)-labelled anti-rabbit IgG,(Sigma- 
Aldrich )/TBS containing 0.5 % BSA (w/v) where rabbit-anti-ES-62 serum was 
used as the primary antibody
1:30000 dilution AP-conjugated anti mouse IgGI (Sigma-Aldrich) diluted in 
TBS pH 8.5 containing 0.5 % BSA (w/v) where TEPC15 was used as the 
primary antibody
Substrate Solution
1 tablet Nitroblue tétrazolium and 5-bromo-4-chloro-3-indolyl phosphate 
toluidine substrate (BCiP/NBT, Sigma-Aldrich))/10 ml dH20.
Stop Solution
20 mM Ethylenediaminetetraacetic acid (EDTA)
2.2.3.10 Buffers for Enzvmes for Removal of PC from rES-62
Reaction Buffer for A/-qlvcosidase F
0.05 M EDTA
0.02 M HNa204P.12H20
0.02 % (w/v) Sodium azide (NaNs, Sigma-Aldrich)
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Add EDTA to half the volume, pH to 7.2 using 0.02 M sodium dihydrogen 
orthophosphate, then add the NaNs
Reaction Buffer for Endoalvcosidase H
0.1 M Sodium Acetate (C2H302Na, Sigma-Aldrich)
Reaction Buffer for a-mannosidase
0.005 M Sodium Acetate
0.0002 M Zinc Chloride (ZnCb, Sigma-Aldrich)
Adjust pH to 4.6 using C2H402/Na0 H
Reaction Buffer for Trvpsin 
0.001 M HCI
2.2.3.11 DIG-Glvcan Lectin Blot Kit Reagents
TBS pH 7.5
0.05 M Tris 
0.15 M NaCI
Adjust pH to 7.5 using HCI/NaOH 
Buffer 1
0.001 M Magnesium chloride (MgC^, Sigma-Aldrich)
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0.001 M Calcium chloride (CaCl2.H20, Sigma-Aldrich)
In TBS pH 7.5
Buffer 2 pH 9.5 
0.1 M Tris 
0.05 M MgCIa 
0.1 M NaCI
Adjust pH to 9.5 using HCI/NaOH 
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2.2.3.12 Inoculations
2 \xg/m\ parasite derived (p) or recombinant (r) ES-62 in sterile, endotoxin- 
free PBS pH 7.4
2.2.3.13 Enzvme-Linked Immunosorbent Assav fELISA) Reagents
2.2.3.13.1 Antibodv ELISAS
Wash Buffer 
PBS pH 7.4
Coating Buffer 
PBS pH 9.0
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Adjust pH to 9.0 using NaOH 
PBS/Tween
0.05 % Tween 20 in PBS pH 7.4
Blocking Solution 
4 % BSA in PBS pH 7.4
Antibodv Coniugates
1; 20000 Dilution of horse-radish peroxidase conjugated rabbit anti-mouse 
igG1 or lgG2a (Southern Biotech) in PBS pH 7.4 containing 25 % Sheep 
serum (Diagnostics Scotland, Edinburgh, UK)
3.3’.5.5’-Tetramethvlbenzidine (TMB) for Substrate Solution
0.025 M (w/v) TMB (C16H2ON2, Sigma-Aldrich) in Dimethylsulfoxide (DMSO,
CaHeSO, Sigma-Aldrich)
Store at -20 °C protected from light
Acetate/Citrate Buffer pH 5.5 for Substrate Solution 
0.1 M Sodium Acetate
Adjust pH to 5.5 using solid citric acid (BDH). Store at 4 ®C. This solution only 
lasts for 1 month after making up.
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Substrate Solution 
1 % (v/v) TMB
0.032 % (v/v) Hydrogen peroxide (H2O2, Sigma-Aldrich) 
in Citrate/Acetate Buffer pH 5.5
Stop Solution
10 % Sulfuric Acid (H2SO4, Reidel de Haën, Sigma-Aldrich)
2.2.3.13.2 Cytokine ELISAS: Interferon gamma (IFNvL Interleukin flLV4 and 
IL-10 fKits from eBioscience. UK)
Coating Buffer 
lOx Stock in kit
Coating Antibodies
1:1000 dilution of IFNy Capture Antibody 
1:250 dilution of lL-4 Capture Antibody 
1:250 dilution of IL-10 Capture Antibody 
All diluted in 1x Assay diluent provided with the kit.
Assav Diluent 
5x stock in kit
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Wash Buffer 
PBS pH 7.0
Standards for Cytokine Standard Curves 
2000 pg/ml for IFNy 
500 pg/ml for IL-4 
2000 pg/ml for IL-10
All diluted in 1x assay diluent provided with the kit
Detection Antibodies 
1:1000 dilution for IFNy 
1:250 dilution for IL-4 
1:250 dilution for IL-10
All diluted in 1x assay diluent, provided with kit 
Enzyme Reagent
1:250 dilution of streptavidin-horseradish peroxidase (HRP) conjugate in 1x 
assay diluent, provided with kit
Substrate Solution
1x provided with kit, TMB-based
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stop Solution 
2 N H2SO4
2.2.3.13.3 Cytokine ELISAS: Tumour Necrosis Factor Alpha (TNFa) and IL- 
12p40 (Kits from BD Bioscience)
Coating Buffer for TNFa: 0.1 M Sodium Carbonate pH 9.5
0.1 M Sodium carbonate, anhydrous (Na2C03, BDH)
0.1 M Sodium hydrogen carbonate (NaHCOs, BDH)
Add Na2C03 to NaHCOs to achieve pH 9.5
Coating Buffer for IL-12p40: 0.2 M Sodium Phosphate pH 6.5
0.2 M Di-sodium hydrogen orthophosphate-12-hydrate (Na2HP04.12H20, 
BDH)
0.2 M Sodium di-hydrogen orthophosphate-1-hydrate (NaH2P04.H20, BDH) 
Add Na2HP04 to NaH2P04 to achieve pH 6.5
Assav Diluent
10 % HiFCS in PBS pH 7.0
Capture Antibodies
1:250 dilution of TNFa capture antibody in 0.1 M sodium carbonate pH 9.5
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1:250 dilution of IL-12p40 capture antibody in 0.2 M sodium phosphate pH
6.5
Top Standards for Cvtokine Standard Curves 
5 ng/ml for both TNFa and lL-12p40, diluted in assay diluent
Detection Antibodies
1:250 dilution for both TNFa and IL-12p40 detection antibodies, in assay 
diluent
Enzvme Reagent
1:250 dilution of streptavidin HRP conjugate in assay diluent.
Substrate
1x Sureblue™ TMB Microwell peroxidase substrate (Kirkegaard and Perry 
Laboratories Inc., Insight Biotechnology Ltd., UK)
Stop Solution 
2 N H2SO4
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2.2.3.14 bmPC Culture and Treatment with Modulins 
Trypan Blue for Cell Counting
1 in 10 dilution Trypan Blue (Sigma-Aldrich) in sterile RPMI 
p/r ES-62
2 p,g/ml in sterile, endotoxin-free PBS pH 7.4
Bacterial Lipopolvsaccharide (LPS)
1 ng/ml E.coli serotype 0111 :B4 (Sigma-Aldrich)
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2.2.3.15 Circular Dichroism Analysis 
Phosphate Buffer pH 7.4 
0.0915 M Na2HP04 
0.0583 M NaH2P04
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2.3 METHODS
GENERAL METHODS
2.3.1 Purification and Concentration of Parasite-derived ES-62 (pES-62)
Third stage A.viteae recovered from ticks {Ornithodorus moubata) were 
injected subcutaneously to Infect gerbils {Meriones libycus) using the method 
of Worms, Terry and Terry (1961). After a period of at least two months, adult 
worms were harvested from subcutaneous surfaces and the surrounding 
tissues of the gerbil and washed in RPMI “complete”. The worms were then 
allowed to culture in fresh RPMI “complete” in an atmosphere of 95 % air/5 % 
carbon dioxide (CO2) at 37 °C until the media was spent (indicated by a 
colour change of the medium from red to yellow), when this was removed, 
filtered through a 0.22 |.im membrane to remove larval forms released by the 
females, and replaced with fresh media. ~2 L of the resultant spent media 
was concentrated using a stirred cell ultrafiltration unit (Amicon, Fisher, UK) 
containing a membrane of a 30000 molecular weight cut off (YM30), and the 
media substituted for sterile, endotoxin free PBS pH 7.4 (Lonza, UK) by 
reducing the volume to 50 ml and washing with the PBS. Once the sample 
had been washed three times and the volume reduced to 50 ml again, it was 
then further concentrated to 200-500 \i\ using Centricon microconcentration 
tubes (Amicon, Fisher, UK) with a 100000 molecular weight cut off
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membrane following the manufacturers instructions. Finally, the sample was 
assayed for protein content using the Biorad protein assay reagent according 
to manufacturers instructions (described in section 2.3.2) and the resultant 
pES-62 tested for endotoxin content using a QCL-1000 Chromogenic 
Substrate End Point Kit (described in section 2.3.3). Batch purity and identity 
was confirmed by sodium dodecyl sulfate-poly-acrylamide gel 
electrophoresis (SDS-PAGE) and western blotting, probing with rabbit anti- 
ES-62 sera (described in sections 2.3.19 and 2.3.21).
2.3.2 Protein Assay
A set of standard protein concentrations ranging from 1 mg/ml to 0.016 
mg/ml of an appropriate control protein (in this case BSA dissolved In PBS) 
was created by serially diluting 1 mg/m! BSA/PBS 1:2 seven times. 10 |aI of 
each standard and the sample to be tested was placed into a flat bottom 
medium binding 96-well plates (Thermo Electron Corporation, Fisher) in 
duplicate. 300 i^l of Biorad Protein Assay reagent diluted 1:4 in dH20 was 
then added to each well, and the plate incubated at room temperature for 5 
min, after which the absorbencies at 570 nm were read using an Original 
MultiSkan EX (Thermo Scientific). The protein concentration of the unknown 
sample was then estimated using an equation of the line obtained using the 
standard curve.
9 2 -
2.3.3 Endotoxin Testing of p/rES-62
Endotoxin testing was carried out using the QCL-1000 Chromogenic 
Endotoxin Test, with all steps being carried out on a heat block. A standard 
curve of standard endotoxin {E.coli Strain 0111:B4) contained within the kit 
ranging from 1 EU/ml to 0.01 EU/ml was prepared by reconstituting the 
endotoxin with 1 ml LAL-free water (contained in the kit) and vortexing for 15 
min, then serial 1:2 dilutions were made In pyrogen-free centrifuge tubes 
(Fisher Scientific, UK) using LAL-free water and vortexing samples for 1 min 
between dilutions. 50 \i\ of each standard/sample to be tested was placed in 
a pyrogen free 96 well cell culture plate (TPP) which had been preheated to 
37 °C. 50 pi of freshly reconstituted LAL lysate (contained in the kit) was 
added to each well and the samples incubated for 10 min at 37 °C, 100 pi of 
pre-warmed chromogenic substrate (also contained within the kit) was then 
added to the wells, and the samples incubated for a further 6 min before 
stopping the reaction by the addition of 25 % acetic acid. The samples 
absorbencies were read at 405 nm, and endotoxin content of samples 
estimated using an equation of the line obtained using the standard curve.
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2.3.4 Radiolabelling of pES-62 for Enzyme/Inhibitor Analysis
Adult female A.viteae were cultured in one of the three media mentioned 
below in an atmosphere of 95 % air/5 % CO2 at 37 °C until the media was 
exhausted.
The three types of medium used were RPMI lacking choline (RPMI-c), 
glucose (RPMI-g) or methionine (RPMI-m), and were all based on RPMI 
“complete”. RPMI-c (RPMI “complete" depleted of choline) containing 2 MBq 
[Methyl-^H] Choline chloride (2.22-3.14 TBq/mmol, 60-85 Ci/mmol); RPMI-g 
(RPMI “complete” containing no glucose) containing 2 MBq D-[6-^H]- 
glucosamine hydrochloride (0.56-1.3 TBq/mmol, 15-35 Ci/mmol), or as a 
control to enable assessment of protein synthesis by the inhibitors used, 
RMPi-m (RPMI “complete” depleted of methionine) including 1 MBq L-[^^S]- 
methionine (>37 TBq/mmol, >1000 Ci/mmol). All radiolabels were supplied 
by Amersham Biosciences, UK.
2.3.5 Measurement of Radioactivity
The level of radioactivity contained within 10 pi of each sample was 
measured using a Beckman LS 6500 multipurpose scintillation counter (p-
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counter), in some cases after samples were TCA (Trichloroacetic Acid) - 
precipitated using 10 % (w/v) TCA containing lOmM "cold" label.
2.3.6 TCA Precipitation Analysis
5 pi of normal mouse serum (Sigma-Aldrich) was added to 10 pi of each 
sample in duplicate, 750 pi 10 % (w/v) TCA containing 10 mM “cold” (non­
radioactive) label was added whilst gently vortexing and the sample 
incubated at 4 °C for 15 min to aid precipitation. The samples were then 
centrifuged at 90,000 g for 5 min and supernatant discarded safely. 35 pi 
PBS pH 7.4 was added to the sample, followed by 200 pi formic acid (Sigma- 
Aldrich). The contents were added to a scintillation vial, vortexed after the 
addition of 1 ml of scintillant (Biodegradable Counting Scintillant, BCS, 
Amersham Biosciences) and samples’ radioactivity read in a Beckman LS 
6500 multipurpose scintillation counter p-counter. Controls were also set up 
containing sample, PBS and formic acid, but no mouse serum or TCA to 
enable measurement of the total disintegrations per minute (dpm). The 
percentage incorporation of radiolabel was calculated by dividing the TCA 
dpm value from the total dpm and multiplying by one hundred.
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2.3.7 Enzyme Digestion of ES-62; p-N-acetylhexosaminidase (EC 3.2.1.52, 
Sigma-Aldrich)
After ascertaining the enzymes' activity using an appropriate chromogenic 
substrate (p-nitrophenyl-N-acetyl-p-D-glucosaminide, Sigma-Aldrich), 
duplicate aliquots of 0.05 pg of [^H] choline-labelled ES-62 were incubated 
with 0.8 mUnits (mU) p-N-acetylhexosaminidase in 50 mM sodium citrate 
buffer, pH 4.6 at 37 °C for 1 h along with control tubes where the appropriate 
volume of buffer had been added in lieu of enzyme, and samples then 
analysed by TCA precipitation, as described in section 2.3.5.
2.3.8 Enzyme Digestion of ES-62: Glycerophosphocholine 
Phosphodiesterase (EC 3.1.4.2, Sigma-Aldrich)
After ascertaining the enzymes’ activity using an appropriate chromogenic 
substrate (L-a-glycerophosphorylcholine, Sigma-Aldrich), duplicate aliquots 
of 0.05 pg of [^H] choline-labelled ES-62 were incubated with 0.8 mU 
glycerophosphocholine phosphodiesterase in RPMI 1640 at 37 °C for 1 h 
along with control tubes where the appropriate volume of buffer had been 
added in lieu of enzyme, and samples then analysed by TCA precipitation, as 
described in section 2.3.6.
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2.3.9 Enzyme Digestion of ES-62: Sphingomyelin Phosphodiesterase (EC 
3.1.4.12, Sigma-Aldrich)
After ascertaining the enzymes’ activity using an appropriate chromogenic 
substrate (Trinitrophenylaminolauroylsphingomyelin (TNPAL)-sphingomyelin, 
Sigma-Aldrich), duplicate aliquots of 0.05 pg of pH] choline-labelled ES-62 
were incubated with 0.8 mU sphingomyelin phosphodiesterase in PBS pH
7.4 at 37 °C for 1 h along with control tubes where the appropriate volume of 
buffer had been added in lieu of enzyme, and samples then analysed by TCA 
precipitation, described in section 2.3.5.
2.3.10 Enzyme Digestion of ES-62: Recombinant phosphorylcholine esterase 
(Pee) of Streptococcus pneumoniae (de las Rivas etal., 2001)
Pee was expressed and purified as described previously (de las Rivas et at., 
2001) and duplicate aliquots of 0.6 pg of pH] choline labelled ES-62 were 
incubated with 5.0 pg Pee in 20 mM sodium phosphate pH 7.0 at 37 °C for 1 
h along with control tubes where the appropriate volume of buffer had been 
added in lieu of enzyme, and samples then analysed by TCA precipitation, as 
described in section 2.3.5.
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2.3.11 Use of Inhibitors: Erucylphosphocholine (22,1,cis) (EPC, Alexis 
Corporation, UK) and rac-1-0-octadecyl-2-0-methyl-glycero-3- 
phosphocholine (EtisOCHs, Sigma-Aldrich)
A preliminary titration experiment was carried out to indicate optimum 
working concentrations (i.e. those which would provide inhibition without 
causing general toxic effects, measurable by reduction in protein synthesis 
by the nematodes). After this, triplicate groups of two adult female worms 
were cultured in 10 ml RPMI-c/RPMI-m containing or lacking inhibitor at 5 % 
CO2 and 37 °C for 2 h. The media was removed and replaced with RPMI-c/- 
m containing 2 MBq pH] choIine/p^S] methionine (Amersham Biosciences) 
as appropriate and allowed to culture overnight. The experiment was stopped 
the following day and ES-62 purified from the supernatants using "Centricon” 
ultracentrifugation tubes (Amicon, Fisher, UK) with a 30000 molecular weight 
cut off.
2.3.12 immunoprecipitaion of p^S] Methionine-labelled ES-62
10 pi of radio-labelled sample (~1-5000dpm) was added to 5 pi of rabbit anti- 
ES-62 serum (raised against purified ES-62, Harnett et al., 1989), normal 
rabbit serum, TEPC 15 (1 mg/ml, Sigma-Aldrich), a mouse IgA myeloma 
protein specific for PC, or normal mouse serum. PBS pH 7.2 was added to 
give a final concentration of 100 pi and the samples incubated at 37 °C for 1 
h with gentle agitation. The samples were then left overnight at 4 °C to allow
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precipitates to form. Precipitates were washed with ice-cold 10 mM Tris-HCI, 
50 mM NaCI, 0.1 % NP40 pH 8.3 three times and analysed using SDS- 
PAGE/fluorography, as described in sections 2.3.13 and 2.3.14.
2.3.13 Reducing and Denaturing SDS-PAGE and Staining
12 % NOVEX Acrylamide gels (Invitrogen) were used in some cases: all 
solutions for SDS-PAGE using the NOVEX system were purchased from 
Invitrogen and the same fixing and staining protocols followed as detailed for 
the BioRad system, described below. On other occasions, 12 % gels were 
cast for use with the Mini Protean III (Biorad, UK). Table 2.1 details the 
ingredients of the solutions for casting 12 % resolving and 4 % stacking 
portions of the gel (cast separately). 10 pi Loading buffer was added to 10 pi 
containing 2.5 pg of each sample, along with Kaleidoscope Molecular weight 
markers (Biorad) to allow for sample size estimation, and these were boiled 
for 5 min. The samples were loaded into the wells of the gels and run at a 
constant 200 V with electrophoresis buffer containing SDS for at least 30 
min, or until the dye front had reached the bottom of the gel plate. The gels 
were then removed and placed in fixing solution for 1 h at room temperature 
with gentle agitation, and stained using Sigma Brilliant Blue Colloidal-G stain 
(Sigma-Aldrich, UK) for a minimum for 2 h before de-staining. Finally, the 
gels were pictured using a system comprised of a UVP camera, Mitsubishi 
monitor and Sony vidoegraphic printer UP 860CE, and scanned using a 
CanoScan LiDE 35 Scanner.
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2.3.14 Reducing and Denaturing SDS-PAGE and Fluorography
Reducing and Denaturing SDS-PAGE was carried out as detailed in Section 
2.3.13 with 0.296 kBq Rainbow [^"^C]-iabei!ed molecular weight protein 
markers (Specific activity 148 kBq/ml, Amersham Biosciences, UK) run 
alongside samples to allow molecular weight estimation. The gels were then 
exposed to the fluorographic reagent AMPLIFY (Amersham Biosciences) 
before exposure to pre-fiashed film (Hyperfilm-MP High performance, 
Amersham Biosciences) and storage at -70 °C. After a suitable period, the 
film was developed using an Agfa Curix 60 developer.
CHAPTER 4
2.3.15 Media and Reagents for P.pastoris
P.pastoris GS115 (Invitrogen) was maintained in yeast extract peptone 
dextrose (YPD) broth. MD plates were used for plasmid selection, BMG broth 
for enrichment and BMM broth for induction.
- 1 0 0
2.3.16 Construction of Expression Plasmids
(Carried out by Dr. Marcos J. C. Alcocer, of Division of Nutritional Sciences, 
University of Nottingham)
The ES-62 gene (Harnett et a l, 1999b) was amplified by PCR at 35 cycles of 
94 °C 30 s, 54 °C 30 s, 72 °C 90 s, using Amplitaq (2 U/100 !_il; Applied 
Biosystems) according to the manufacturer’s instructions. The PCR product 
(ca. 1500 base pairs ((bp) was gel-purified, digested with Eco Rl/ Xho I 
enzymes for 4 h at 37 °C and ligated into pPIC9 (Invitrogen) previously 
digested with the same enzymes. The resulting plasmids were transformed 
into E. coli XLIBIue (Stratagene) and selected under ampicillin (100 pg/ml) 
according to standard protocols (Ausubel et a l, 2001). Plasmids containing 
the inserted gene were purified (midi kit - Qiagen) and sequenced using the 
ABI Prism BigDye Terminator Cycle Sequencing Kit and an automated 
sequencer (Applied Biosystems).
2.3.17 Transformation and Expression in P. pastoris
(Carried out by Dr. Marcos J. C. Alcocer, of Division of Nutritional Sciences, 
University of Nottingham)
pPIC9-derived plasmids containing ES-62-encoding sequences were 
linearised at the Sal I site for 4 h at 37 °C. The linearised plasmids were then
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transformed into P. pastoris GS115 (5 j.ig/transformation) and the 
transformed strains were selected on MD plates following electroporation 
according to the manufacturer’s instructions (Invitrogen). Clones able to grow 
in the absence of histidine were inoculated into a sterile 96 well plate format 
containing BMG and incubated overnight at 30 °C. The 96 clones were then 
expanded in 24 well plates containing BMG (1.5 ml/well) and incubated 
overnight at 30 °C. After centrifugation (750 g for 15 min), the 24 well plates 
were emptied by suction and BMM broth (containing methanol at 0.5 % v/v) 
added. Expression ensued in an orbital shaker (2.5 g) over 48 h with addition 
of methanol (0.5 %) every 12 h. The 24 well plates were then centrifuged 
(750 g for 15 min) and the supernatant (500 pi) transferred under vacuum to 
a wetted Polyvinylidene fluoride membrane (PVDF, Millipore) in a dot blot 
format system. The membrane was then blocked by incubation with 10 ml of 
BSA, (5 % w/v) in TBS pH 7.5 (20 mM Tris pH 7.5, 0.9 % (w/v) NaCI) for 1 h. 
All incubations were performed at 37 °C in a standard hybridisation oven. 
After 3 washes (5 min each) with TBST (TBS plus Tween 20-0.1 % v/v), the 
membranes were incubated for 2 h with KK6 diluted (1:1000) in TBST plus 
20 % (v/v) of P.pastoris supernatant extract that was previously prepared and 
did not contain the target protein. The membrane was then washed 3 times 
with TBST and incubated for a further 1 h with the secondary HRP-labelled 
anti-mouse IgG, diluted 1:20000 in TBST. After the 3 washes with TBST the 
membrane was incubated with BCIP/NBT substrate. Once the reaction was 
completed, the blot was washed with 20 mM EDTA (BDH) and dried.
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Analysis revealed that most of the wells in the culture plate contained rES- 
62.
2.3.18 Large-scale Production of rES-62
A positive clone was selected and grown at high density (Optical Density 
(OD)eoo nm 3-6) in 2 X  2 L flasks containing MMG at 28 °C. The culture was 
then centrifuged (200 g for 10 min) and the pellet re-suspended in MMM and 
incubated with agitation (2.5 g) at 28 ""C for 48-72 h with the addition of 
methanol to a final concentration of 0.5 % (v/v) every 24 h. After induction, 
the supernatant was separated from the cells by centrifugation (200 g for 10 
min) and then filtered through a 0.22 pm membrane. The supernatant was 
then concentrated and the salt eliminated by buffer exchange (PBS pH 7.4, 
Biowhittaker, Lonza) using a tangential flow system (Vivascience, molecular 
weight cut off 100000). The sample was then further concentrated using 
Amicon centricon tubes with a 100000 molecular weight cut off membrane. 
Finally, the sample was assayed for protein content using the Biorad protein 
assay reagent as described in section 2.3.3.1 and then stored at -20 °C in 10 
% glycerol, 0.01 M MgS04.
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2.3.19 Site Direct Mutagenesis of Intact Plasmids
(Carried out by Dr. Marcos J. C. Alcocer, of Division of Nutritional Sciences, 
University of Nottingham)
In order to introduce point mutation on the pPIC9 based constructs, the 
general procedure described by Chen & Ruffner (1998) with minor 
modifications has been followed. Essentially two 5’phosphorylated primers 
complementary to different strands and separated by 300 bp between the 
3’ends were used. One of the primers carried the inserted mutation. The 
reaction mixture (50 pi) contained 10 ng of native plasmid, 10 pmol of each 
primer, 10 nmol of dNTPs, 5 nmol of ATP, 2.5 U plaque forming units {Pfu) 
DNA polymerase (Stratagene), 4 U Pfu DNA ligase (Stratagene), in 1 ml 
cloned pfu DNA polymerase reaction buffer consisting of 20 mM Tris-HC! (pH 
8.8), 10 mM KCI, 10 mM (NH4)2S04, 2 mM MgS04, 1% Triton X-100 and 100 
pg/mi BSA. The mixture was pre-incubated at 70 °C for 10 min allowing the 
ligase to repair any nicks in the template. It was then subjected to thermal 
cycling at 95 °C for 10 s (dénaturation), 50 °C for 30 s (annealing), 72 °C for 
17 min (extension), 95 °C for 10 s (dénaturation) and 72 °C for 17 min 
(annealing, extension and ligation) for 20 cycles. The amplified plasmid was 
then digested with Opr?I restriction enzyme (10 U) in the same PCR buffer at 
37 °C for 2 hours in order to remove the starting template DNA and
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subsequently introduced into E. co//XL1 Blue strain by electroporation. After 
ampicillin selection the transformed clones were amplified and sequenced 
following standard techniques.
2.3.20 Non-reducing and Non-denaturing SDS-PAGE and Staining
This was carried out using the BioRad Mini Protean III system, and the gels 
were cast using the same protocol outlined above in section 2.3.13, with the 
omission of SDS from the solutions in table 2.1. 10 pi of samples containing
2.5 pg protein were then loaded into the wells of the gel, along with 
Kaleidoscope Molecular weight markers to allow for rough sample size 
estimation, (accurate size estimation is not possible using this technique), 
and the gel run in electrophoresis buffer without SDS at a constant voltage of 
200 until the dye front had reached the bottom of the plates. The fixing and 
staining protocol is as described above in section 2.3.13.
2.3.21 SDS-PAGE and Western blotting
Western analysis was performed according to the manufacturer’s instructions 
(NOVEX, Invitrogen): after being subjected to SDS-PAGE, as described in 
section 2.3.13, proteins were transferred to Hybond-G (nitrocellulose 
membrane, Amersham) using the NOVEX XCell II Blot module (NOVEX, 
Invitrogen). The membrane was then blocked by incubation with 50 ml of 4 % 
BSA (w/v) in TBS pH 8.5 for 1 h, and all incubations were performed at room
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temperature with gentle agitation. Afl:er 3 x 10min washes with TBS pH 8.5, 
the membranes were incubated overnight with Rabbit ES-62 anti-serum 
diluted 1:500 in TBS pH 8.5 containing 2.5 % (w/v) BSA on some occasions, 
and TEPC 15 diluted 1:1000 in TBS pH 8.5 containing 2.5 % (w/v) BSA on 
others. The membrane was then washed 3 times with TBS and incubated for 
a further 2 h with the AP conjugated secondary antibody anti-rabbit IgG 
(Sigma-Aldrich), diluted 1:100000 in TBS containing 0.5 % BSA (w/v) where 
rabbit-anti-ES-62 serum was used as the primary antibody, and anti rabbit 
IgG (Sigma-Aldrich) diluted 1:30000 in TBS pH 8.5 containing 0.5 % BSA 
(w/v) where TEPC 15 was used as the primary antibody). After the 3 washes 
with TBS the membrane was incubated with BCIP/NBT substrate. Once the 
reaction was completed, the blot was washed with 20 mM EDTA and dried.
2.3.22 Dot Blotting
Dot blotting was undertaken by transferring 5pl of sample onto Hybond-C 
(Amersham Biosciences). The membrane was then blocked by incubation 
with 10 ml 4 % (w/v) BSA in TBS pH 8.5 for 30 min, and all Incubations were 
performed at room temperature with gentle agitation. After 3 x lOmin washes 
with TBS pH 8.5, the membranes were incubated for 1 h with KK6 diluted 
(1:1000) in TBS pH 8.5 containing 2.5 % BSA (w/v). The membrane was 
then washed 3 times with TBS pH 8.5 and incubated for a further 1 h with the 
secondary AP-iabelled anti-mouse IgG, diluted 1:20000 in TBS containing 
0.5 % BSA (w/v). After the 3 washes with TBS pH 8.5 the membrane was
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incubated with BCIP/NBT substrate. Once the reaction was completed, the 
blot was washed with 20 mM EDTA and dried.
2.3.23 N-Glycosidase F Digestion of rES-62
10 pg rES-62 was added to reaction buffer (0.05 M EDTA, 0.02 M Sodium 
Phosphate, 0.02 % NaNa) and SDS added to a final concentration of 0.1 %. 
This was boiled for 10 min and allowed to cool before adding NP40 to a final 
concentration of 0.75 %. 2 U of /V-Glycosidase (Glyko, Prozyme, Europa 
Bioproducts, UK) F per 10 pg of glycoprotein, or the corresponding volume of 
reaction buffer for negative controls was added, and samples were incubated 
at 37 °C overnight with gentle agitation. pES-62 was used as a positive 
control. The digests were then subjected to SDS-PAGE and staining, as 
detailed in section 2.3.13.
2.3.24 Endoglycosidase H Digestion of rES-62
After the activity of the enzyme had been ascertained using a known 
substrate, RNAse B (Sigma-Aldrich), 10 pg rES-62 was added to 100 mM 
Sodium Acetate Buffer pH 5.5 containing 0.1 M 2-ME and a 1.2 fold excess 
of SDS in relation to protein concentration. It is to be noted that if the 
concentration of protein is lower than 100 pg/ml, the final concentration of 
SDS must not exceed 0.02 %, as this may inhibit the enzyme. After boiling 
for 10 min, 250 mU of Endoglycosidase H (Roche Diagnostics, UK) to 1
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mg/m! glycoprotein was added, or the corresponding volume of reaction 
buffer for negative controls was added, and the samples were incubated at 
37 °C overnight with gentle agitation. The digests were then subjected to 
SDS-PAGE and staining, as detailed in section 2.3.13.
2.3.25 a-Mannosidase Digestion of rES-62
The activity of the enzyme was first ascertained using a known substrate (p- 
Nitrophenyl-a-D-mannopyranoside, Sigma-Aldrich). 10 pg rES-62 was 
incubated in 0.05 M Sodium Acetate, 0.2 mM ZnCE at a 1:1 ratio with a- 
Mannosidase (Sigma-Aldrich), or the corresponding volume of reaction buffer 
for negative controls at 37 °C overnight, and the digests then subjected to 
HPLC analysis.
2.3.26 Trypsin Digestion of rES-62
0.5 pi of 2 % SDS was added to 10 pg rES-62 and boiled for 10 min, then 
allowed to cool. 0.5 pi of 15% NP40 and 2.5 pg trypsin (Roche Diagnostics), 
or corresponding volume of 1 mM HCI for negative controls was added, and 
samples were incubated overnight at room temperature with gentle agitation 
with pES-62 as a positive control. The digests were then subjected to SDS- 
PAGE and staining, as detailed in section 2.3.13.
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2.3.27 Determination of Degree of Mannose Content of Recombinant Forms 
of ES-62
2.5 pg of pES-62, rES-62 I and II, and KOs 1,2 and 3 were subjected to SDS- 
PAGE, as detailed in section 2.3.13 and the proteins on the gel transferred to 
a nitrocellulose membrane, as described in section 2.3.21, in preparation for 
western blotting. The blot was probed with snowdrop Galanthus nivalus 
Agglutinin (GNA) lectin from the DIG Glycan Differentiation Kit (Roche 
Diagnostics). All stages were carried out at room temperature with gentle 
agitation, unless otherwise stated. The membrane was blocked for 30 min 
using blocking solution provided with the kit. The membrane was then 
washed twice for 10 min with TBS pH 7.5 (0.05 M Tris, 0.15 M NaCI) and 
once for 10 min with Buffer 1 (TBS pH 7.5 + 1 mM MgCE and 1 mM 
CaCl2.H20). The membrane was then incubated for 1 h with 50 ml Buffer 1 
containing GNA at a concentration of 1:1000. After washing three times for 
10 min, each wash with TBS pH 7.5, the membrane was then incubated for 1 
h in 50 ml TBS pH 7.5 containing anti-digoxenin-AP at a concentration of 
1:1000. After washing three times with TBS pH 7.5, the membrane was 
incubated with NBT/x-phosphate substrate at a 1:50 dilution in buffer 2 (0.1 
M Tris, 0.05 M MgCb, 0.1 M NaCI, pH 9.5) with no shaking until colour 
developed. The reaction was then stopped by washing the membrane in 
dH20 and the membrane dried.
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2.3.28 High Performance Liquid Chromatography (HPLC) Separation of 
Recombinant ES-62 K01
HPLC separation of recombinant ES-62 K01 was carried out by Dr. Günter 
Lochnit and Prof. Rudolf Geyer, of Institute of Biochemistry, University of 
Giessen
2.3.29 Carbohydrate Constituent Analysis
Carbohydrate constituent analyses were carried out by Dr. Günter Lochnit 
and Prof. Rudolf Geyer, of Institute of Biochemistry, University of Giessen as 
detailed elsewhere (Geyer et al., 1982).
CHAPTER 5
2.3.30 Animals and Inoculations
For immunisation studies: BALB/c mice were bred at the University of 
Strathclyde, and used at 6-8 wks old. Three groups of five female BALB/c 
mice received weekly subcutaneous injections of 2 pg per animal of either 
pES-62 or rES-62. Weekly serum samples were taken and antibody levels to 
ES-62 and rES-62 measured by as described in section 2.2.31.
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WT BALB/c and C57/BL6 mice were purchased from Harlan Olac (Bicester, 
UK). TLR4 ko and MyD88 ko mice (on a C57/BL6 background) were 
generously donated by Professor S. Akira, University of Osaka, Osaka, 
Japan and were housed at the Universities of Manchester with the aid of Dr. 
K. Else and Cambridge, UK, with the help of Dr. S. Totemeyer. Mannose 
receptor ko mice were a kind gift from Professor S. Gordon, Sir William Dunn 
School of Pathology, Oxford and Professor Michael Nussenzweig, The 
Rockefeller University, New York, USA.
2.3.31 Antibody ELIS As
Flat bottom medium binding 96-well plates were coated with 100 pi 
phosphate buffered saline (PBS) pH 9.0 containing pES-62 or rES-62 at a 
concentration of 2 pg/mi overnight at 4 °C. After washing, the plates were 
blocked for 1 h at 37 °C with 150 pl/weil 4 % (w/v) BSA in PBS. The plates 
were then washed with PBS pH 7.0 plus 0.05% (v/v) Tween 20 (PBS/tween) 
and duplicate samples of sera from the immunisation study were added at a 
concentration of 1:100 and serially diluted threefold down the length of the 
plate in PBS/Tween and the plates incubated for 1 h at 37 °C. After washing, 
wells were incubated with 100 pl/well of a 1:20000 dilution of peroxidase- 
conjugated rabbit anti mouse IgGI or lgG2a for 1 h at 37 °C. The plates were 
washed three times and 100 pl/well substrate added and the plates 
incubated at room temperature in the dark for 15 min to allow colour
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development. The reaction was stopped by the addition of 50 pl/well 10 % 
(v/v) H2SO4 and the absorbance read at 450 nm. Data are expressed as 
reciprocal end point dilutions, with error bars calculated by standard error of 
the mean.
2.3.32 Cytokine ELISAs
IL-12p40, TNFa, IFNy, IL-4 and IL-10 ELISAs were carried out according to 
manufacturers instructions (IL-12p40 and TNFa; BD PharMingen, San Diego, 
USA; IFNy, IL-4 and IL-10 eBioscience, UK)).
High-binding 96-well plates (Greiner Bio-One Ltd, UK) were coated with 50 pi 
coating buffer (IL-12p40 - 0.2 M sodium phosphate, pH 6.5, TNFa - 0.1 M 
sodium carbonate pH 9.5, eBioscience kits included a coating buffer) 
containing the appropriate cytokine capture antibody at the concentration 
indicated by the manufacturer: IL-12p40. TNFa, IL-4 and IL-10 - 1:250; IFNy - 
1:1000 overnight at 4 °C. After washing three times in PBS/tween, the plates 
were blocked for 1 h at room temperature with 75 pl/well 10 % HiFCS (v/v) in 
PBS pH 7.0 for BD kits (assay diluent) and kit provided assay diluent for 
eBioscience kits. The plates were then washed three times with PBS/tween 
and triplicate samples of cell culture supernatant added and a standard curve 
of doubling dilutions of standard cytokine starting at a concentration indicated 
by the manufacturer and diluted in assay diluent (IL-12p40 and TNFa - 5 
ng/ml; IFNy and IL-10 - 2 ng/ml; IL-4 - 500 pg/ml) created. The plates were
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then incubated for 2 h at room temperature. After washing five times with 
PBS/tween, wells were incubated for 1h at room temperature with 50 pl/well 
of assay diluent containing the appropriate detection antibody at the 
concentration indicated by the manufacturer: IL-12p40, TNFa, IL-4 and IL-10 
- 1:250; IFNy - 1:1000. The plates were washed five times with PBS/tween, 
and 50 pl/well of enzyme reagent (Streptavidin HRP conjugate for both kits) 
at a concentration of 1:250 in assay diluent added and the plates incubated 
for 30 min at room temperature. After submerging wells in PBS/tween for 30 
s/1 min prior to aspiration, followed by washing seven times with PBS/tween, 
50 pl/well substrate (TMB substrate included in kit for eBioscience kits, 
SureBlue™ TMB Microwell peroxidase substrate for BD kits) added and the 
plates incubated at room temperature in the dark for a maximum of 15 min to 
allow colour development. The reaction was stopped by the addition of 50 
pl/well 2N H2SO4 and the absorbance read at 450 nm and 570 nm. Data are 
expressed as reciprocal end point dilutions, with error bars calculated by 
standard error of the mean.
2.3.33 Culture of bmDC
After the femurs had been dissected from BALB/c mice, all muscle tissue 
was removed from the bones using gauze. The bones were then placed in a 
60 mm dish of 70 % alcohol for 1 min, washed twice with PBS and 
transferred into a fresh dish containing RPMI 1640. Once both ends of the 
femurs had been cut using scissors in the dish, the marrow was flushed from
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within using a syringe filled with 2 ml of RPMI, fitted with a 25-gauge needle. 
The tissue was then suspended and passed through a 100 pm nylon mesh 
(“nitex”, Cadisch Precision Meshes, UK) to eliminate any fragments of bone 
or other debris. The red blood cells were then lysed by exposing the cell 
suspension to 0.168 M ammonium chloride for 7 min on ice. The cells were 
then washed twice with fresh media by centrifugation at 300 g for 5 min, 
discarding the supernatant, re-suspending the cells and then replacing the 
supernatant with fresh media, and bone marrow cells seeded on to low- 
adherence 75 cm^ flasks (Corning, Fisher) containing bmDC media at 37 °C 
in a humidified incubator.
On day 4, 10 ml fresh media was added to the flasks to replenish cells.
On day 6, loosely adherent cells were removed by gentle pipetting and 
centrifugation and used as immature DC.
2.3.34 Treatment of bmDC with Moduiins
bmDC cells were cultured using the protocol outlined in section 2.3.32. On 
day 6, after washing the cell suspension twice by adding fresh DC media, 
spinning the sample at 300 g for 5 min and re-suspending the cells in fresh 
DC media, 20 pi of the resultant cell sample was added to 20 pi of trypan 
blue (1:10 dilution in RPMI 1640) and the number of cells counted using a 
haemocytometer, and the following formula utilised
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Total number of cells = (number of cells counted/number of squares counted) 
X  number of squares in the haemocytometer x dilution factor x volume which 
cells were re-suspended in x 10 .^
The DCs were then seeded into 24 well plates at 2x10^ cells per well in 1 ml 
media and were grown for a further 24 h at 37 °C, in the presence or 
absence of 2 pg/ml ES-62 or rES-62.
On day 7, the cells were grown for a further 24 h at 37 °C in the presence or 
absence of 1 pg/ml LPS {E. coli serotype 0111:B4, Sigma-Aldrich). Both 
duplicate plates were exposed to ES-62/rES-62 for 24 h as detailed above. 
On the day 8 (co-culture day), The plates were spun at 300 g for 5 min and 
the supernatant removed for analysis of cytokine content by ELISA.
2.3.35 Statistics
Statistical significance of ELISA data was calculated using students t test. 
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2.3.36 Circular Dichroism
(Carried out by Dr. Alexandra S. Solovyova and Dr. Olwyn Byron of Division 
of Infection and Immunity, Institute of Biomedical and Life Sciences, 
University of Glasgow)
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Circular dichroism (CD) spectra of rES-62 were recorded at 20 °C using a 
JASCO J-600 spectropolarimeter (JASCO UK Ltd, UK). The far ultra violet 
(UV) CD spectrum (260-190 nm) and near UV CD spectrum (320-260 nm) of 
rES-62 was measured using a 0.02 cm path length quartz cell. The protein 
concentration was 0.5 mg/ml in phosphate buffer (91.5 mM Na2HP04, 58.5 
mM NaH2P04, pH 7.4). Secondary structure estimations were obtained using 
the Provencher and Glockner method (Provencher & Glockner, 1981).
2.3.37 Analytical Ultracentrifugation (AUC)
(Carried out by Dr. Alexandra S. Solovyova and Dr. Olwyn Byron of Division 
of Infection and Immunity, Institute of Biomedical and Life Sciences, 
University of Glasgow)
Sedimentation velocity (SV) and sedimentation equilibrium (SE) experiments 
were performed at 4 °C in a Beckman Coulter (Palo Alto, CA, USA) Optima 
XL-I analytical ultracentrifuge using both absorbance at 278 nm and 
interference optics. The partial specific volume ( v) for the protein part of rES- 
62 was calculated from its AA sequence, using the program SEDNTERP 
(Laue et al., 1992). The contribution of the carbohydrate part was estimated 
using following formula (Durchschlag, 1986)
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Vp + Vi
V complex = : (1)
where Vp and Vj are the partial specific volumes of the glycosylated
the protein, protein part alone and the carbohydrate part respectively; 0, is the 
amount of carbohydrate in grams per gram of protein. The partial specific 
volume for the glycosylated form of rES-62 was calculated using values valid 
for a temperature of 20 °C and then extrapolated to the experimental 
temperature following the method of Durchschlag (1986)
V t  =  V2o +  4.25x 10“‘ (T-293.15) (2)
where T is the experimental temperature (K).
The density and viscosity of PBS buffer at the experimental temperature was 
calculated using SEDNTERP. The distribution of sedimenting material was 
modelled as a distribution of Lamm equation solutions (Schuck, 2000) where 
the measured boundary a(r,t) was modelled as an integral over the 
differential concentration distribution c(s). 
a(r, t) = J  c(s)x(s, D, r, t)ds + q) (3)
where cp is a noise component, r is the distance from the centre of rotation
and t is time. The expression %(s, D, r, t) denotes the solution of the Lamm
equation for a single species (Lamm, 1929) by finite element methods 
(Schuck, 1998). Implemented in the program SEDFIT
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(www.analyticalultracentrifugation.com) the integral Eq. 3 is solved 
numerically by discretisation into a grid of 150 sedimentation coefficients for 
interference data and 200 coefficient for absorbance data and the best-fit 
concentrations for each plausible species are calculated via a linear least 
squares fit. The sedimentation velocity profiles were fitted using a maximum 
entropy régularisation parameter of p = 0.95. This model was applied to 
describe the heterogeneity of the material moving in the AUC cell. Also, SV 
boundaries were treated as comprising discrete independent species for the 
exact determination of sedimentation coefficients (s) for the species 
observed. Sedimentation coefficients were extrapolated to zero concentration 
and converted to standard conditions: those that would be measured at 20 
°C in water.
Equilibrium in SE experiments was attained after 45 hours. The speeds of 
rotation were selected so that the value for the parameter a (the reduced 
apparent molecular weight) (Yphantis, 1960) was between 2 and 4 for each 
plausible oligomeric species. Thus, SE traces for rES-62 were obtained at 
8000 revolutions per second (rpm), 11500 rpm, 16500 rpm, 20000 rpm and 
23000 rpm. True optical baselines were obtained after a further 6 h of 
rotation at 48000 rpm. The concentration of samples in the SE experiments 
ranged between 1.5 p.M and 23 pM of rES-62 monomer. SE data were fitted 
globally using the Beckman XL-A - XL-I software implemented in Microcal 
ORIGIN 6.0 and the NONLIN program (Johnson et al., 1981) (WINDOWS
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version) and also the program SEDPHAT
(www.analvticalultracentrifuqation.com) (Vistica e t al, 2004).
2.3.38 Small-angle X-ray Scattering
(Carried out by Dr. Alexandra S. Solovyova and Dr. Olwyn Byron of Division 
of Infection and Immunity, Institute of Biomedical and Life Sciences, 
University of Glasgow)
rES-62 was extensively dialysed against PBS buffer prior to small-angle x- 
ray scattering experiments. Concentrated rES-62 was microfuged (20800 g) 
for 20 minutes and then transferred into a capillary and placed in the SAXS 
beamline at the ELLETRA synchrotron (Trieste, Italy) with an electron energy 
of 2 GeV and a wavelength of 1.5 A. Two camera lengths were used in the 
experiments: 1.5 m to cover a momentum transfer range of 0.01 < s < 0.3 
and 0.8 m for 0.1 < s < 0.5 A"\ where s = (4:rcsin6)/X, and 20 is the scattering 
angle. The ID  detector was calibrated using a sample of silver bionate. For 
the short camera length the concentration of the protein was 10 mg/ml while 
for the long camera length the sample concentration was 7 mg/ml. 
Experimental data were collected and averaged as 30x60 s frames for both 
camera lengths. The data were normalised for buffer scattering and detector 
response using in-house software run on an IgorPro platform.
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TABLES
Table 2.1
Composition of Resoiving (12 %) and Stacking (4 %) Geis
12% 4%
dHzO 3.4 ml 6.1 ml
30 % Acrylamlde 4 ml 1.3 ml
Tris Buffer 2.5 ml 1.5 M Tris Buffer 2.5 ml 0.5 M Tris Buffer
SDS 10 % (w/v) 100 [.il 100 i-il
0.1 g/ml Ammonium Persulfate 
((NH4)2S20a, Sigma-Aldrich) 50 ml 50 ml
TEMED (N’N’N’N’-
Tetramethylethylenediamine, Sigma- 10 p,l 5 |.il
Aldrich)
Composition of resolving (12 %) and stacking (4 %) portion of gels for use
with the Mini Protean III system (BioRad, UK). For non-reducing gels the
SDS was not included.
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Table 2.2
Composition of Loading Buffer for PAGE under denaturing and
reducing conditions
Deionized H2O 3.55 ml
0.5 M Tris-HCI pH 6.8 1.25 ml
Glycerol 2.5 ml
10 % (w/v) SDS 2 ml
0.5 % (w/v) Bromophenol Blue 0.2 ml
Composition of loading buffer for PAGE under denaturing and reducing 
conditions. The working loading buffer contains 5 % 2-ME, and is mixed 1:2 
with sample.
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Table 2.3
Composition of Loading Buffer for PAGE under non-denaturing and
non-reducing conditions
Deionized H2O 5.55 ml
0.5 M Tris-HCI pH 6.8 1.25 ml
Glycerol 3 ml
0.5 % (w/v) Bromophenol Blue 0.2 ml
Composition of Loading Buffer for PAGE under non-denaturing and non­
reducing conditions. The sample is mixed 1:2 with loading buffer.
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Chapter 3: New Attempts to Produce 
PC-free ES-62 Using Enzymes and 
Enzyme inhibitors
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3.1 INTRODUCTION
The major contribution of the PC moiety of ES-62 to the molecule's 
immunological properties has long been known. PC has been implicated in: 
B cell anergy associated with low levels of PC similar to those seen in 
filariasis sufferers (Harnett and Harnett, 1993; Harnett et al., 1999a); IL-10 
production by B1 cells (Palanivel et al., 1996); blocking an lgG2a response to 
ES-62 in mice (Houston et al., 2000) and inhibiting antigen receptor 
stimulated polyclonal activation of the human T-cell line Jurkat (Harnett et al., 
1998; Harnett et al., 1999a). The latter is consistent with Lai et al.’s (1990) 
finding that B.malayl PC-containing molecules were capable of inhibiting 
proliferation of human T lymphocytes.
In order to further investigate the role of PC in ES-62's Immunomodulatory 
activities, ES-62 lacking PC was produced using inhibitors of enzymes 
involved in N-linked oligosaccharide processing. The enzymes examined in 
particular were 1-deoxymannojirimycin (dMM) (Houston, Cushley and 
Harnett 1997), an analogue of mannose which inhibits the addition of GlcNAc 
by preventing the removal of terminal mannose residues by Mannosidase I 
(Elbien, 1987, Figure 3.1) as it has been known for some time now that PC is 
attached to ES-62 via GlcNAc (Haslam et a i, 1997); or with an inhibitor of 
PC synthesis, HC-3, the choline kinase inhibitor (Houston and Harnett, 
1999b, Figure 3.2). Although some work was carried out using this material 
(Houston et al., 2000), the use of these inhibitors to produce PC-free ES-62
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was ultimately found to be too inconsistent with respect to efficacy to warrant 
routine application. It was decided to widen the focus of the investigation, 
and attempt production of PC-free ES-62 with enzymes and inhibitors related 
to those used previously, in an effort to remedy the efficacy issues 
encountered.
The enzymes which were chosen were: p-N-acetylhexosaminidase, an 
exoglycosidase which removes GlcNAc from the non-reducing end of 
oligosaccharides/glycosides (Jones & Kosman, 1980); 
glycerophosphocholine phosphodiesterase and sphingomyelin 
phosphodiesterase, two phosphodiesterases with differing specificities and 
recombinant phosphorylcholine esterase of Streptococcus pneumoniae (Pee) 
(de las Rivas et a!., 2001), which was considered a promising candidate, due 
to its ability to cleave PC from carbohydrate (Holtje and Tomasz, 1974).
The two Inhibitors chosen to investigate, similar to HC-3, targeted the 
Kennedy pathway of phosphatidylcholine biosynthesis (reviewed by Croft, 
Siefert and Duchene, (2003); Miquel et a!., 1998). Both enzymes inhibit CDP- 
choline synthesis via citidylyl transferase (Geilen, Wieder and Re utter, 1992; 
Baburina and Jackowski, 1998 respectively). These were erucyl 
phosphocholine (C22,i,cis) (EPC), an alkylphosphocholine related to 
Hexadecylphosphocholine (HEPC) (Ci6:o), a phospholipid analogue and rac- 
1-0-octadecyl-2~0-methyl-glycero-3-phosphocholine (EtisOCHa), an alkyl 
glycerophosphocholine , both of which have been used as chemotherapy 
against a number of species of protozoan parasites (reviewed by Croft,
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Siefert and Duchene, 2003). Our lab has previously attempted inhibition of 
PC attachment to ES-62 using HEPC, but finding a concentration which was 
non-toxic to the worms whilst preventing PC attachment and 
phosphatidylcholine biosynthesis proved impossible (Houston and Harnett, 
1999b).
It is therefore hoped that the enzymes and inhibitors decided upon for further 
investigation will succeed in removing PC from ES-62, allowing for PC-free 
ES-62 to be compared with the naturally occurring PC-containing ES-62 
(pES-62), in an effort to precisely define the extent of the role of PC in the 
immunomodulatory activities of ES-62.
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3.2 RESULTS
3.2.1 Enzyme Digestion Attempts: p-N-acetylhexosaminidase
The level of radioactivity of pH]-giucosamine-labelled ES-62 was consistently 
reduced by -35 % by |3-N-acetylhexosaminidase (Fig. 3.3), although when 
the reaction was repeated using [^H]-choline labelled ES-62, no significant 
loss of radioactivity was recorded (Fig. 3.4), suggesting the enzyme is unable 
to cleave the terminal GlcNAc residues to which PC is attached.
3.2.2 Enzyme Digestion Attempts: phosphodiesterases
No PC was removed from ES-62 by glycerophosphocholine 
phosphodiesterase, although -35 % could be removed from the denatured 
protein (results not shown), whilst -25 % of the radioactivity was removed 
routinely by sphingomyelin phosphodiesterase (Fig. 3.4).
3.2.3 Enzyme Digestion Attempts: Pee
The best reduction In PC seen using Pee was -40 % (Fig. 3.4). This could 
not be improved upon by increasing either digestion time or concentration of 
enzyme, and in general the results yielded by the enzyme were quite 
variable.
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3.2.4 Inhibitors: EPC
The ability of 10 mM EPC to inhibit incorporation of [^H]-choline into ES-62 
was extremely variable, rarely significant although at best reduced [^H]- 
choline attachment by -50% (Fig. 3.5). Under identical conditions, by 
measurement of pS]-methionine incorporation, the levels of ES-62 protein 
synthesis and secretion were found to be unaffected (Fig. 3.6).
3.2.5 Inhibitors: EtiaOCHa
A consistent reduction of >50 % of [^H]-labelled choline incorporation was 
seen when worms were cultured in the presence of 10 pM EtiaOCHs (Fig. 
3.5), with no discernable impact on methionine incorporation (Fig. 3.6). 
Raising the concentration to 20 pM resulted in -70 % reduction (Fig. 3.5), 
and again, this was not due to toxic effects, as methionine incorporation 
remained unaffected (Fig. 3.6). Higher concentrations of inhibitor were found 
to be toxic and so were not investigated further (results not shown).
In order to investigate whether the 70 % reduction in pH]-choline 
incorporation was due to 70 % of the radioactivity of all of the ES-62 being 
lost, or whether 70 % of the ES-62 contained no radioactivity as a result of 
the inhibitor, immunoprécipitation of control or 20 pM EtigOCHs produced 
[^®S]-methionine labelled ES-62 using TEPC 15 (a myeloma derived antibody
128 -
specific for PC, Leon and Young, 1971) was carried out. It would seem that 
the former theory is more likely, as -90 % of the ES-62 derived from 
EtisOCHs cultured worms was immunoprecipitable, indicating that the 
majority of ES-62 from the inhibitor-exposed group has reduced PC, but that 
only -10 % is truly PC-free.
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3.3 DISCUSSION
Since discovering that PC could be completely removed from ES-62 using 
the enzyme A/-glycosidase F (Harnett et al., 1993), to date no other enzyme 
has been found with this ability. It is regrettable that in order to achieve total 
removal of PC from ES-62, the protein first has to be denatured, and that the 
enzyme removes all carbohydrate from the protein. The resultant PC-free 
ES-62 will therefore not be in the same form as the naturally occurring, 
nematode derived PC-containing ES-62, which had been indicated to form a 
tetramer in its natural state by gel filtration in 1993 (Harnett et al.) and later 
confirmed by sedimentary equilibrium (SE) data (Ackerman et a i, 2003) i.e. it 
will be monomeric and deglycosylated. Consequently, use of this enzyme 
means that immunomodulatory effects of pES-62 lacking the PC moiety 
whilst retaining intact glycans cannot be fully investigated.
In BALB/c mice, injection of pES-62 is known to cause an almost exclusive 
Th2 response (Harnett et al., 1999a). When PC-free material produced using 
HC-3 or dMM was used previously, BALB/c mice immunised with the 
material exhibited a mixed Th1/Th2 antigen specific response (Houston et 
al., 2000), regardless of which inhibitor had been employed. As these 
enzymes target addition of PC to ES-62 in different ways, the glycan 
structures remaining on PC-free pES-62 produced by these methods will 
vary. This suggests PC, rather than specific carbohydrate structures, to be 
the main suppressor of a Thi response to pES-62 in mice. Nevertheless, a
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role for glycans in the immunomodulation associated with pES-62 cannot be 
ruled out yet, and as such, a more efficient method for producing ES-62 
lacking only PC is still greatly desirable.
p-A/-acetylhexosaminidase, an enzyme known to cleave terminal (3-linked 
GlcNAc residues (Jones and Kosman, 1980) was used in an attempt to 
remedy this. As it is these residues to which PC is attached on ES-62, it was 
hoped that dénaturation might not be required, as the GlcNAc would be more 
accessible to the enzyme than the target of /V-glycosidase F, and that the 
remainder of the ES-62 glycan structures would remain relatively intact. It 
was of some concern, however, that the attachment of PC to GlcNAc would 
be sufficient enough a change to interfere with the enzyme’s ability to remove 
the residue. Unfortunately, the data indicate that this fear has been borne 
out, as although -35 % of the pH]-glucosamine radiolabel had been removed 
from ES-62, this figure was not improved upon when denatured radiolabelled 
ES-62 was incubated with the enzyme, and no radiolabel was removed at all 
when [^H]-choline labelled ES-62 was subjected to the same procedure.
Only one of the two phosphodiesterases we attempted to remove PC with 
had an effect on the molecule in its natural state. Glycerophosphocholine 
phosphodiesterase was completely unable to remove any radiolabel from the 
ES-62, although a figure of -35 % removal was achievable by subjecting 
denatured ES-62 to a prolonged exposure to the enzyme (results not shown). 
This most likely indicates that these conditions allow for better access of the 
enzyme to its target. Sphingomyelin phosphodiesterase normally generates
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ceramide and PC via the hydrolysis of sphingomyelin (Liu et al., 1998), and 
was able to remove -25 % of [^H]-choline from ES-62.
Pee produced very variable amounts of PC removal, which could not be 
enhanced or stabilised by increased assay length/enzyme concentration. 
This has been previously reported in the course of digestion attempts of PC- 
containing pneumococcal cell walls with the enzyme (Holtje and Tomasz, 
1974; de las Rivas et al., 2001; Vollmer and Tomasz, 2001). Two 
explanations have been suggested by these investigators: either the 
remaining PC residues are inaccessible to the enzyme, as the studies 
mentioned reported further PC release upon the addition of fresh 
S.pneumoniae cell wall preparations, indicating that the enzyme is still active; 
or that Pce’s action is quite discrete, targeting only one of two PC-sugar 
interactions within the cell wall repeating unit (Behr et al., 1992; Fischer et 
al., 1993). Both arguments are equally plausible in our case, as it has been 
shown that there may be more than one PC group on each A/-glycan on ES- 
62 (Haslam et al., 1997), and ES-62 exposed to Pee (and thus containing 
less PC) Is still able to bind TEPC 15, indicating the PC remains accessible. 
The molecule’s sensitivity to the enzyme cannot be improved by dénaturation 
(results not shown). In light of the latter two results, weight is lent to the 
theory of differing specificity.
As a result of these experiments, which again showed the process of 
removing PC from ES-62 whilst retaining the natural structure of the 
molecule to be extremely difficult when approached by enzymatic removal or
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enzyme inhibitor-based methods, it was decided to try a new approach: to 
insert the gene for ES-62 into a recombinant protein expression system 
which would not contain the machinery necessary to add PC onto the 
resultant protein. Attempts using E.coli had resulted in an Insoluble protein 
(Ackerman PhD Thesis, 2002), and utilisation of the Baculovirus system led 
to suspected viral DNA contamination problems which could not be 
remedied, making the protein produced unviable for further characterisation 
(Ackerman PhD Thesis, 2002). It was therefore decided to use the Pichia 
pastoris system (Invitrogen), as it was hoped that this system would provide 
the eukaryotic post-translational modifications necessary to create a soluble 
working protein, whilst side-stepping the problematic issues of viral DNA 
contamination seen with the Baculovirus system, and hyper-glycosylation, 
which is often seen when using Saccharomyces cerevisiae based protein 
expression systems. The following chapter details the production and initial 
characterisation of recombinant ES-62 (rES-62) produced in this way.
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3.4 FIGURES
Figure 3.1. Sugar Biosynthetic Pathway in the 
Endoplasmic Reticuium and Goigi
Schematic representation of the sugar biosynthetic 
pathway from the ER and Goigi Apparatus, illustrating 
where dMM exerts its effect. In the ER (conserved 
from yeast to mammals) - Man9GlcNAc2 Glucose3 is 
first trimmed by Glucosidase I to 
MangGlcNAc2Glucose2 , then trimmed to Man8GlcNAc2 
by Glucosidase II and ER mannosidase. In the cis 
region of the Goigi apparatus, Man8GlcNAc2 is trimmed 
to Man5GlcNAc2 by Mannosidase I (inhibited by dMM). 
As the A/-glycan moves through the medial Goigi, an 
extra GlcNAc residue is added by GlcNAc transferase I 
and two more mannose residues are removed by 
mannosidase II, to create ManaGlcNAcs
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Figure 3.2. The Kennedy Pathway of 
Phosphatidylcholine Synthesis.
Diagram showing the Kennedy Pathway of 
phospholipid synthesis, illustrating where HC-3 exerts 
its effect. Choline is converted to phosphorylcholine 
(PC) by choline kinase, which is inhibited by HC-3. 
Phosphocholine citidyltransferase converts PC to 
CDP-choline, which is then converted to PtdChol by 
choline phosphotransferase. Finally PtdChol can be 
converted to sphingomyelin by SM synthase.
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Figure 3.3. Enzymatic Cleavage of PC from 
Blosynthetlcaily [^H]-glucosamlne Labelled ES-62
ES-62 biosynthetically labelled with pH]-glucosamine 
was incubated in the presence or absence of enzyme 
for 1 h at 37 °C. The reaction mixture was then 
subjected to TCA precipitation analysis. Data 
represent triplicate determinations. ^Represents p< 
0.05.
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Figure 3.4. Enzymatic Cleavage of PC from 
Blosynthetlcaily [^H]-chollne Labelled ES-62.
ES-62 biosynthetically labelled with [^H]-choline was 
incubated in the presence or absence of enzyme for 1 
h at 37 °C. The reaction mixture was then subjected to 
TCA precipitation analysis. Results obtained with 
inhibitors have been expressed as a percentage of the 
control to enhance interpretation. Data represent 
triplicate determinations, ^represents p< 0.05.
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Figure 3.5. Effects of inhibitors on PC Addition to 
ES-62: [^H]-choline labelled ES-62
Adult A.viteae were cultured in the presence or 
absence (control) of inhibitor with [^H]-choline. ES-62 
was then prepared from spent media and subjected to 
TCA precipitation. Data are presented in dpm and 
represent triplicate determinations. * represents p< 
0.05.
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Figure 3.6. Effects of Inhibitors on PC Addition to 
ES-62: f®S]-methionlne labelled ES-62
Adult A.viteae were cultured in the presence or 
absence (control) of inhibitor with [^^S]-methionine. 
ES-62 was then prepared from spent media and 
subjected to TCA precipitation. Data are presented in 
dpm and represent triplicate determinations, 
^represents p< 0.05.
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Chapter 4: Production and 
Biochemical Characterisation of rES 
62 from Pichia pastoris
1 4 0 -
4.1 INTRODUCTION
As seen in the previous chapter, the use of enzymes and inhibitors with a 
view to producing ES-62 free of PC whilst leaving the glycan structures to 
which the moiety is attached intact is not a simple procedure. Although some 
PC-free material was produced, In the main, the best effect achievable was a 
reduction in the levels of PC attached to ES-62, and some of the enzymes 
targeted glycosidic bonds, meaning some sugars were inevitably lost. The 
best reduction seen using the enzyme inhibitors investigated was ~70 %, 
though immunoprécipitation showed that only -10 % of this material could be 
considered truly PC-free: the levels of PC on the remainder of the sample 
must be reduced. It was for these reasons that it was decided to attempt to 
produce ES-62 using an expression vector without the ability to add PC post- 
translationally - Pichia pastoris.
This expression vector has a very simple lifecycle, and an ability to produce 
high quantities of a protein of eukaryotic origin, whilst secreting very few 
proteins of its own. The convenience of producing a parasite-derived 
molecule in such a way is an obvious advantage. It was hoped that the gene 
expression system, being eukaryotic in nature, would side-step solubility 
issues previously encountered when an Escherichia co//-based system was 
attempted (Ackerman 2002, PhD Thesis), as it would be able to perform the 
post-translational modifications necessary for production of a correctly folded 
protein, whilst avoiding hyperglycosylation issues frequently encountered
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when using a Saccharomyces cerevisiae-based system. The procedure was 
Indeed successful, and an abundant supply of recombinant protein was 
available for use. This chapter describes its characterisation.
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4.2 RESULTS
4.2.1 Oligomerisation and Antigenicity of Recombinant ES-62
An advantage of employing the Pichia pastoris expression system to produce 
secreted proteins is that the very low level of additional protein both secreted 
by the yeast and present in the culture medium means that most of the 
protein present In the latter is the recombinant protein. We therefore adopted 
a very simple purification scheme, removing all proteins of molecular mass < 
100000 from the medium by ultrafiltration. The medium was then 
concentrated and the sample analysed by PAGE under non-reducing and 
non-denaturing conditions. Two major polypeptides were observed, both 
diffuse in nature, one migrating slightly more slowly than the parasite-derived 
molecule and one rather faster (Fig. 4.1). Two further minor bands of likely 
lower molecular mass were also observed, one surprisingly (given the 
purification strategy) migrating more rapidly than OVA. Interestingly, unlike 
parasite-derived ES-62, which monomerises from a tetramer when examined 
by SDS-PAGE under reducing conditions (Harnett et al., 1993), all four 
polypeptides present in the concentrated Pichia culture medium showed little 
evidence of a change in mass (result not shown). In light of this result, it was 
decided to attempt digestion of the recombinant material with the serine 
protease trypsin. Trypsin targets peptide bonds C terminally at lysine and
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arganine, and its ability to fully digest proteins is used to the advantage of 
those wishing to discover their sequence. As can be seen (figure 4.2), the 
effect of trypsin on rES-62 was very poor, whereas the pES-62 was 
completely digested. There appeared to be no further digestion of the rES-62 
by trypsin when samples were left to digest for a period of two overnights 
(results not shown).
However, western blotting using the rabbit polyclonal antiserum against ES- 
62, suggested that the three bands of higher molecular mass might 
correspond to recombinant ES-62 (Fig. 4.3). To confirm that the recombinant 
protein lacked PC it was analysed using TEPC 15, a myeloma-derived 
antibody directed against PC. It can be seen in Figure 4.4 that only the 
parasite-derived protein is recognised by this antibody, confirming the 
absence of PC from the recombinant molecule. It was thus tentatively 
considered that the recombinant molecule might consist of several forms of 
ES-62 corresponding in size to tetramers, dimers and monomers with the 
oligomers being stable structures not amenable to dissociation. Consistent 
with this it was found that the recombinant molecule could not be completely 
monomerised even after boiling for ten minutes in the presence of 
mercaptoethanol. The changes in oligomerisation and susceptibility to 
monomerisation witnessed with the recombinant ES-62 raised the possibility 
that it might show some changes in conformation that could result in loss of 
peptide epitopes. However when the recombinant material was re-analysed 
by dot blotting for interaction with KK6, a mAb that recognises a
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conformational epitope on the parasite-derived protein (Stepek et al., 2002), 
binding was stili clearly apparent (Fig 4.5).
4.2.2 Amino Acid Sequence and Carbohydrate Constituent Analysis of 
Recombinant ES-62
Complete sequencing of the recombinant cDNA clone revealed three base 
mismatches. This corresponded to three AA changes at positions 245 
(glycine (G) > aspartic acid (D), 286 (lysine (K) > glutamic acid (E)) and 346 
(asparagine (N) > serine (S)) on the mature, secreted parasite-derived 
molecule (Flarnett et ai., 1999a). Preliminary lectin-binding analysis 
suggested that the recombinant material had higher mannose content than 
the parasite-derived material (discussed in section 4.2.4). The recombinant 
material was thus subjected to carbohydrate constituent analysis and its 
carbohydrate content was found to be ~6 % with a mannose/A/- 
acetylglucosamine ratio greater than 12:1. This compares with roughly 3 % 
carbohydrate for the parasite-derived protein, which also has much less 
mannose as a percentage (Flaslam et ai., 1997).
4.2.3 Effects of Changes in Giycosyiation on Oiigomerisation and Antigenicity 
of Recombinant ES-62
Mature ES-62 has four potential N-Xype giycosyiation sites although structural 
analysis of peptides derived from the molecule suggests that the site closest
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to the C-terminus (AA position 381) is not utilised (unpublished result). In an 
attempt to investigate the effect of giycosyiation on the structure and 
antigenicity of recombinant ES-62 three mutants were prepared each lacking 
one of the three remaining /V-type giycosyiation sites. Such treatment was 
found to have no effect on oligomerisation of the mutants as each consisted 
of a mixture of monomers, dimers and tetramers, as observed with the non­
mutated recombinant material (Fig 4.6).
4.2.4 Glycan Analysis of Recombinant and Recombinant Giycosylation-site 
Knock-out ES-62
An initial dot-blot using a glycan differentiation kit (results not shown) 
indicated that the main glycans attached to the recombinant and KOs were of 
the high mannose type, as by far the most convincing binding was seen 
using a lectin from Galanthus nivalis (Snowdrop) agglutinin (GNA), which 
recognises terminal mannose a(1-3), a(1-6) or a(1-2) linked to mannose 
(Shibuya et al., 1988; Kaku, Goldstein and Oscarson, 1991), a result which 
was in agreement with the carbohydrate constituent analysis results. Further 
investigation indicated the rES-62 to contain more high-mannose structures 
than any KOs. All P/cA/a-derived samples seemed to have more glycans of 
high-mannose type than the control lectin (Carboxy-peptidase Y), indicating a 
high degree of giycosyiation. It was therefore decided to use the glycans 
differentiation kit to probe a western blot of parasite-derived, recombinant 
and KOI, 2 and 3 ES-62 (Fig. 4.7). The results show that not only do the
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KOs seem to have less glycan structures than the recombinant, but also that 
all the P/c/?/a-derived samples contain a much higher content of high 
mannose structures than ES-62 from A.viteae.
4.2.5 Effects of Changes in Giycosyiation on Carbohydrate Constituent 
Analysis of Recombinant ES-62
When the three /V-type giycosyiation site KOs were analyzed for 
carbohydrate constituent content, it was also found that all the KOs still had a 
high proportion of mannose compared to the parasite-derived ES-62 (results 
not shown).
4.2.6 Effects of Changes in Amino Acid Composition on Oligomerisation and 
Antigenicity of Recombinant ES-62
To investigate the effect of the three AA changes, a new clone (rES-62 II) 
was selected that was shown to be mutation-free by complete sequence 
analysis. Analysis of the recombinant protein by non-denaturing PAGE 
revealed the same pattern of bands as observed for the original recombinant 
protein (Fig. 4.8).
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4.2.7 Recombinant ES-62 Sensitivity to Enzyme Digestion Compared to 
A.viteae ES-62
The eukaryotic nature of yeast glycoprotein processing and secretion makes 
Pichia an ideal expression system. These similarities, however, only hold 
true until the glycoproteins are transferred to the Golgi apparatus, where the 
yeast oligosaccharide processing events vary considerably from the events 
in higher eukaryotic cells (reviewed by Bretthauer and Castellino, 1999; 
Gereghino and Gregg, 2000). Therefore, it is logical to assume that the yeast 
will produce ES-62 whose glycome may not be entirely identical to parasite- 
derived material. It was therefore decided to compare the sensitivity of rES- 
62 and pES-62, to certain enzymes that target various sugar bonds to further 
assess the glycan structures attached to the recombinant protein. It was 
hoped that this would provide an explanation for the differences becoming 
apparent between the parasite-derived and recombinant material (for 
example, the seeming invulnerability of the recombinant material to 
dénaturation). These differences seemed incongruous when considered 
along with the similarities seen i.e. recognition of the recombinant by various 
antibodies that recognise the parasite-derived material in western blots, 
it was first attempted to digest the recombinant material using A/-Glycosidase 
F, an enzyme that specifically cleaves all types of asparagine-bound N- 
glycans, (Tarentino, Gomez and Plummer, 1985; Ghu, 1986) with the 
exception of A/-glycans with a difucose core (Tretter, Altmann and Marz, 
1991). pES-62 has been shown to be sensitive to digestion with this enzyme
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in the past (Harnett et al., 1993). Although, as shown previously, it can be 
seen that the enzyme has cleaved carbohydrate from ES-62 of A.viteae, 
Figure 4.9 shows that the A/-glycosidase F has failed to remove the glycans 
from rES-62 or any of the KOs.
Although the parasite-derived ES-62 has previously been shown to be 
insensitive to Endoglycosidase H, it was decided to investigate the sensitivity 
of rES-62 to the enzyme, due to evidence showing the glycans of many of 
the proteins produced using the Pichia system to be sensitive to this enzyme 
(Bretthauer and Castellino, 1999). However, again, it can be seen in Figure 
4.10 that the Endoglycosidase H seems to have had no effect on the rES-62. 
Recombinant ES-62 KOI was analysed using HPLC after being incubated 
with and without with a-Mannosidase from Canavalia ensiformis (Jack Bean), 
which hydrolyses terminal mannose residues on oligosaccharides or 
glycopeptides attached via a1-2,3,or -6 linkages (Li, 1967), which are 
commonly found in outer chain elongation of proteins produced by Pichia 
(reviewed by Gemmil and Trimble, 1999). HPLC of the recombinant KOI 
showed a fairly heterogeneous solution that eluted most of the species much 
earlier than with pES-62 normally does (20 min RT). As can be seen in figure 
4.11, after the enzyme treatment, the earlier eluting species disappeared, 
and the sample became more homogeneous: it can be seen that much of the 
mannose residues have been removed by the enzyme, confirming Pichias 
addition of mannose to the protein.
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4.3 DISCUSSION
The Pichia pastoris recombinant protein expression system was considered 
as a method for producing PC-free ES-62 for two reasons. Firstly, it was 
considered unlikely that P. pastohs would possess the biochemical 
machinery to transfer PC to A/-type glycans as to date it has only been 
observed in nematodes. Secondly, it was thought that the system would 
resolve the problem of unreliable efficacy associated with previously 
described methods (e.g. Houston and Harnett, 1999b), and with the attempts 
detailed in chapter 3. Both of these predictions turned out to be accurate as 
an adequate supply of PC-free material was readily produced. From the gels 
carried out, it appeared that not all of the recombinant material was able to 
tetramerise, instead being comprised of discrete monomeric, dimeric and 
tetrameric species, which proved extremely difficult to dissociate. Despite 
this, the rES-62 did react with a mAb against a conformational epitope on the 
pES-62 providing encouragement for the view that the molecule was likely to 
be more or less normally folded.
DMA sequencing of the recombinant clone had been undertaken at the 
beginning of the project to confirm identity but only at the N-terminal and 
hence the existence of the three base mutations was unknown. Unfortunately 
each of these resulted in a change in AA composition and equally 
unfortunate, in each case the change was not to a similar category of AA. 
Furthermore, each of the three AAs in ES-62 obtained from A. viteae is
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conserved in ES-62 derived from B. malayi (77% conservation overall: 
Stepek et al., 2004) raising the possibility that they could be important in 
producing correct protein folding. Certainly one of them - is in a 
predicted region of a-helix (Ackerman et al., 2003) and also of note is that 
is present in a region of the parasite-derived protein that shows 
homology to leucine rich repeats that could conceivably be involved in 
protein dimérisation. Nevertheless, when we came to examine a recombinant 
clone whose AA sequence was equivalent to that of the pES-62 it behaved in 
the same manner as the original recombinant clone with respect to 
oligomerisation and in binding a mAb directed against the pES-62.
Regarding giycosyiation, it had been expected that there would be an 
increase in mannose content typical of Pichia (Grinna and Tschopp, 1989) at 
the expense of complex glycan formation although the latter is fairly minimal 
in pES-62 in any case (Haslam et al., 1997). What was clear, however, was 
that there had been significant increase in the extent of giycosyiation with the 
implication that much larger glycan chains would be present. This is not 
entirely unheard of in proteins produced in Pichia, though it is thought to be a 
rare occurrence (reviewed by Gereghino and Gregg, 2000). What effect this 
would have on ES-62 structure Is uncertain but it is known that giycosyiation 
of proteins may stabilise secondary structure elements. Examination of any 
effect was attempted by mutating distinct A/-type giycosyiation sites. This, 
however, had no effect on oligomerisation or antigenicity with respect to the 
three mutants. Knocking out two or even all three giycosyiation sites and
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measuring the effect of this was considered, but previous experience of 
attempting to express ES-62 in E. coli suggested that the resultant material 
might prove to be insoluble (Ackerman, C. J., 2002 and unpublished results). 
Giycosyiation is the most intricate type of modification to be carried out co- or 
post-translationaliy on a protein (Spiro, 1973). It has been conserved 
throughout evolution, which emphasises its importance, although for a long 
time researchers struggled to ascribe it a general role in glycoproteins (Varki, 
1993). The nature of effects of /V-glycosylation on the protein to which it is 
attached is difficult to predict, seeming to vary from protein to protein, with 
different and sometimes conflicting roles being described for the sugars on 
different glycoproteins. Lis and Sharon (1993) proposed the hypothesis that, 
broadly speaking, assisting correct protein folding, and stabilising this 
conformation once achieved are the main functions of protein giycosyiation. 
This theory has been borne out by several investigators: in the case of free 
a-subunit of human chorionic gonadotropin (hGC), it was found that a semi­
glycosylated version deteriorated more rapidly when stored in solution for a 
prolonged period of time (Erbel et al., 2000). Wang et al. (1996) found that 
the oligosaccharides of glycoproteins appeared to stabilise the confirmation 
of the protein and add to its thermal stability when they examined a panel of 
five differentially glycosylated glycoproteins, and that these effects were 
intimately associated with the levels of giycosyiation on the molecule. They 
also showed that protein solubility was Increased in denatured and partially 
denatured proteins containing carbohydrates, and that their presence
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appeared to prohibit aggregation, leading to an increased yield of 
renaturation after cooiing. Although this evidence has been gathered mostly 
through removing sugars from glycoproteins and comparing characteristics of 
these molecules with intact versions of the molecule, the fact that Pichia has 
added demonstrably more oligosaccharides to rES-62 than are on pES-62 
may account for its mixture of apparently independent monomeric, dimeric 
and tetrameric species in comparison to the almost exclusively tetrameric 
pES-62. When the a-subunit of hGC is expressed alone (as opposed to in 
conjunction with the (3-subunit, with which it forms the heterodimeric, active 
hormone) it is over-glycosylated. This version of the free a-subunit becomes 
practically incapable of association with free (3-subunit, limiting heterodimer 
formation and thus active hormone. When the free a-subunit is isolated from 
cells grown in the presence of an inhibitor of a mannosidase II (swainsonine), 
the ability to form the heterodimer with the (3-subunit is restored (Blithe, 
1990).
The Erythhna corallodendron lectin self-associates in a radically different way 
from the dimer form typically seen in homologous lectins from other legumes 
(e.g. Con A and pea lectin), due to a heptasaccharide iinked at Asn17 of both 
of the subunits preventing the aforementioned dimer’s formation (Shaanan, 
Lis and Sharon, 1991). Perhaps the recombinant version of ES-62 is so 
swathed in glycans that it is interfering with the moiecule's self-association 
abilities.
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Trimming of these glycans using various enzymes targeting glycosidic bonds 
also proved largely unproductive, but even trypsin digestion of the 
recombinant was incomplete. The rES-62 appears to be particularly 
insensitive to enzymes. The major differences between the natural and the 
recombinant versions of ES-62 uncovered so far seem to lie In the extent of 
giycosyiation in each molecule - it is possible that the impact of yeast 
giycosyiation on the molecule could have affected the recombinant 
molecule’s structure and sensitivity to enzymes, creating quite a different 
glycoprotein to that of the natural molecule. However, it has been highlighted 
that although much is known about yeast giycosyiation, the early studies that 
provided much of this knowiedge employed rather abrasive methods that 
may have destroyed more sensitive structures (some of which could have 
been enzyme resistant, reviewed by Gemmill and Trimble, 1999). It has also 
been pointed out that the use of exo- and endoglycosidase enzymes for 
analysis can be misleading, as naturally not every combination of linkages 
can be tested, and as a consequence of this, predicted sensitivity of certain 
linkages may not necessarily be proven. rES-62 may contain a combination 
of glycan linkages which may have been predicted to be sensitive to 
digestion, but which shield each other from digestion. HPLC separation of a 
sample of rES-62 KOI before and after incubation with a-mannosidase 
revealed that the species that eluted earlier than the pES-62, seen in the 
non-incubated sample were absent in the enzyme-incubated sample. When 
a carbohydrate constituent analysis of these earlier eluting species was
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carried out, they were shown to contain a higher amount of mannose than 
those that eluted later, indicating that the Pichia system has indeed added 
mannosyl residues to the recombinant molecule.
It has been shown that glycosylated lipids used as carriers for drugs and 
gene delivery effectively target hepatocytes and m(j) (reviewed by Hashida, 
Kawakami and Yamashita, 2005). Mannosylated proteins have been proven 
to target non-parenchymal cells of the liver (Ogawara et a/., 1999), whilst 
mannosylated cationic liposome-based gene delivery systems have been 
shown to target m<\> (Kawakami et al., 2000). Since Pichia is known to 
preferentially (and almost exclusively) extend oligosaccharides by the 
addition of mannose (Grinna and Tschopp, 1989), if rES-62 was proven to be 
as robust as it appears, it may have appiications in drug delivery to these 
types of cells in, for example, cancer therapy, where the anti-tumour drugs 
can have serious side effects in non-cancerous tissues.
It was not surprising to find that the majority of the sugars attached to the 
P/c/?/a-derived ES-62 samples appeared to be of the high mannose type, 
given the nature of the expression vector chosen (Grinna and Tschopp, 
1989); however, it was originally thought that using Pichia as opposed to 
S.cerevisiae could provide the eukaryotic post-translational modifications 
necessary whilst side stepping the issue of protein hyper-glycosylation. It 
seems that although it has been shown that on average, Pichia adds much 
shorter oligosaccharides to proteins than S.cerevisiae (Grinna and Tschopp, 
1989; Tschopp et al., 1987), perhaps in comparison to A.viteae (which
- 155
produces ES-62 whose total carbohydrates consist of a much lower 
percentage of mannose (Haslam et a i, 1997)), the difference between the 
extent of giycosyiation of the two is still considerable. Although the use of the 
/V-glycosylation site at AA 381 in A.wfeae-derived ES-62 has been 
discounted (unpublished results), Pichia may not be as discriminatory in its 
addition of mannose to this, due to a difference in protein folding.
The resistance of the recombinant molecule to dénaturation and various 
enzymes suggests that although the recombinant version of the protein is 
unable to exist as a completely tetrameric species, the monomers, dimers 
and tetramers it does form have greater integrity (being less amenable to 
dissociation), possibly due to the post-translational modifications carried out 
by Pichia, which would include giycosyiation of the molecule. The differences 
discovered between rES-62 and pES-62 in this chapter may suggest a 
difference in the way in which the two forms of the molecule interact with the 
immune system, for example their effects on APCs such as DCs and the 
subclasses of antibody which are generated: this will be investigated in the 
next chapter.
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4.4 FIGURES
Figure 4.1. PAGE Comparison of Parasite-derived 
(p) and Recombinant (r) ES-62.
2.5 [ig of pES-62 (lane 1 ), and rES-62 (lane 2) with 
ovalbumin (lane 3) as a control were run on 12 % 
polyacrylamide gels under non-reducing, non­
denaturing conditions (A). The gels were fixed and 
stained with Sigma Brilliant Blue Colloidal-G Stain. 
The solid arrows indicate pES-62 (lane 1), rES-62 
(Lane 2) and ovalbumin (lane 3).
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Figure 4.2. rES-62 Digestion with Trypsin.
p and rES-62 which had been incubated with trypsin, 
as per manufacturers Instructions, and the digested 
samples were run on 12 % polyacrylamide gels under 
reducing, denaturing conditions. The gels were fixed 
and stained with Sigma Brilliant Blue Colloidal-G Stain. 
Lane 1 - rES-62 plus Trypsin, Lane 2 - rES-62 Control, 
Lane 3 - pES-62 Plus Trypsin, Lane 4 - pES-62 
Control.
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Figure 4.3. SDS PAGE and Western Blotting 
Comparison of pES-62 and rES-62 Using Rabbit 
Polyclonai Anti-pES-62 Serum.
2.5 i^g of pES-62 (iane 1), and rES-62 (lane 2) with 
ovalbumin (lane 3) as a control were run on 12 % 
polyacrylamide gels under reducing and denaturing 
conditions The polypeptides were then transferred to 
a nitrocellulose membrane and probed with a 
polyclonal rabbit anti-pES-62 serum followed by an 
anti-rabbit IgG alkaline-phosphatase - conjugated 
secondary antibody and then Sigma Fast 5-Bromo-4- 
Chloro-3-lndolyl Phosphate/Nitro Blue Tétrazolium 
substrate (BCIP/NBT). Molecular weight markers 
(kDa) are indicated on the left of the gels.
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Figure 4.4. SDS PAGE and Western Biotting 
Comparison of pES-62 and rES-62 Using TEPC 15.
2.5 \iQ of pES-62 (lane 1), and rES-62 (lane 2) with 
ovalbumin (lane 3) as a control were run on 12 % 
polyacrylamide gels under reducing and denaturing 
conditions The polypeptides were then transferred to a 
nitrocellulose membrane and probed with TEPC 15 
followed by an anti-mouse Ig alkaline-phosphatase- 
conjugated secondary antibody and then Sigma Fast 
BCIP/NBT substrate. Molecular weight markers (kDa) 
are indicated on the left of the gels.
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Figure 4.5. Dot Blotting Comparison of pES-62 and 
rES-62 Using KK6, a Monoclonal Antibody Specific 
for pES-62.
1.25 of pES-62 (iane 1), and rES-62 (lane 2) with 
ovalbumin (lane 3) as a control were placed on 
nitrocellulose Hybond-C (Amersham) and analysed by 
dot blot using a monoclonal anti-ES-62 antibody 
directed against a conformationai epitope on the 
parasite-derived ES-62 tetramer.
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Figure 4.6. PAGE Comparison of A/-type 
Giycosyiation Knock-Out rES-62 Mutants.
2.5 |ig of pES-62 (lane 1), rES-62 (lane 2), /V-type 
giycosyiation site 1 (AA 194) knockout (KOI, lane 3), 
/V-type giycosyiation site 2 (AA 235) knockout (K02, 
lane 4), /V-type giycosyiation site 3 (AA 325) knockout 
(K03, lane 5), were run on 12 % polyacrylamide gels 
under non-reducing, non-denaturing conditions. The 
gels were fixed and stained with Sigma Brilliant Blue 
Colloidal-G Stain.
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Figure 4.7. Determination of Degree of High 
Mannose Content of rES-62 and Giycosyiation 
Site-knock-outs 1,2 and 3.
1.25pg each of pES-62 (lane 1), rES-62 I (lane 2) and 
II (lane 3) and giycosyiation site knock-outs 1 (lane 4), 
2 (lane 5) and 3 (lane 6) were run on 12 % 
polyacrylamide gels under reducing, denaturing 
conditions. The polypeptides were then transferred to 
a nitrocellulose membrane and probed with GNA 
lectin, then with anti-digoxenin conjugated to AP, and 
finally Nitro Blue Tetrazolium/x-phosphate substrate, 
all from the DIG Glycan Differentiation Kit (Roche 
Diagnostics). The arrow on the left indicates the 
position of the pES-62 band, which is very faint.
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Figure 4.8. PAGE Comparison of rES-62 (I) and (II).
2.5 ^ 9  of pES-62 (lane 1), rES-62 (I) (lane 2), and 
rES-62 (II) (Lane 3) were run on 12 % polyacrylamide 
gels under non-reducing, non-denaturing conditions. 
The gels were fixed and stained with Sigma Brilliant 
Blue Colloidal-G Stain.
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Figure 4.9. rES-62 digestion with A/-glycosidase F.
p and rES-62 which had been incubated with A/- 
giycosidase F, as per manufacturers instructions, and 
the digested samples were run on 12 % 
polyacrylamide gels under reducing, denaturing 
conditions. The gels were fixed and stained with 
Sigma Brilliant Blue Colloidal-G Stain. Lane 1 - 0.5 gig 
pES-62 plus A/-glycosidase-F, Lane 2 - 0.5 \xg pES-62 
control Lane 3 - 0.5 \xg rES-62 plus A/-Glycosidase-F, 
Lane 4 - 0.5 (ig rES-62 Control.
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Figure 4.10. rES-62 Digestion with 
Endogiycosidase H.
rES-62 which had been incubated with 
Endogiycosidase H, as per manufacturers instructions, 
and the digested rES-62 was run on 12 % 
polyacrylamide gels under reducing, denaturing 
conditions. The gels were fixed and stained with Sigma 
Brilliant Blue Colloidal-G Stain. Lane 1 - rES-62 plus 
Endogiycosidase H, Lane 2 - rES-62 Control.
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Figure 4.11. rES-62 Digestion with a-Mannosidase.
The mannose content of recombinant glycosyiation- 
site knockout 1 (KOI) was analysed using HPLC 
before and after digestion using the enzyme a- 
mannosidase as per manufacturers instructions.
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Chapter 5: Immunological 
Characterisation of rES-62 from Pichia
pas tons
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5.1 INTRODUCTION
Given the rationale behind choosing Pichia as a protein expression vector, 
detailed in the previous chapter, it was surprising to find that the molecule 
differed so much from pES-62 regarding giycosyiation and enzyme 
sensitivity. However, the recognition of rES-62 by both poiy- and monoclonal 
anti-ES-62 antibodies suggested the material was an adequate PC-free 
version of ES-62, and the protein was used in immunoiogicai studies.
BALB/c mice were injected for a period of 10 weeks with pES-62 or rES-62 
and the IgGI antibodies generated were analysed for their recognition of 
both parasite-derived and recombinant ES-62 by ELISA.
The IgGI antibodies of BALB/c mice immunised with pES-62 or rES-62 were 
also analysed for recognition of denatured and non-denatured forms of the 
two proteins to establish the nature of the epitopes recognized by the 
antibodies. They were also analysed for recognition of recombinant material 
from the new mutation-free clone (rESli) once the three base-pair 
mismatches had been discovered, to ascertain what, if any effects these 
changes had exerted on the immunological recognition of the molecule; and 
for recognition of rES-62 /V-glycosyiation site knock-outs, to gauge the impact 
of lessened carbohydrate attachments on the molecule’s recognition by the 
immune system.
The abilities of rES-62 to induce and modulate production of IL-12p40 by 
bmDCs from wild type (WT) C57BL/6s, Toll like receptor (TLR) 4 ko, Myeloid
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differentiation factor (MyD)88 ko, WT C3H/HeN and C3H/HeJ mice (which 
contain a mutation which leaves them unable to respond to bacterial LPS, 
the classical TLR4 ligand, Poltorak et al., 1998) was investigated by ELISA. 
rES-62 induction of iL-12p40 was also examined in dmDCs from mannose 
receptor ko (MR ko) mice (as the increase in mannose levels of rES-62 
compared to pES-62 prompted the theory that the recombinant material may 
be recognised through this receptor) and was compared with the induction of 
IL12p40 production by bmDCs by the rES-62 giycosyiation knock-outs, 1,2 
and 3.
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5.2 RESULTS
5.2.11mmunogenicity of Recombinant ES-62
As SDS-PAGE/Western blot analysis suggested that almost all of the protein 
in the sample was indeed recombinant ES-62 (Figure 4.2), it was considered 
of suitable purity for further analysis. The sample was thus subcutaneously 
injected into mice and serum samples taken and tested for antibodies against 
the recombinant and parasite-derived molecules by ELISA. The recombinant 
ES-62 was found to induce a strong IgGI antibody response (Fig. 5.1) but 
unlike PC-free ES-62 produced by earlier methods (Houston et a!., 2000) no 
igG2a (result not shown). To our surprise, the IgGI antibodies generated 
against the A.wfeae-derived material in mice completely failed to recognise 
the recombinant material (Fig. 6.1). Likewise antibodies produced in 
response to rES-62 completely failed to recognise the A.wfeae-derived 
material (Fig. 5.2). Antibody recognition of denatured forms of both proteins 
was investigated with both mouse sera to determine whether epitopes 
recognised were likely to be conformational. It appears that the pES-62 
epitopes are indeed mostly conformational in nature, as the recognition of the 
denatured parasite-derived protein was greatly reduced, relative to the non­
denatured (Fig. 5.3). However, antibody interaction with the denatured rES- 
62 appears to be essentially no different from that witnessed with the non­
denatured rES-62 (Fig. 5.4), suggesting that the epitopes recognized on the
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recombinant molecule are not conformational. It can also be seen that 
antibodies raised against rES-62 do not recognize denatured pES-62, or vice 
versa: thus this does not look like a case of the recombinant simply being 
denatured, especially taking into account the difficulties encountered when 
attempting to denature rES-62 (discussed In Chapter 4).
5.2.2 Effects of Changes in Giycosyiation on Immunogenicity of Recombinant 
ES-62
When the serum of BALB/c mice injected with either pES-62 or rES-62 was 
analysed for antibody recognition of the three A/-type giycosyiation site KOs, 
each was recognised by the murine antiserum against the recombinant but 
not the parasite-derived material (Fig 5.5).
5.2.3 Effects of Changes in Amino Acid Composition on Immunogenicity of 
Recombinant ES-62
When the recognition of recombinant material from the new mutation free 
clone (rESII) by antibodies in the serum of BALB/c immunised with pES-62 or 
rES-62 was investigated, this protein was also recognised by murine 
antibodies raised against the recombinant protein only: again there was no 
cross-reactivity with antibodies raised against the parasite-derived protein 
(Fig. 5.6).
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5.2.4 Effects of rES-62 on iL-12 Production by bmDCs
When bmDCs from WT C57BL/6 mice were pre-treated with 2 p,g/ml rES-62 
for 18 h prior to stimulation with 100 ng/ml Salmonelia minnesota LPS for 24 
h, rES-62 exposure mimicked the previously shown effects of pES-62 on 
LPS-lnduced IL-12 production (Goodridge et ai., 2005 and 2004) (figure 5.7); 
treatment resulted in low level IL-12p40 production, but prevented the full 
induction of IL-12 by LPS.
5.2.5 Investigation of the Involvement of TLR4 and the Mannose Receptor in 
Stimulation of Cytokine Production by rES-62
When bmDCs from various mouse strains (TLR4 knock out (ko) (figure 5.8A), 
MyD88 ko (figure 5.8B), WT C3H/HeN (figure 5.8C) and C3H/HeJ (figure 
5.8D) were treated with 2 j.ig/ml rES-62 for 24 h and the supernatants 
analysed for IL-12p40 levels by ELISA, it appeared that the modulation of 
cytokines production by rES-62 occurs independently of both TLR4 and 
MyD88, as an IL-12p40 response to rES-62 was seen in all of the mutants 
analysed.
In addition to lacking PC, the carbohydrate component of rES-62 differs from 
that of pES-62. The natural protein contains ~3 % carbohydrate, of which 
iess than 50 % is mannose, whereas rES-62 is ~6 % carbohydrate and
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virtually all of this is mannose (Egan et al., 2006). It was therefore 
hypothesized that the recombinant material may be recognized by the MR on 
cells, as pES-62, which contains less mannose was recognised by a soluble 
form of the receptor (Harnett, unpublished results). To investigate this 
possibility the three A/-giycosylation mutants of rES-62 that had been 
generated were utilised, to determine whether reduced mannose affects the 
recognition of the recombinant material. When bmDCs from C57BL/6 or MR 
ko mice were treated with 2 ^ig/ml rES-62 or rES-62 giycosyiation site knock­
out 1,2 or 3 for 24 h, it was found that the stimulatory effects of rES-62 were 
not altered by the substitution of the key giycosyiation sites at Thr215, 
Ser256 and Ser346 (figure 5.9). Furthermore, the effects of pES-62, rES-62 
and the rES-62 mutants were also intact in bmDCs from MR ko mice (figure 
5.10).
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5.3 DISCUSSION
Bearing in mind the anti-ES-62 polyclonal and monoclonal antibody 
recognition of the rES-62, it was surprising to find that antibodies generated 
against recombinant ES-62 in mice completely failed to recognise the 
parasite-derived material. Likewise polyclonai anti-sera generated against 
pES-62 in mice at the same time showed virtually no reactivity for the 
recombinant material.
Further analysis by ELISA suggested that whereas the majority of antibodies 
induced by pES-62 recognised conformational peptide epitopes, this was not 
true of the recombinant molecule. There are several possible explanations 
for this difference: the recombinant material used to coat the ELISA plate 
may not have been fully denatured (as discussed in Chapter 4); the epitopes 
recognized by the antiserum against the recombinant molecule may be 
largely carbohydrate in nature; or the peptide epitopes on the recombinant 
molecule are essentially sequential, and therefore are unaffected by 
dénaturation. Overall, it could well be that the lack of immunological cross­
reactivity between the two molecules may be due to the recombinant material 
having a less folded structure than the parasite-derived material. It does not 
appear likely that the protein is simply denatured: the murine anti-rES-62 
antibody completely fails to recognise denatured pES-62 (Figures 5.3 and 
5.4).
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The contribution to altered immunogenicity of the changes in AA sequence 
and giycosyiation of the recombinant was investigated, and was found to 
have no real impact. Neither the new mutation-free version of rES-62 nor the 
giycosyiation KOs were recognised by anti-sera raised against pES-62. 
Furthermore, all versions were equally well recognised in comparison to the 
original rES-62 by the antibodies raised against this material. Consistent with 
this, the total of the three AA changes in the rES-62 sequence was found to 
have very little effect on overall predicted secondary structure when this was 
assessed (result not shown).
The results of the immunological studies are curious: given the marked 
differences exposed between rES-62 and pES-62 and discussed thus far 
both biochemically and immunologically, it was interesting to see that the 
rES-62 did not induce the antibody profile seen with previous PC-free ES-62 
(produced using inhibitors of A/-Iinked oligosaccharide processing (dMM) or 
PC synthesis (HC-3)). This previously produced PC-free ES-62 produced a 
mixed lgG1/lgG2a response (Houston et al., 2000), but rES-62 gave the 
same IgGI skewed response as pES-62. Previously produced PC-free ES- 
62 produced this mixed lgG1/lgG2a response regardless of which inhibitor 
had been used: dMM inhibits mannosidase I in the cis golgi (Fig. 3.1), and 
would lead to an increase in high-mannose glycan structures present on ES- 
62. HC-3, being an inhibitor of PC synthesis via blocking choline kinase (Fig. 
3.2), would likely lead to complex glycan formation on ES-62 as normal 
complex glycan formation is blocked by PC addition. As both versions of PC-
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free ES-62 gave the same Th1/Th2 mixed antibody profile, it was therefore 
proposed that PC was the main suppressor of a Th1 response to pES-62 in 
mice. However, in light of the results using rES-62, which contains no PC, 
clearly a role for the glycans of pES-62 in the molecule's immunomodulation 
capabilities cannot be ruled out yet. Carbohydrate structures from parasitic f
and non-parasitic nematodes have been demonstrated to drive development 
of a Th2 phenotype in lymphoid cells (Tawill et al., 2004). Lymphoid cells of 
mice pre-immunised with whole worm extracts of B.malayl (BmA) or 
C.elegans (CeA) differentiated into a population dominated by CD4^, IL-4 but 
not IFNy producing cells. Furthermore, when the carbohydrates of the worm 
extracts were targeted using periodate treatment, lymphoid cells stimulated 
with the resultant antigens produced significantly less IL-4 than those cells 
which were cultured with extracts that had undergone a mock treatment.
However, the authors of this work did state that their findings contained no
evidence concerning whether these responses were due to PC moieties f
(known to be attached to the glycans), or whether the glycans themselves
Îwere exerting an effect.
Equally intriguingly, exposure to PC-free rES-62 both In vitro and In vivo also ï
Imimicked the ability of ES-62 to modulate DC cytokine production, but this 
effect was discovered to be independent of both TLR4 and MyD88. Thus 
rES-62 is clearly modulating IL-12 production by a different mechanism from 
pES-62 and PC-Ova, and this mechanism is not likely to involve a TLR.
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It became clear that rES-62, despite being dominated by mannose, was not 
signalling via the mannose receptor. This again somewhat mirrors the 
situation seen with pES-62, where although initial studies showed the 
molecule to be able to interact with the mannose receptor, subsequent work 
illustrated that it appeared to behave as normal with DCs and mcj) of mannose 
receptor knock out mice (Harnett and Harnett, unpublished observations 
2004). Thus, the theory postulated in the previous chapter regarding the use 
of rES-62 for targeting drugs to hepatocytes and mcj) via the mannose 
receptor may not be valid.
Taken together, the data from the cytokine production and experiments 
looking into the mechanism of cytokine production in DCs from various 
mouse strains indicate that the effects of ES-62 are mediated largely by PC, 
but that without PC the glycoprotein appears to possess some 
immunomodulatory potential. These results are consistent with previous 
studies (e.g. Houston et a/., 2000) in supporting an important role for PC in 
ES-62's immunomodulatory activity. Immunomodulatory activity was also 
demonstrated for PC-free rES-62, but although the results are very 
interesting, doubts exist as to the validity of this “control”. This is because, 
although arriving at the same biological outcome, pES-62 and rES-62 utilize 
different receptor recognition and intracellular signal transduction activation. 
Thus, until a form of ES-62 free from PC, but containing no other differences 
is available in suitable quantities for experimentation, the question as to
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whether the protein component is immunomodulatory under normal 
circumstances must remain open.
Work by Deehan et al. (2002) and Kean et al. (2006) has shown the PC 
moieties of Ascaris suum to be immunomodulatory. When the effects of 
synthetic PC-containing glycolipids on DCs and mcj) were investigated, the 
results were varied. GL2, which contained no PC had no effect on DCs or 
mcj), whilst GL3, which does contain PC was able to cause up-regulation of 
co-stimulatory molecules on both cell types, stimulate the induction of pro- 
infiammatory cytokines, and inhibit induction of these pro-inflammatory 
cytokines by IFNy/LPS. The fact that the only effects which were seen with 
GL1, which also contains PC, were a slight increase in co-stimulatory 
molecules, serves as a reminder of how complex the process of 
immunomodulation often is: there is no question that PC is a major 
immunomodulatory factor, but it would appear that other structural features 
are required for its action (Deehan et al., 2002; Kean et al., 2006). The work 
carried out in this thesis has helped to identify the pathways involved in ES- 
62’s immunomodulatory abilities, and further highlighted PC's importance in 
these signalling events. This has paved the way for novel drugs to be 
designed based on molecules such as ES-62 with the aim of interfering with 
these pathways, though at this stage, there is much to be done in the 
investigation of PC and immunomodulation.
As all biochemical and immunological routes explored in attempts to explain 
the emerging differences between the two molecules thus far had failed to
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give conciusive results, it was decided to subject the rES-62 to biophysical 
analyses similar to that which had already been carried out on pES-62 
(Ackerman et al., 2003) and this will be discussed in the next chapter.
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5.4 FIGURES
Figure 5.1. Recognition of rES-62 by IgGI 
Antibodies in Serum of Mice Inoculated with rES- 
62 or pES-62.
Groups of five BALB/C mice were injected weekly with 
2 |Lig p or rES-62 and serum samples taken. Samples 
were analysed by ELISA for rES-62 specific 
responses in duplicate and mean values calculated ± 
standard error of the mean. Results are expressed as 
reciprocal end-point dilution.
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Figure 5.2. Recognition of pES-62 by lgG1 
Antibodies In Serum of Mice Inoculated with rES- 
62 or pES-62.
Groups of five BALB/C mice were injected weekly with 
2 (ig pES-62 or rES-62 and serum samples taken. 
Samples were analysed by ELISA for pES-62 specific 
lgG1 responses in duplicate and mean values 
calculated ± standard error of the mean. Results are 
expressed as reciprocal end-point dilution.
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Figure 5.3. Recognition of Denatured and Non­
denatured pES-62 by lgG1 Antibodies in Serum of 
Mice Inoculated with pES-62.
Groups of five BALB/C mice were injected weekly with 
2 \xQ pES-62 or rES-62 and serum samples taken. 
Samples were analysed by ELISA for denatured and 
non-denatured pES-62 specific lgG1 responses in 
duplicate and mean values calculated ± standard 
error of the mean. Results are expressed as 
reciprocal end-point dilution.
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Figure 5.4. Recognition of Denatured and Non­
denatured rES-62 by lgG1 Antibodies in Serum of 
Mice inoculated with rES-62.
Groups of five BALB/C mice were injected weekly with 
2 \xg pES-62 or rES-62 and serum samples taken. 
Samples were analysed by ELISA for denatured and 
non-denatured rES-62 specific lgG1 responses in 
duplicate and mean values calculated ± standard error 
of the mean. Results are expressed as reciprocal end­
point dilution.
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Figure 5.5. Comparison of Recognition of ^-type 
Glycosylatlon-slte Knock-Out rES-62 Mutants by 
lgG1 Antibodies in Serum of Mice Inoculated with 
pES-62 or rES-62.
Groups of five BALB/c mice were injected weekly with 
2 |ig pES-62 or rES-62 and serum samples taken. 
Samples were analysed by ELISA for recognition of 
each of 3 distinct A/-type glycosylation site knock-out 
rES-62 mutants by lgG1 antibodies in duplicate and 
mean values calculated ± standard error of the mean. 
Results are expressed as reciprocal end-point 
dilutions.
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Figure 5.6. Comparison of Recognition of rES-62 (I) 
and (II) by lgG1 Antibodies in Serum of Mice 
Inoculated with pES-62 or rES-62.
Groups of five BALB/c mice were injected weekly with 
2 rig of p or rES-62 (I) and serum samples taken. 
Samples were analysed by ELISA for rES-62 (II) 
specific lgG1 responses in duplicate and mean values 
calculated ± standard error of the mean. Results are 
shown as reciprocal end point dilutions.
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Figure 5.7. Modulation of IL-12 Production by rES- 
62: WT C57BL/6 Mice
bmDCs from wild type C57BL/6 mice were pre-treated 
with 2 rig/ml rES-62 for 18 h prior to stimulation with 
100 ng/ml S. minnesota LPS for 24 h. IL-12 p40 levels 
in culture supernatants were assayed by ELISA; data 
are presented as mean plus standard deviation of 
triplicate culture. ***p<0.001, **p<0.01. Data are 
representative of at least three experiments.
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Figure 5.8. Modulation of IL-12 Production by rES- 
62: TLR4 ko, MyDSB ko, C3H HeN and C3H HeJ 
Mice
bmDCs from (A) TLR4 ko, (B) MyD88 ko, (C)
C3H/HeN and (D) C3H/HeJ mice were treated with 2 
rig/ml rES-62 for 24 h. IL-12 p40 levels in culture 
supernatants were assayed by ELISA; data are 
presented as mean plus standard deviation of triplicate 
culture. ***p<0.001. Data are representative of at least 
three experiments.
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Figure 5.9. Investigation into the Involvement of 
TLR4 in Cytokine Production Stimulated by rES- 
62.
bmDCs from wild type C57BL/6 mice were treated with 
2 rig/ml rES-62 or rES-62 glycosylation mutants for 24 
h. IL-12 p40 levels in culture supernatants were 
assayed by ELISA; data are presented as mean plus 
standard deviation of triplicate culture. ***p<0.001.
Data are representative of at least 2 experiments.
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Figure 5.10. Investigation into the Involvement of 
the Mannose Receptor in Cytokine Production 
Stimulated by rES-62.
bmDCs from MR ko mice were treated with 2 fxg/ml 
rES-62 or rES-62 glycosylation mutants for 24 h. IL-12 
p40 levels in culture supernatants were assayed by 
ELISA; data are presented as mean plus standard 
deviation of triplicate culture. ***p<0.001. Data are 
representative of at least 2 experiments.
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Chapter 6: Biophysical 
Characterisation of rES-62 from Pichia
pastoris
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6.1 INTRODUCTION
The data from the previous two chapters provided a body of evidence 
suggesting that the recombinant material was not simply a facsimile of ES-62 
without the PC moiety. In fact, it was indicated that the molecule could be 
radically different from the pES-62, based on both biochemical and 
immunological characteristics. Attempts instigated within these studies to 
explain these differences had failed to offer any conclusive answers. It was 
therefore decided to send some material to collaborators at the University of 
Glasgow to enable a biophysical characterisation of the molecule in 
comparison to the characterisation carried out for the A.viteae-demedi 
molecule (Ackerman et a!., 2003). This included far UV CD spectrum 
analysis, size distribution analysis, analytical centrifugation techniques and 
small angle scattering, to assess the secondary structure and folding of the 
recombinant, and to give an Insight into the shape of the recombinant in 
solution.
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6.2 RESULTS
6.2.1 Secondary Structure and Folding of Recombinant ES-62
There is a broad negative peak in the far UV CD spectrum of rES-62 (Fig. 
6.1, solid line) with a minimum around 203nm and a positive maximum peak 
around 185nm (these peaks correspond to the n to irtransition). The shape 
of the spectrum and the lack of a dominant negative minimum around 220nm 
suggest that the protein contains predominantly (3-sheet, p-turn and 
unordered structure. Secondary structure estimations were obtained using 
the program CONTIN (Provencher and Glockner, 1981) since other 
programs such as SELCON3 (Sreerama and Woody, 1993) and CDSSTR 
(Hennessey and Johnson, 1981) failed to fit the data. The CONTIN 
procedure (Provencher and Glockner, 1981) gives secondary structure 
estimations of 10% a-helix, 39% p-sheet, 21% p-turn and 30% remainder. 
Comparing these results with the secondary structure estimations from the 
far UV CD spectrum analysis carried out on the parasite-derived ES-62 
previously (Fig. 6.1, dashed line), which gave values of 40% a helix, 16% p- 
sheet, 16% p-turn and 28% remainder (Ackerman et al., 2003) we can 
conclude that the proteins exhibit marked differences in conformation. It 
would appear that the recombinant material has refolded most of its a-helix 
structure to p-sheets/turns but retained the same amount of unordered 
structure.
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The near UV CD spectrum shows that the aromatic residues are located in 
asymmetric environments characteristic of the tertiary structure of a folded 
protein. Tryptophan residues in folded proteins generally give peaks close to 
290 nm; tyrosine and phenylalanine residues give rise to peaks between 275 
and 282 nm and 255 nm and 270 nm respectively.
Recombinant ES-62 was examined for heterogeneity using c(s) size- 
distribution analysis of sedimentation velocity (SV) data (Schuck et a i, 2002). 
There were at least three peaks evident in the c(s) distribution pattern, with a 
major peak centred on an apparent sedimentation coefficient (s%^) of 5 S
and two less well-defined peaks at 3 and 8 S (Fig. 6.2). Integration of the 
c(s) distribution for the three major peaks yielded the weight average 
sedimentation coefficient (Sw) for these species. The concentration 
dependence of Sw does not demonstrate the appearance of heavier species 
as concentration is increased but shows the expected concentration 
dependence of peak position: a movement towards lower s with increasing 
concentration (thermodynamic non-ideality). Therefore any redistribution 
between the rES-62 oligomeric species was not observed over the >10-fold 
concentration range examined, suggesting that the system is not in 
thermodynamic equilibrium, but instead comprises discrete independent 
oligomers.
Direct fitting of SV boundaries gave sedimentation coefficients at infinite 
dilution and under standard conditions (s°2o,w) of 3.4, 5.3 and 8.2 S (Fig. 6.3) 
with good fits to the experimental data (not shown). The three species could
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be monomeric, dimeric and tetrameric rES-62. In order to compare these 
findings with the results for parasite-derived ES-62 (Ackerman et al., 2003), 
the value of the sedimentation coefficient for tetrameric parasite-derived ES- 
62 was deconvoluted to possible sedimentation coefficients for monomeric 
and dimeric species assuming that the oligomerisation occurs “side-to-side”. 
The data in Table 6.1 show the sedimentation coefficients for each oligomer 
from the recombinant material and the “deconvoluted” s for parasite-derived 
ES-62. The fact that s for each oligomer of rES-62 is much less than that 
estimated for the parasite-derived counterpart implies rES-62 is more 
elongated/asymmetric than the parasite-derived protein.
The weight average molecular weight for rES-62 in solution was found at 
different rotation speeds in a sedimentation equilibrium experiment (data not 
shown). Thus, at a low rotation speed of 8000 rpm the weight average 
molecular mass (264 ± 50 kDa) was above the expected molecular mass for 
rES-62 tetramer (233 kDa) suggesting the presence of higher molecular 
weight aggregates. As the speed of rotation was increased the average 
molecular weight decreased reflecting a mixture of monomers and dimers 
(81 ±13 kDa). The SE scans were treated using the equilibrium dissociation 
model, which did not give a significant improvement in fit to the data. 
Therefore we can conclude that these species are not undergoing equilibrium 
dissociation but exist independently, in agreement with the findings from SV 
experiments.
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6.2.2 Small Angle Scattering
rES-62 scattered X-rays very well in solution, but significant differences 
between the parasite-derived and recombinant protein were observed. The 
overall shape of the rES-62 scattering curve is typical of that from very 
elongated particles (Volkov and Svergun, 2003). This is in contrast with 
parasite-derived ES-62, which is a rather globular particle (Ackerman et al., 
2003). Since the AUC data have demonstrated clearly that rES-62 is very 
heterogeneous in solution it is not possible to use existing software routines 
for the determination of a solution structure for this kind of sample. At 
present we can reach only qualitative conclusions about rES-62 in solution.
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6.3 DISCUSSION
Far UV CD Spectrum analysis provides a much stronger signal than near UV 
CD spectrum analysis, meaning much less protein is necessary in the 
sample to obtain results. The amount of sample is also less than one would 
require for high resolution nuclear magnetic resonance (NMR) spectroscopy, 
which can only be carried out effectively with high concentrations of protein. 
The sample volume can be as low as 1 ml - 50 |il, and although 100-500 fxg 
of protein would allow for a thorough examination of optimal conditions, etc. 
10 p.g is sufficient to generate credible data. Experiments can be carried out 
very quickly (30 min), in comparison with X-ray crystallography, which can 
take weeks or months in some Incidences (reviewed by Kelly and Price, 
2000). As the procedure is non-destructive, the material analysed can be 
recovered and re-analysed under different conditions.
Although UV CD Spectrum analysis is able to distinguish a-helices and 13- 
sheets and turns, it is unable to determine their location in the molecule, and 
does not provide much data on quaternary structure. However, secondary 
structure algorithms can be applied to the data to increase its resolution 
(Ribas de Pouplana et al., 1991). We employed sedimentation velocity and 
small angle scattering techniques to aid in the prediction of the 3D shape and 
self-association of the recombinant, to give a fuller picture of the molecule in 
solution. Near UV CD Spectrum analysis is dependant on the AA side 
chains, and can give tertiary folding information based on tryptophan,
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tyrosine and phenylalanine (reviewed by Kelly and Price, 2000). It has been 
shown that factors such as aromatic side chains, especially tryptophan can 
contribute to the far UV CD spectrum (Woody and Dunker, 1996; Greenfield, 
1999), as can disulfide bonds (Greenfield, 1999; Chaffotte, Guillou and 
Goldberg, 1992), and that the length and regularity of structural elements in 
peptides and proteins can influence the nature of the spectra produced (Hirst 
and Brooks, 1994). These elements can be overcome using the CONTIN 
procedure (Provencher and Glockner, 1981), where the curve obtained is 
compared with data from 16 proteins that have been analysed previously by 
X-ray Crystallography to provide extremely clear interpretations of structures. 
Further evidence for this was provided by Tetin, Prendergast and 
Venyaminov (2003), who found that secondary structure prediction from far 
UV CD spectra using modern algorithms are robust. Structures predicted did 
not appear to be affected by the contributions of aromatic AA side chains to 
the spectra when they compared the forecasts of shapes of three antibody 
F'ab fragments to the existing X-ray data in the Protein Data Bank.
The biophysical analyses we carried out were to shed light on why the two 
molecules were behaving so differently, when their biochemical and 
immunological attributes were compared in the previous two chapters.
It was indicated by far UV CD spectrum analysis that the recombinant 
material showed features of a tertiary protein structure, but that a significant 
portion of its secondary structure had been converted from a-helix to |3-sheet. 
This will result in an overall change in shape for the recombinant protein from
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the somewhat globular shape of pES-62 to a much more elongated 
molecule. This shift in shape was also indicated by small angle scattering 
and by sedimentation velocity experiments. It was pleasing that all three 
analyses agreed upon this change in shape, as this drastic alteration would 
most definitely impact on the lack of cross-reactivity seen between pES-62 
and rES-62 and the antibodies raised against the two molecules, and 
possibly help to explain why denaturing the rES-62 did not affect its 
recognition by antibodies raised against the non-denatured rES-62 (Chapter 
5). If the molecule did have this more linear shape, it would perhaps not alter 
as much upon dénaturation as pES-62 due to the globular shape of the latter. 
The folding of proteins, as it is presently understood, is dependent on the 
side chains of the AAs in the backbone, which inform whether a-helices or 13- 
sheets are formed, and thus inform the whole shape of the molecule 
(reviewed by Rose et a/., 2006). The a-helix is a more likely secondary 
structure for a protein to assume, given that the R groups of the AAs of the 
protein backbone face outwards in this conformation, and avoid disrupting 
the central helix core (Hart, Hart and Craine, 1995). In p-sheet structures, the 
R groups of AAs are oriented above and below the plane of the sheet 
alternately: as might be expected, this type of structure may be prevented 
from forming if there are numerous larger side chains on the AAs which form 
the backbone (due to repulsion from these groups), and so p-sheets are only 
important in proteins found to have a high percentage of small R groups 
(Hart, Hart and Craine, 1995). Another theory of protein folding has emerged
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in the last ten years or so, suggesting that the protein backbone sequence 
itself limits the number of conformations possible for the protein, and that the 
final form of the molecule is dictated from this restricted range by the side- 
chains of the AAs in the backbone (Banavar et al., 2004; Rose et al., 2006). 
Neither the established nor the more recent theory of protein folding offer any 
explanation for why the recombinant version of ES-62 appears to have 
refolded from an a-helix to a p-sheet, as the gene sequence and therefore 
the peptide sequence of both molecules has been confirmed to be the same 
by full length sequencing. At present, one of the only possible factors that 
can be the cause of this shift in structure is the abundance of extra sugars 
attached to rES-62, as this is the main biochemical difference that has been 
observed. Although a-helices are the basis of fairly firm structures such as 
keratins and collagens, the rigidity of these structures is improved by many 
disulfide crosslinks (Hart, Hart and Craine, 1995). a-helix dominated globular 
proteins (such as pES-62), which are often enzymes, can be more sensitive 
to extremes of conditions such as pH and temperature. The p-sheet/turn 
structure of rES-62 in combination with its increased glycosylation may have 
raised the stability of the molecule, altering the conditions under which it 
would denature. It might also be folded in such a way that glycosidic bonds 
which would be accessible in the pES-62 are now sheltered, providing 
another possible explanation for the lack of sensitivity to enzymes seen in 
Chapter 4. The change in conformation of rES-62 may have led to a loss of 
exposed self-association sites, leaving it unable to form tetramers as pES-62
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does. The sedimentation velocity experiments also suggested that the 
recombinant material was not in a state of thermodynamic equilibrium, 
monomerising and tetramerising as with pES-62. It was suggested that rES- 
62 was a mixture of discrete, independent monomeric, dimeric and tetrameric 
species, confirming what was initially observed when the molecules were 
subjected to non-reducing, non-denaturing PAGE (Fig. 4.1). This view was 
also supported by analysis of the sedimentation equilibrium results. A 
combination of increased rigidity, coupled with an inability to form the same 
quaternary structure as pES-62 could explain why it appears that the 
recombinant in solution displays no dynamic equilibrium between species, it 
would appear that any multimeric species are static, unable to interact with 
each other. These stable monomers and dimers could lack secondary 
structural features stabilised by tetra mers I ation, a self-interaction that may 
not be possible due to the highly increased amounts of glycans attached to 
the molecule. These discrete populations of species may also be explained 
by the change in secondary (and therefore tertiary) structure: it may be that 
the globular shape of pES-62 is important for fostering/allowing interactions 
between smaller units to form the tetramers characteristic of the parasite- 
derived molecule in solution (Harnett et aL, 1993; Ackermann et al., 2003) 
and that the elongated shape of the rES-62 makes this more difficult to 
achieve, so that if these interactions are formed, they are more rigid in 
nature, and not amenable to equilibrium.
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Table 6.1. Sedimentation coefficients for ES-62 extrapolated to zero 
concentration and corrected to standard conditions
s 20,wfor ES-62 (S)
Species
Recombinant
protein
Estimated from the parasite-derived ES-62 
(tetramer) (Ackerman et al., 2003) assuming 
“side-to-side” oligomerisation
“Monomer” 3.4 ± 0.03 4.38
“Dimer” 5.3 ± 0.05 6.57
“Tetramer" 8.2 ±0.15 9.85*
'Experimentally measured number
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6.4 FIGURES
Figure 6.1. Circular DIchroism and Sedimentation 
Velocity Characterisation of rES-62: Far UV Circular 
DIchroism Spectrum
Far UV Circular dichroism spectrum for rES-62 (solid 
line) and parasite-derived ES-62 (dashed line) in 
phosphate buffer (91.5 mM Na2 HP0 4 , 58.5 mM 
NaH2 P0 4 , pH 7.4). The spectra were normalized for 
concentration.
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Figure 6.2. Circular Dichroism and Sedimentation 
Velocity Characterisation of rES-62: Size Distribution 
c(s)
Size distribution c(s); interference data obtained for 
monomeric loading concentrations of 165 i^M {solid line) 
123 [xM (dashed line) 82 [xM (dotted Une) 41 \iM (dashed^ 
dotted Une) 12 |xM (short dashed Une) 10 \x M  (dashed- 
dotted-dotted line).
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Figure 6.3. Sedimentation Velocity Characterisation 
of rES-62.
The concentration dependence of s: “monomer” 
(squares), “dimer” (circles), “tetramer” (triangles). The 
horizontal solid line marks the sedimentation coefficient 
obtained experimentally for parasite-derived ES-62 
(Ackerman et al. 2003); dotted lines are the linear 
extrapolation of S2o,w to zero concentration for the three 
species.
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Chapter 7: Discussion
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Virtually all of the immunomodulatory properties of ES-62 appear be able to 
be mimicked by PC conjugated to other proteins. This might tempt one to 
ascribe all of these functions to the PC moiety. In order to fully establish the 
extent of the contribution of PC attached to ES-62, the logical approach 
would be to prepare material lacking PC and compare it to the original 
material. After many years of investigating various different enzymes and 
enzyme inhibitors in the quest to remove, or prevent attachment of, PC to 
ES-62, it has become apparent that this is, as is often the case, much more 
easily said than done.
7.1 PRODUCTION OF ES-62 LACKING PC
In this thesis, I examined two more enzyme inhibitors and four more 
enzymes to this end. Unfortunately, as with previous attempts, although 
these experiments provided us with more information, none yielded total 
removal of PC. It was for this reason that it was decided to insert the gene for 
ES-62 into a recombinant gene expression vector that would not contain the 
machinery necessary to add PC to secreted proteins. Previously, our group 
had investigated the possibilities of using the archetypal recombinant 
expression vector, E.coli, and a baculovirus system. However, despite best 
efforts, the material produced using both methods proved to be unusable 
experimentally, due to solubility problems in the E.co//-produced rES-62 and 
possible DNA contamination associated with the baculovirus system-
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produced material (Ackerman, 2002 PhD Thesis). Due to these hindrances, 
the yeast protein expression system, Pichia pastoris, detailed in chapter four 
was decided upon to produce rES-62 lacking PC, and from first impressions, 
although the recombinant material appeared to have some structural 
differences, there appeared to be enough similarities between the two to 
consider rES-62 a serviceable PC-free version of ES-62.
7.2 EMERGING DIFFERENCES BETWEEN rES-62 AND pES-62
From the outset, rES-62 had appeared to differ from pES-62 biochemically, 
revealing a different pattern of bands on both native and SDS PAGE gels, 
and was impervious to digestion with A/-glycosidase F, which has been 
shown to cleave pES-62 in the past. However, the recognition of the rES-62 
by polyclonal- and in particular a monoclonal-antibody that recognised a 
conformational epitope, anti-pES-62 serum gave hope that the molecule was 
more or less correctly folded, suggesting the material to be usable as a PC- 
free version of ES-62.
However, as detailed in chapter 5, the more the properties of rES-62 versus 
pES-62 were explored, the wider the berth between the two seemed to grow. 
It was discovered that despite generating an almost exclusive Th2 response 
in BALB/c mice as pES-62 does, there was no cross-reactivity between 
antibodies raised against the rES-62 and pES-62. Probing of the involvement 
of TLR4 and MR in the recombinant's stimulation of cytokine production in
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bmDCs revealed it to appear to be using quite a different mechanism of 
immunomodulation to pES-62. In light of this difference, the evidence 
showing the rES-62 to arrive at the same biological outcome as the parasite- 
derived material was quite confounding. The recombinant differed when 
compared to previous PC-free ES-62, as this latter material had produced an 
lgG2a response (Houston et al., 2000), whilst the rES-62 did not produce 
such a response.
What had originally started as an investigation into the properties of PC-free 
ES-62 became an exploration of the unique properties of the recombinant 
material, and an attempt to explain why it differed so greatly from the 
parasite-derived protein.
7.3 POSSIBLE EXPLANATIONS FOR THE DIFFERENCES 
BETWEEN rES-62 AND pES-62 SEEN
7.3.1 Glycosylation and Processing of Proteins by Yeast
rES-62 has been shown to have much higher levels of glycosylation (detailed 
in chapter 4), in particular of mannosyi residues attached, and the results of 
the biophysical analyses, detailed in chapter 6 revealed that the recombinant 
was a completely different shape, both at quaternary and secondary 
structure levels. Self-association of the recombinant version was also
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different, unearthing a plausible explanation for most of the biochemical and 
immunological differences observed in the course of the comparison.
The differences observed between rES-62 and pES-62 are maybe not so 
surprising, as although the gene encoding A.viteae ES-62 has been inserted 
into Pichia, and, as such, the AA sequence of the protein should remain 
identical, there are several other elements to take into consideration. Many 
events taking place after transcription and translation influence a protein’s 
eventual structure and shape. Tertiary and quaternary structure are 
influenced by the interactions of the side-chains attached to AAs, which are 
in turn influenced by the charges on the side-chains. Pichia, being a yeast, is 
able to carry out post-translational modifications and protein folding 
necessary for production of a working eukaryotic protein. Once proteins 
reach the Golgi apparatus, yeast and higher eukaryotic glycosylation of 
proteins differ: yeasts do not trim glycans as far as higher eukaryotic cells 
(reviewed by Cereghino and Cregg, 2000). Most yeast-derived proteins are 
devoid of complex oligosaccharides comprising sialic acid, galactose (gal), 
fucose (fuc) and A/-acetylgalactosamine (GalNAc) (Bretthauer and 
Casteilino, 1999): Kluyveromyces iactis is the only yeast whose ability to add 
GlcNAc to its glycoprotein glycans has been proven, with few others being 
predicted to do so (reviewed by Gemmill and Trimble, 1999).
Although it was expected that the recombinant material would contain more 
mannose due to knowledge of the post-translational modifications favoured 
by the chosen expression vector (Grinna and Tschopp, 1989), it was
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surprising to find the extent of the glycosylation of the recombinant material 
in comparison to that of the pES-62, as Pichia has been shown not to 
glycosylate proteins to the same degree as S.cerevisiae (Grinna and 
Tschopp, 1989; Tschopp et al., 1987). The A/-glycosylation site at AA 381 is 
thought to be unused in pES-62 (unpublished results), but this does not 
necessarily discount its use by the yeast, which would help to explain the 
increase in glycosylation.
7.3.2 Effects of Glycosylation on Protein Folding
As this difference between the extent and nature of the glycosylation of rES- 
62 compared to pES-62 has been revealed to be the main molecular 
discrepancy between the two proteins, one would imagine this to be the most 
likely explanation for the change in shape of the recombinant molecule.
The role of /V-linked oligosaccharides in protein folding is somewhat unclear, 
and appears to be rather variable: many groups report that their presence is 
necessary for correct folding of many glycoproteins (Ronnett et al., 1984; 
Slieker, Martensen and Lane, 1986; Konig, Ashwell and Hanover, 1988). It 
has also been reported, however, that the folding and secretion of numerous 
glycoproteins is completely independent of the sugar potions of the molecule 
(Breitfeld, Rup and Schwartz, 1984; George, Ruoho and Malbon, 1986; Van 
Koppen and Nathanson, 1990) as their removal has no impact on these 
functions. Throughout the literature, almost every imaginable scenario 
regarding A/-g!ycans and folding in their absence from glycoproteins has
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been reported. Misfolding of vesicular stomatitis virus (VSV) G protein was 
induced by abolition of the two A/-glycosylation sites of the protein. This was 
rectified by the creation of two new /V-gly cosy I ation sites at different locations 
(Machamer and Rose, 1988a and 1988b). It has been shown in some cases 
that certain A/-glycans on a protein are crucial for correct folding, whilst 
removal of others on the same protein has no consequence for folding 
(Dube, Fisher and Powell, 1988 and Semenkovich et al., 1990). In other 
cases, a reasonable portion of the protein is able to form correctly in the 
absence of the A/-glycans, whereas in yet others all the A/-glycans are 
required for correct folding (Hickman and Kornfeld, 1978; Taylor and Wall, 
1988).
The issue of the general involvement of /V-glycans in protein folding is clearly 
a contentious one, though in our case it may well be that the added glycans 
provided by Pichia has increased the rigidity of the recombinant molecule, 
leading to its different shape to the pES-62, and making it unable to self­
associate in a dynamic fashion, and meaning the multimers it does form have 
increased resistance to dénaturation and to enzyme digestion.
7.3.3 The Impact of Glycosylation on the Immune Response to rES-62 in 
Comparison to pES-62
The results of the immunisation study revealed differences in the sub-classes 
of antibody induced by the rES-62, and what was expected based on 
previous experiments employing PC-free ES-62 (Houston et al., 2000). The
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results also demonstrated that antibodies raised against rES-62 did not 
recognise pES-62, and antibodies produced against pES-62 failed to 
recognise rES-62. As the largest biochemical difference observed between 
the two species was related to the glycans attached to rES-62 (mentioned 
earlier), this would be the most likely explanation for these differences in 
immunogenicity. When possible explanations for the lack of cross-reactivity 
were explored by comparing recognition of denatured and non-denatured p 
and rES-62, recognition of denatured pES-62 was decreased in comparison 
to non-denatured material, whereas recognition of rES-62 was unaffected by 
denaturing. This suggested that either the rES-62 was not denatured as 
expected, or that the dénaturation of rES-62 was not affecting recognition 
due to either the epitopes on rES-62 being carbohydrate in nature, or that the 
rES-62 was not folded in the same manner as the pES-62, and contained 
linear peptide epitopes which would not change with dénaturation.
For a long time it was presumed that the protein components were the 
targets of the antibodies against glycoproteins, but over the years, a strong 
case for carbohydrate rather than protein epitopes dominating the immune 
responses to glycoproteins has been built up. Childs et al. (1984) 
demonstrated antigen cross-reactivity seen between glycoproteins of quite 
different function and polypeptide structure to be due to antibodies directed 
against the carbohydrate moieties: purified epidermal growth factor receptor 
was recognised by a panel of six monoclonal antibodies directed against 
different blood groups. The types of structure recognised were, in general.
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based on Gaipi-3GicNAc and GaI(31-4GicNAc, and were more likely to be 
linked to the receptor via W-glycans, as there is no evidence of 0 -linked 
structures existing in epidermal growth factor receptor from the cell line used 
(A431) (Mayes and Waterfield, 1984; Childs et aL, 1984; Cummings, 
Soderquist and Carpenter, 1985). It has also previously been observed that 
in Haemonchus confo/ifi/s-infected sheep, the main epitope recognised by 
IgE antibodies Is the core a l ,3 fucose on the glycans of the parasite (van Die 
e ta i, 1999). The Fuca(1-3)GlcNAc moiety has emerged as a major antigen 
in glycoproteins found in plants (Ramirez-Soto and Poretz, 1991; Wilson et 
al., 1998) as well as insects (Prenner et al., 1992).
Langerhans cell (a type of DC) phenotype was shown to be altered, and 
migration of these cells from the skin was reduced by the phosphoglycan 
moiety of Leishmania Lipophosphoglycan (LPG) (Ponte-Sucre, Heise and 
Moll, 2001). Okano et al. (1999) demonstrated that SEA which had been 
treated with periodate (a treatment verified to alter the structures of the 
carbohydrates of SEA whilst leaving proteins intact (Velupillai et al., 1997)) 
induced significantly less Th2~type cytokines than the native or the mock- 
treated SEA. Analysis of the DC-SIGN receptor revealed strong binding to 
glycoconjugates of Helicobacter pylori, S.mansoni, M.tuberculosis and 
Leishmania mexicana (Appelmelk et al., 2003). This interaction may have 
implications for cytokine secretion and antigen presentation, and so could 
have a role in the longevity of these organisms in the host. Although it has 
previously been shown that the majority of the immunomodulatory effects of
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ES-62 appear to centre round the PC moiety, it has been inferred that 
glycans also have the ability to drive a Th2 response (Tawill et al., 2004). 
Thus, the extra glycans on rES-62 may have led to its increased stability 
(making it more difficult to denature, and so what was assumed to be 
denatured rES-62 coat in the immunological comparison may indeed not 
have been fully denatured). They may also have played a part themselves, 
not only in maintaining the Th2 skewed response to rES-62 in BALB/c mice, 
but also in constituting the main epitope recognised by antibodies directed 
against rES-62 in the serum of immunised mice. This would seem likely due 
to the huge increase in glycans attached to the recombinant in comparison to 
the parasite-derived material. Lastly, the glycans present appear to be the 
most likely explanation for the significant change in shape of the molecule, 
which would most definitely contribute to the lack of cross-reactivity seen 
between rES-62 and pES-62.
7.3.4 Differences in Shape and Self-association Between rES-62 andpES-62
rES-62's capacity to withstand digestion and heat suggests it to be a very 
robust protein indeed. Recently, the papaya Kunitz-type trypsin inhibitor has 
been found to be a (3-sheet glycoprotein that is incredibly resistant to 
extremes of pH, strong chemical dénaturants and to temperature (Azarkan et 
al., 2006). It has also been shown to be highly stable against non-specific 
proteases, even after a 24 hr incubation period. The authors point to the 
carbohydrate chains and the (3-sheet structure as the most likely cause of its
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increased resistance to proteases when compared to a soybean trypsin 
inhibitor equivalent. As rES-62 also appears to have increased carbohydrate 
moieties in comparison to pES-62, and has changed shape to become 
mainly comprised of (3-sheet structures, the improved stability of rES-62 in 
comparison to pES-62 might similarly be explained.
The lack of cross-reactivity seen between r and pES-62 in the ELISA study 
would appear to be linked to the significant changes in shape between the 
two molecules. In light of the radical changes in shape the recombinant 
material seems to have undergone, it is intriguing that the recombinant ES- 
62 is recognised by the mAb KK6. Obviously, in spite of the changes in 
structure this epitope is retained; perhaps it is present only on the tetrameric 
forms of rES-62.
Regardless of whether glycans do or do not influence correct folding of 
proteins, this does not account for our recombinant molecule refolding from 
a-helix to p-sheet and (3-turn in the presence of such a density of glycans. As 
bulky side chains on AAs make it difficult for p-sheets to form (Hart, Hart and 
Craine, 1995), it is hard to imagine a protein shrouded in /V-glycans refolding 
into this structure. The experts who carried out the biophysical analyses have 
pointed out that although these techniques give an insight into the most likely 
structure of the protein being investigated, they become less reliable when 
looking at multimeric proteins. The fact that the main species of rES-62 in 
solution appeared to be discretely dimeric in nature means the exact
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increases in percentages of |3-sheet and turn of rES-62 in comparison to 
pES-62 may not be as pronounced in reality.
In many cases where proteins switch from a-helix to |3-sheet (e.g. proteins 
specifically engineered to do so) there is a trigger, such as metal ion binding 
(Pagel et al., 2005) or pH change (Pagel et al., 2006). Groft et al. (1999) 
found that they could alter the conformation of CspB-3 (a peptide 
representing a portion of the 5 |3-stranded major cold shock protein of 
Bacillus subtilis) by altering only the relative acetonitrile concentration (this is 
required to solubilise the protein in solution). It was possible for the group to 
start with an unfolded protein at low concentrations, move to an a-helical 
structure, and then on to a p-sheet dominated form. Again, although of 
interest, this gives us no clues as to why rES-62 folding would differ so 
greatly from pES-62, as the buffer conditions both proteins are stored in are 
the same.
An intriguing theory for why the a-helices In rES-62 appear to have converted 
into a (3-sheet and turns is that of giycation, also known as the Maillard 
reaction. Giycation Is a post-translational process whereby sugars non- 
specifically and irreversibly bind to certain AA side chains (being arginine and 
lysine). Exposing proteins to high concentrations of sugar results in creation 
of a reversible Schiff’s base, which can lead to covalent bonding e.g. the 
advanced giycation end products (AGE) peptides (Thomas et al., 2004). 
Gomes et al., (2006) describe giycation as “equivalent to a point mutation, 
exerting profound effects on protein structure stability and function”. The
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localised distortions caused by the products of giycation have the potential to 
affect the overall shape of the protein, e.g. a rise in p-structures, which can 
lead to aggregation (Obrenovich and Monnier, 2004). In recent years, 
giycation has been implicated in the complications associated with several 
diseases such as diabetes, Alzheimer’s and even in aging. The pathology 
associated with these diseases seems dependent on the conversion of 
proteins from a-helices to p-sheets, which can, in turn, lead to aggregation 
(Gomes et al., 2006; reviewed by Harding and Ganea 2006).
Given enough time, any reducing sugar will react with any protein, but some 
sugars and proteins are more reactive than others. Mannose is a reducing 
sugar that has been shown to be more reactive than glucose when incubated 
with proteins in PBS (Roscic and Horvat, 2006). Glucose is a fairly un­
reactive sugar, which has led to researchers to speculate that this could be a 
contributing factor in why our metabolism has evolved around it (Bunn and 
Higgins, 1981). The increased glycolytic reactivity of both mannose and 
galactose compared to glucose became more pronounced when the 
investigators used methanol as a solvent and incubated proteins with 
mannose, glucose and galactose for 6 days at 37®C (Roscic and Horvat, 
2006). Could it be that mannose utilised by Pichia to extend the glycan 
chains on rES-62 is glycating the recombinant molecule due to the 
favourable methanol environment required to induce production of the protein 
coded for by the inserted gene?
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Although it may seem unlikely that the yeast would be unable to curb 
giycation of heterologous proteins, the properties of glycated proteins 
reported thus far certainly bear a resemblance to the data gathered on rES- 
62 during the experimental work presented here. Glycated proteins have 
been shown to be less sensitive to digestion with trypsin (Gomes et al., 
2006), and a paper published this year presents a body of evidence based 
on investigations into glycated haemoglobin (Hb) very similar to the 
observations regarding rES-62 contained within this thesis (Ghoshmoulick et 
al., 2007). The authors discovered when they subjected glycated and non­
glycated Hb to non reducing PAGE conditions, the glycated protein seemed 
to be of a lower molecular weight, which they ascertained could be due to a 
shift in the tetramer-dimer equilibrium to favour dimeric species. This paper 
also showed that lower levels of giycation appeared to coincide with the 
occurrence of a dimeric population when the protein was examined by SDS- 
PAGE, and that a higher level of giycation resulted in intensified protein 
fragmentation. If rES-62 were being glycated, this may help explain the 
evidence for discrete populations of monomeric, dimeric and tertrameric 
species, and thus why there is a lower proportion of tetrameric species in 
rES-62 compared to pES-62 in solution. Furthermore, when glycated and 
non-glycated Hb were subjected to SDS-PAGE, the group observed a 
pattern of bands corresponding to both monomeric and dimeric Hb. The 
dimeric species observed appeared to be cross-linked, and proved to be 
resistant to SDS, remarkably similar to the situation we ourselves have
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outlined here, in relation to the recombinant version of ES-62. The paper 
goes on to present analyses of the CD spectra of glycated Hb using the 
CONTIN procedure, which demonstrate a decrease in the proportion of a- 
helical structure accompanied by a corresponding increase of random coil 
and p-sheet in comparison to non-glycated Hb. The emergence of cross- 
linked ^-structures in a protein has previously been demonstrated to occur 
after a period of prolonged glycation (Bouma et al., 2003), but in the case of 
Hb, the process appears to be happening in a relatively short period of time. 
The authors believe their work to be the first to reveal the p-sheets to be 
formed from previously a-helically structured regions of the protein.
In the case of rES-62, the experts cast doubt on the accuracy of the levels of 
p-sheet/turn predicted, due to the difficulty in achieving clear readings for 
multimeric proteins, and the level of unordered structure is forecast to remain 
roughly the same. Despite these incongruities, the results described recently 
for glycated Hb have an interesting parallel with the observations on rES-62 
made during this investigation, suggesting a possible role for glycation in 
imparting the unusual properties of rES-62 which have been discovered. 
Thus, sugars cross-linking rES-62 to itself, which could, in turn, bend the 
backbone in such a way as to trigger the major structural changes seen in 
comparison to pES-62 could account for the recombinant’s imperviousness 
to enzymes and to dénaturation by heat and SDS. Finally, the authors also 
report that glycation can be subdued by shifting the tetramer-dimer 
equilibrium of the protein in solution to tetramer. Conversely, if the bias in
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solution is on dimeric forms, the propensity for glycation to occur is higher. It 
is possible that the sugars that seem to be preventing rES-62 from assuming 
the tetrameric form characteristic of pES-62 are also increasing the likelihood 
of glycation occurring, leading to cross-linking and the distinct monomeric, 
dimeric and tetrameric species of rES-62 seen in solution.
If glycation were a factor in the radical change in shape of rES-62, this could 
also shed light on the ability of rES-62 to induce IL-12p40 in a TLR4- 
independent manner. A recent review suggests the receptor for AGEs 
(RAGE) could signal through NFkB, and via this, an inflammatory response 
in a similar manner to TLRs (Lin, 2006).
7.4 CONCLUDING REMARKS
This study provides a lesson relating to the use of recombinant parasite 
proteins in immunological studies. Clearly recognition by antibodies against 
the parasite-derived protein may be insufficient to allow the use of such 
recombinant proteins as immunomodulatory mimics of parasite-derived 
molecules, or indeed for use in vaccination. Further analysis with respect to 
conformation may be warranted to ensure that unexpected immunogenicity 
properties are not encountered.
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7.5 FUTURE WORK
The future work that I propose be done involves a more concrete method of 
determining the exact structure of rES-62, possible involving NMR and/or X- 
ray crystallography. The data from these techniques would be time- 
consuming to collect, due to the amounts of protein required, and the length 
of time needed to use these techniques. Data may also prove to be difficult to 
interpret, bearing in mind the results of a recent investigation highlighting the 
interference of sugars on the resolution of protein structures encountered 
when using such traditional procedures (Khajehpour, Dashnau and 
Vanderkooi, 2006).
This thesis has helped to further define the pathways ES-62 and PC utilise to 
bring about their characteristic immunomodulatory phenotype. As mentioned 
earlier, novel dugs based on small molecule derivatives of ES-62 and/or PC, 
could be designed to target these signalling pathways and hopefully mimic 
the immunomodulatory properties of ES-62. The activity of such molecules 
could be compared with known results for pES-62 and PC-BSA/PC-Ova. By 
identifying and characterising which small ES-62/PC-like molecules were 
able to mimic pES-62's abilities regarding cytokine induction and inhibition in 
DCs, mcj) and mast cells for example, this would hopefully allow us to pinpoint 
the exact portions of PC responsible for these modulations of the immune 
response. This, in turn, could indicate possible candidate drugs for the 
treatment of the inflammatory diseases pES-62 has thus far been proven to
2 2 2
successfully modulate, such as rheumatoid arthritis (reviewed by Harnett, 
Mclnnes and Harnett, 2004).
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